WO2024022444A1 - 稠环类化合物、其制备方法及其在医药上的应用 - Google Patents

稠环类化合物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
WO2024022444A1
WO2024022444A1 PCT/CN2023/109598 CN2023109598W WO2024022444A1 WO 2024022444 A1 WO2024022444 A1 WO 2024022444A1 CN 2023109598 W CN2023109598 W CN 2023109598W WO 2024022444 A1 WO2024022444 A1 WO 2024022444A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
pharmaceutically acceptable
general formula
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/109598
Other languages
English (en)
French (fr)
Inventor
李心
蔡国栋
沈峰
贺峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Priority to CN202380046968.5A priority Critical patent/CN119365465A/zh
Priority to KR1020257005109A priority patent/KR20250042155A/ko
Priority to JP2025502591A priority patent/JP2025524846A/ja
Priority to CA3261072A priority patent/CA3261072A1/en
Priority to EP23845651.1A priority patent/EP4563580A4/en
Publication of WO2024022444A1 publication Critical patent/WO2024022444A1/zh
Priority to MX2025001020A priority patent/MX2025001020A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present disclosure belongs to the field of medicine and relates to a fused ring compound, its preparation method and its application in medicine.
  • the present disclosure relates to fused ring compounds represented by general formula (IN), their preparation methods and pharmaceutical compositions containing such compounds, and their use in the preparation of drugs for inhibiting KRAS G12D.
  • RAS is one of the oncogenes with the highest mutation rate in tumors. About 30% of human malignant tumors are related to mutations in the RAS gene.
  • the RAS family includes KRAS, NRAS and HRAS, of which KRAS mutations are the most common, accounting for approximately 85%.
  • KRAS mutations are common in solid tumors, with high frequency mutations found in the three most lethal cancers in humans: lung cancer (17%), colorectal cancer (33%), and pancreatic cancer (61%).
  • 97% are mutations in the 12th or 13th amino acid residue, among which G12D is an important mutation.
  • Data analysis of European and American populations shows that in pancreatic cancer, colorectal cancer and non-small cell lung cancer, G12D mutations account for 36%, 12% and 4% of patients respectively.
  • KRAS After KRAS is activated, it regulates cell proliferation, survival, migration, metabolism and other functions through numerous downstream signaling pathways represented by RAF-MEK-ERK, PI3K-AKT-mTOR and TIAM1-RAc. After the KRAS gene is mutated, the protein remains in an activated state, resulting in continued activation of downstream signaling pathways and promoting tumorigenesis.
  • KRAS protein lacks small molecule binding sites in the traditional sense and has ultra-high affinity to guanylate, making it extremely difficult to inhibit, it has long been considered an undruggable drug target.
  • KRAS has been and remains a target of great concern for drug development.
  • G12C inhibitors there is still a lack of KRAS inhibitors that are effective against other mutations, leaving most patients with KRAS mutations still untreatable.
  • G12D as a mutant that is widely expressed in a variety of tumors, the development of inhibitors against it has important clinical significance.
  • Ring C is heterocyclyl
  • R x1 is a hydrogen atom or R x ; preferably, R x1 is R x ;
  • G 0 is selected from O, S, S(O), S(O) 2 , CR G0a R G0b and NR G0c ;
  • G 2 is NR d ;
  • T is a chemical bond or selected from CR a R b , NRT and O;
  • Q is N or CR 2a ;
  • Ring A is aryl or heteroaryl
  • L is selected from single bonds, O and NR e ;
  • R a , R b , RG0a , RG0b , RG1a , RG1b , RG1c and RG1d are the same or different, and are each independently selected from hydrogen atoms, halogens, alkyl groups, alkoxy groups, haloalkyl groups, and haloalkoxy groups. group, cyano group, amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl; or, R G1a , R G1b and the connected carbon atoms together form a cycloalkyl group; or, R G1c , R G1d and The attached carbon atoms together form a cycloalkyl group;
  • Each R 1 is the same or different, and each is independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) u -NR f R g , hydroxyl and hydroxyalkyl;
  • R 2a and R 4a are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) v -NR h R i , hydroxyl, hydroxyalkyl and cycloalkyl;
  • Each R 3 is the same or different, and each is independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) w -NR j R k , -(CH 2 ) w1 -(O) x1 -C(O)NR j1 R k1 , -(CH 2 ) w2 -(O) x2 -C(O)OR j2 , nitro, hydroxyl, hydroxyalkyl , cycloalkyl, heterocyclyl, aryl and heteroaryl;
  • R 61 , R 62 , R 63 and R 64 are the same or different, and are each independently selected from hydrogen atoms, halogens, alkyl groups, haloalkyl groups, hydroxyalkyl groups and cycloalkyl groups;
  • R 5a and R 5b are the same or different, and are each independently selected from a hydrogen atom, halogen, alkyl, haloalkyl, cyano, hydroxyl and hydroxyalkyl; or
  • R 5a and R 5b together with the attached carbon atoms form a cycloalkyl or heterocyclyl group, and each of the cycloalkyl or heterocyclyl groups is independently selected from the group consisting of halogen, alkyl, haloalkyl, and alkoxy. , substituted by one or more identical or different substituents in haloalkoxy, cyano, amino, hydroxyl and hydroxyalkyl;
  • u, v, w, w1, w2, y, y1 and y2 are the same or different, and are each independently selected from 0, 1, 2 and 3;
  • x1, x2, z1 and z2 are the same or different, and are each independently selected from 0 or 1;
  • r 0, 1, 2 or 3;
  • p 0, 1, 2, 3, 4 or 5;
  • q 0, 1, 2, 3, 4, or 5;
  • t1 is 0, 1, 2, 3, 4 or 5.
  • the compound represented by the general formula (IN) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IN') or a pharmaceutically acceptable salt thereof:
  • a 0, 1, 2, 3 or 4;
  • G 0 , G 1 , G 2 , T, ring A, ring C, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , R x1 , p, t1 and r are as in the general formula (IN).
  • the present disclosure provides a compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof:
  • Ring B is heterocyclyl
  • G 0 is selected from O, S, S(O), S(O) 2 , CR G0a R G0b and NR G0c ;
  • G 2 is NR d ;
  • T is a chemical bond or selected from CR a R b , NRT and O;
  • Q is N or CR 2a ;
  • Ring A is aryl or heteroaryl
  • L is selected from single bonds, O and NR e ;
  • R a , R b , RG0a , RG0b , RG1a , RG1b , RG1c and RG1d are the same or different, and are each independently selected from hydrogen atoms, halogens, alkyl groups, alkoxy groups, haloalkyl groups, and haloalkoxy groups. group, cyano group, amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl; or, R G1a , R G1b and the connected carbon atoms together form a cycloalkyl group; or, R G1c , R G1d and The attached carbon atoms together form a cycloalkyl group;
  • Each R 1 is the same or different, and each is independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) u -NR f R g , hydroxyl and hydroxyalkyl;
  • R 2a and R 4a are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) v -NR h R i , hydroxyl, hydroxyalkyl and cycloalkyl;
  • Each R 3 is the same or different, and each is independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) w -NR j R k , -(CH 2 ) w1 -(O) x1 -C(O)NR j1 R k1 , -(CH 2 ) w2 -(O) x2 -C(O)OR j2 , nitro, hydroxyl, hydroxyalkyl , cycloalkyl, heterocyclyl, aryl and heteroaryl;
  • R 61 , R 62 , R 63 and R 64 are the same or different, and are each independently selected from hydrogen atoms, halogens, alkyl groups, haloalkyl groups, hydroxyalkyl groups and cycloalkyl groups;
  • R 5a and R 5b are the same or different, and are each independently selected from a hydrogen atom, halogen, alkyl, haloalkyl, cyano, hydroxyl and hydroxyalkyl; or
  • R 5a and R 5b together with the attached carbon atoms form a cycloalkyl or heterocyclyl group, and each of the cycloalkyl or heterocyclyl groups is independently selected from the group consisting of halogen, alkyl, haloalkyl, and alkoxy. , substituted by one or more identical or different substituents in haloalkoxy, cyano, amino, hydroxyl and hydroxyalkyl;
  • u, v, w, w1, w2, y, y1 and y2 are the same or different, and are each independently selected from 0, 1, 2 and 3;
  • x1, x2, z1 and z2 are the same or different, and are each independently selected from 0 or 1;
  • r 0, 1, 2 or 3;
  • p 0, 1, 2, 3, 4, or 5;
  • q 0, 1, 2, 3, 4, or 5;
  • t 0, 1, 2, 3, 4 or 5.
  • the compound represented by the general formula (IN), (IN'), (IM) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IM') or Its medicinal salts:
  • a 0, 1, 2, 3 or 4;
  • G 0 , G 1 , G 2 , T, ring A, ring B, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , p, t and r are as in the general formula (IM) defined in.
  • the compound represented by general formula (IN), (IM) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof :
  • G 0 is selected from O, S, S(O), S(O) 2 , CR G0a R G0b and NR G0c ;
  • G 2 is NR d ;
  • T is a chemical bond or selected from CR a R b , NRT and O;
  • Q is N or CR 2a ;
  • Ring A is aryl or heteroaryl
  • L is selected from single bonds, O and NR e ;
  • R a , R b , RG0a , RG0b , RG1a , RG1b , RG1c and RG1d are the same or different, and are each independently selected from hydrogen atoms, halogens, alkyl groups, alkoxy groups, haloalkyl groups, and haloalkoxy groups. group, cyano group, amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl; or, R G1a , R G1b and the attached carbon atoms together form a cycloalkyl group; or, R G1c , R G1d and The attached carbon atoms together form a cycloalkyl group;
  • Each R 1 is the same or different, and each is independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) u -NR f R g , hydroxyl and hydroxyalkyl;
  • R 2a and R 4a are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) v -NR h R i , hydroxyl, hydroxyalkyl and cycloalkyl;
  • Each R 3 is the same or different, and each is independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) w -NR j R k , -(CH 2 ) w1 -(O) x1 -C(O)NR j1 R k1 , -(CH 2 ) w2 -(O) x2 -C(O)OR j2 , nitro, hydroxyl, hydroxyalkyl , cycloalkyl, heterocyclyl, aryl and heteroaryl;
  • R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g and R 6h are the same or different, and each is independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy group , haloalkyl, haloalkoxy, cyano, amino, -(CH 2 ) y -NR m R n , -(CH 2 ) y1 -(O) z1 -C(O)NR m1 R n1 , -(CH 2 ) y2 -(O) z2 -C(O)OR m2 , nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or
  • R 6a and R 6e form a bridge with the attached carbon atom, R 6a and R 6g with the attached carbon atom, R 6c and R 6e with the attached carbon atom or R 6c and R 6g with the attached carbon atom.
  • the bridge has 1, 2, 3 or 4 CH 2 , any of which CH 2 can be optionally replaced by O, S, NH, the bridge is optionally selected from halogen, alkyl, haloalkyl, Substituted with one or more of the same or different substituents of alkoxy, haloalkoxy, cyano, amino, hydroxyl and hydroxyalkyl; or
  • Alkyl or heterocyclyl, the cycloalkyl or heterocyclyl is optionally selected from halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, amino, hydroxyl and hydroxyalkyl Substituted with one or more identical or different substituents;
  • R 5a and R 5b are the same or different, and are each independently selected from a hydrogen atom, halogen, alkyl, haloalkyl, cyano, hydroxyl and hydroxyalkyl; or
  • R 5a and R 5b together with the attached carbon atoms form a cycloalkyl or heterocyclyl group, and each of the cycloalkyl or heterocyclyl groups is independently selected from the group consisting of halogen, alkyl, haloalkyl, and alkoxy. , substituted by one or more identical or different substituents in haloalkoxy, cyano, amino, hydroxyl and hydroxyalkyl;
  • u, v, w, w1, w2, y, y1 and y2 are the same or different, and are each independently selected from 0, 1, 2 and 3;
  • x1, x2, z1 and z2 are the same or different, and are each independently selected from 0 or 1;
  • r 0, 1, 2 or 3;
  • p 0, 1, 2, 3, 4, or 5;
  • q 0, 1, 2, 3, 4 or 5.
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (I) or a pharmaceutically acceptable salt thereof is of the general formula
  • a 0, 1, 2, 3 or 4;
  • G 0 , G 1 , G 2 , T, ring A, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and r are as defined in general formula (I).
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (I) or (I') or a pharmaceutically acceptable salt thereof in Selected from Preferably It is further preferred to G 0 , G 1 , G 2 , R 1 and p are as defined in general formula (I).
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (I) or (I') or a pharmaceutically acceptable salt thereof wherein G 0 is selected from O, CR G0a R G0b and NR G0c , R G0a and R G0b are the same or different, and are each independently selected from hydrogen atoms, halogens, C 1-6 alkyl and C 1-6 haloalkyl, R G0c is a hydrogen atom or a C 1-6 alkyl group; preferably, G 0 is selected from O, CH 2 and NH; further preferably, G 0 is O.
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (I) or (I') or a pharmaceutically acceptable salt thereof wherein G 1 is CR G1a H, RG1a is as defined in the general formula (IN); preferably, G 1 is CR G1a H, RG1a is selected from hydrogen atoms, halogens, C 1-6 alkyl and C 1- 6 haloalkyl; further preferably, G 1 is CR G1a H, RG1a is a hydrogen atom or C 1-6 alkyl group; further preferably, G 1 is CR G1a H, RG1a is C 1-6 alkyl; more preferably Preferably, G 1 is CR G1a H, and R G1a is methyl.
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (I) or (I') or a pharmaceutically acceptable salt thereof where -G 0 -G 1 - is selected from -O-CH 2 -, -NH-C(O)-, -NH-CH 2 -, -CH 2 -CH 2 - and -O-CH 2 -CH 2 -; preferably -O-CH 2 - or -NH-C(O)-; further preferably -O-CH 2 -; in some embodiments, -G 0 -G 1 - is -O-CH(CH 3 )-.
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (I) or (I') or a pharmaceutically acceptable salt thereof where T is a chemical bond.
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (I) or (I') or a pharmaceutically acceptable salt thereof wherein R 5a and R 5b are the same or different, and are each independently selected from hydrogen atom, halogen, C 1-6 alkyl, C 1-6 haloalkyl, hydroxyl and C 1-6 hydroxyalkyl, or R 5a , R 5b and the attached carbon atom together form a 3 to 8-membered cycloalkyl group; preferably, R 5a and R 5b are hydrogen atoms, or R 5a and R 5b together with the attached carbon atom form a 3 to 6-membered cycloalkyl group. group; more preferably, R 5a and R 5b are hydrogen atoms, or R 5a and R 5b together with the attached carbon atom form a cyclopropyl group.
  • a pharmaceutically acceptable salt thereof in for -CH 2 -or
  • the compound represented by general formula (IN), (IM), (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (II') or a pharmaceutically acceptable salt thereof.
  • Ring A, G 2 , Q, L, R G1a , R 1 , R 3 , R 4a , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and q are as follows As defined in general formula (I); preferably, R G1a is C 1-6 alkyl.
  • the compound represented by the general formula (IN), (IM), (I) or (II') or a pharmaceutically acceptable salt thereof is represented by the general formula (II) Compounds or pharmaceutically acceptable salts thereof:
  • Ring A, G 2 , Q, L, R 1 , R 3 , R 4a , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and q are as shown in the general formula ( as defined in I).
  • the general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (IVV') The compound represented by the general formula (III') or a pharmaceutically acceptable salt thereof:
  • R 3a and R 3b are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, hydroxyl, hydroxyalkyl , cycloalkyl and heterocyclyl;
  • R G 2 , Q, L, R G1a , R 1 , R 4a , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h and p are as defined in general formula (I) ;
  • R G1a is C 1-6 alkyl.
  • the general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), ( III'), (IVV') or a pharmaceutically acceptable salt thereof which is a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof:
  • R 3a and R 3b are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, hydroxyl, hydroxyalkyl , cycloalkyl and heterocyclyl;
  • G 2 , Q, L, R 1 , R 4a , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h and p are as defined in general formula (I).
  • the compound represented by the general formula (IN), (IN') or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IVV') or a pharmaceutically acceptable salt thereof of salt:
  • R 3a and R 3b are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, hydroxyl, hydroxyalkyl , cycloalkyl and heterocyclyl;
  • Ring C, G 2 , Q, L, R G1a , R 1 , R 4a , R 6 , R x1 , t1 and p are as defined in the general formula (IN); preferably, R G1a is C 1-6 alkyl .
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (IVV') or a pharmaceutically acceptable salt thereof is a general Compounds represented by formula (IV') or (VV') or pharmaceutically acceptable salts thereof:
  • R 61 , R 62 , R 63 and R 64 are the same or different, and are each independently selected from hydrogen atoms, halogens, alkyl groups, haloalkyl groups, hydroxyalkyl groups and cycloalkyl groups;
  • t 0, 1, 2, 3 or 4;
  • R 3a and R 3b are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, hydroxyl, hydroxyalkyl , cycloalkyl and heterocyclyl;
  • Ring B is heterocyclyl
  • R x1 , t1, ring C, G 2 , Q, L, R G1a , R 1 , R 4a , R 6 and p are as defined in the general formula (IN); preferably, R G1a is C 1-6 alkyl .
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (IVV') or a pharmaceutically acceptable salt thereof is a general Compounds represented by formula (IV') or pharmaceutically acceptable salts thereof:
  • R 61 , R 62 , R 63 and R 64 are the same or different, and are each independently selected from hydrogen atoms, halogens, alkyl groups, haloalkyl groups, hydroxyalkyl groups and cycloalkyl groups;
  • t 0, 1, 2, 3 or 4;
  • R 3a and R 3b are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, hydroxyl, hydroxyalkyl , cycloalkyl and heterocyclyl;
  • Ring B, G 2 , Q, L, R G1a , R 1 , R 4a , R 6 and p are as defined in the general formula (IM); preferably, R G1a is C 1-6 alkyl.
  • the compound represented by the general formula (IN), (IN') or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (VV') or a pharmaceutically acceptable salt thereof of salt:
  • R 3a and R 3b are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, hydroxyl, hydroxyalkyl , cycloalkyl and heterocyclyl;
  • Ring C, G 2 , Q, L, R G1a , R 1 , R 4a , R 6 , R x1 , t1 and p are as defined in the general formula (IN); preferably, R G1a is C 1-6 alkyl .
  • the compound represented by the general formula (IN), (IN'), (IM), (IM'), (VV') or a pharmaceutically acceptable salt thereof is a general Compounds represented by formula (V') or pharmaceutically acceptable salts thereof:
  • R 61 , R 62 , R 63 and R 64 are the same or different, and are each independently selected from hydrogen atoms, halogens, alkyl groups, haloalkyl groups, hydroxyalkyl groups and cycloalkyl groups;
  • t 0, 1, 2, 3 or 4;
  • R 3a and R 3b are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, hydroxyl, hydroxyalkyl , cycloalkyl and heterocyclyl;
  • Ring B, G 2 , Q, L, R G1a , R 1 , R 4a , R 6 and p are as defined in the general formula (IM); preferably, R G1a is C 1-6 alkyl.
  • the compounds represented by the general formulas (II'), (III'), (IV'), (V'), (IVV'), (VV') or pharmaceutically acceptable compounds thereof salt used which Selected from Preferably selected from More preferably
  • R G1a is selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl
  • G 2 , R 1 and p are as defined in general formula (I).
  • the compound represented by (IV'), (IVV') or a pharmaceutically acceptable salt thereof which is a compound represented by the general formula (III'-1) or a pharmaceutically acceptable salt thereof:
  • R G1a is selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl; preferably, R G1a is C 1 -6 alkyl;
  • G 2 , Q, L, R 1 , R 3a , R 3b , R 4a , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h and p are as in the general formula (III' ) as defined in.
  • the compounds represented by the general formula (IN), (IN'), (IM), (IM'), (IV'), (IVV') or their pharmaceutically acceptable Salt which is a compound represented by general formula (IV'-1) or a pharmaceutically acceptable salt thereof:
  • R G1a is selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl; preferably, R G1a is C 1 -6 alkyl;
  • Rings B, G 2 , Q, L, R 1 , R 3a , R 3b , R 4a , R 6 , R x , t and p are as defined in general formula (IV′).
  • the compound represented by the general formula (IN), (IN'), (VV') or a pharmaceutically acceptable salt thereof is represented by the general formula (VV'-1) Compounds or pharmaceutically acceptable salts thereof:
  • R G1a is selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl; preferably, R G1a is C 1 -6 alkyl;
  • Rings C, G 2 , Q, L, R 1 , R 3a , R 3b , R 4a , R 6 , R x 1 , t 1 and p are as defined in the general formula (VV′).
  • the compounds represented by the general formula (IN), (IN'), (IM), (IM'), (V'), (VV') or their pharmaceutically acceptable Salt which is a compound represented by general formula (V'-1) or a pharmaceutically acceptable salt thereof:
  • R G1a is selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl; preferably, R G1a is C 1 -6 alkyl;
  • G 2 , Q, L, R 1 , R 3a , R 3b , R 4a , R 6 , R x , t and p are as defined in the general formula (V′).
  • the compound represented by the general formula (IM), (IM'), (IV'), (IV'-1), (V'), (V'-1) or Its pharmaceutically acceptable salt wherein ring B is a 3 to 8-membered heterocyclyl group; preferably, ring B is selected from morpholinyl, Tetrahydropyrrolyl, piperidinyl, Further preferably, Ring B is selected from piperidinyl, tetrahydropyrrolyl, More preferably, ring B is selected from piperidinyl, tetrahydropyrrolyl,
  • the general formula (IN), (IN'), (IV'), (IV'-1), (V'), (V'-1), (IVV') the compound represented by (VV'), (VV'-1) or a pharmaceutically acceptable salt thereof, wherein ring C is a 3 to 8-membered heterocyclyl group; preferably, ring C is selected from azetidinyl, Morpholinyl, Tetrahydropyrrolyl, piperidinyl,
  • the compound represented by the general formula (IM), (IM') or a pharmaceutically acceptable salt thereof wherein Selected from R 61 , R 62 , R 63 and R 64 are as defined in general formula (IV'); preferably selected from More preferably selected from
  • the compound represented by the general formula (IM), (IM') or a pharmaceutically acceptable salt thereof wherein Selected from Preferably, Selected from More preferably, for
  • the compound represented by the general formula (IM), (IM') or a pharmaceutically acceptable salt thereof wherein for R 62 and R 63 are the same or different, and each is independently a hydrogen atom or halogen; in some embodiments, for R 62 and R 63 are both halogen; in some embodiments, for R 62 is a halogen, and R 63 is a hydrogen atom.
  • the compound represented by the general formula (IV'), (IV'-1), (V'), (V'-1) or a pharmaceutically acceptable salt thereof wherein Selected from R 61 , R 62 , R 63 and R 64 are as defined in general formula (IV'); preferably selected from R 61 is a C 1-6 alkyl group, R 62 and R 63 are the same or different, and each is independently a hydrogen atom or halogen, R 64 is a hydrogen atom or a C 1-6 alkyl group; more preferably, it is selected from
  • the compound represented by the general formula (IV'), (IV'-1), (V'), (V'-1) or a pharmaceutically acceptable salt thereof wherein Selected from R 61 , R 62 , R 63 and R 64 are as defined in general formula (IV'); preferably selected from R 61 is a C 1-6 alkyl group, R 62 and R 63 are the same or different, and each is independently a hydrogen atom or halogen, R 64 is a hydrogen atom or a C 1-6 alkyl group; more preferably, it is selected from It is further preferred to be selected from
  • the compound represented by the general formula (IV'), (IV'-1), (V'), (V'-1) or a pharmaceutically acceptable salt thereof wherein for R 62 and R 63 are the same or different, and each is independently a hydrogen atom or halogen; in some embodiments, for R 62 and R 63 are both halogen; in some embodiments, for R 62 is a halogen, and R 63 is a hydrogen atom.
  • the compound represented by the general formula (IN), (IN'), (IVV'), (VV'), (VV'-1) or a pharmaceutically acceptable salt thereof, in Selected from R 61 , R 62 , R 63 and R 64 are as defined in general formula (IN); preferably selected from R 61 is C 1-6 alkyl, R 62 and R 63 are the same or different, and each is independently a hydrogen atom or halogen, and R 64 is a hydrogen atom or a C 1-6 alkyl group; further preferably, it is selected from More preferably selected from
  • the compound represented by the general formula (IN), (IN'), (IVV') or a pharmaceutically acceptable salt thereof wherein Selected from R 61 , R 62 , R 63 and R 64 are as general formula (IN) as defined in; preferably selected from R 61 is a C 1-6 alkyl group, R 62 and R 63 are the same or different, and are each independently a hydrogen atom or halogen, R 64 is a hydrogen atom or a C 1-6 alkyl group; further preferably, selected from More preferably, selected from More preferably selected from More preferably, for
  • the compound represented by the general formula (IN), (IN'), (IVV') or a pharmaceutically acceptable salt thereof wherein for R 62 and R 63 are the same or different, and each is independently a hydrogen atom or halogen; in some embodiments, for R 62 and R 63 are both halogen; in some embodiments, for R 62 is a halogen, and R 63 is a hydrogen atom.
  • the compound represented by the general formula (IN), (IN'), (VV'), (VV'-1) or a pharmaceutically acceptable salt thereof wherein for R 62 and R 63 are as defined in general formula (IN); preferably R 62 and R 63 are the same or different, and are each independently a hydrogen atom or halogen; more preferably, they are selected from
  • the general formula (IN), (IN'), (IM), (IM'), (IV'), (IV'-1), (V'), (V '-1), (IVV'), (VV'), (VV'-1) or a pharmaceutically acceptable salt thereof wherein R 62 and R 63 are the same or different, and each is independently a hydrogen atom Or halogen; preferably, R 62 and R 63 are the same or different, and each is independently a hydrogen atom or F.
  • R G1a Selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; preferably, R G1a is a hydrogen atom or C 1-6 alkyl; further preferably, R G1a is C 1-6 alkyl ; More preferably, R G1a is methyl.
  • the general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (III'), (III'-1), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) A compound or a pharmaceutically acceptable salt thereof, wherein R G1a is selected from halogen, C 1-6 alkyl and C 1-6 haloalkyl; preferably, R G1a is C 1-6 alkyl; more preferably, R G1a is methyl.
  • the general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II') or (II) is represented by A compound or a pharmaceutically acceptable salt thereof, wherein ring A is a 6- to 10-membered aryl group or a 5- to 10-membered heteroaryl group; preferably, ring A is selected from naphthyl, phenyl, pyridyl, benzothienyl, benzothiazolyl and benzopyrazolyl; more preferably, ring A is selected from naphthyl, phenyl and benzothienyl; further preferably, ring A is phenyl or naphthyl; more preferably, it is naphthyl.
  • the general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II') or (II) is represented by A compound or a pharmaceutically acceptable salt thereof, wherein each R 3 is the same or different, and each is independently selected from halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1- 6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano, amino, -(CH 2 ) w -NR j R k , hydroxyl and C 1-6 hydroxyalkyl, R j and R k is the same or different, and each is independently a hydrogen atom or a C 1-6 alkyl group, w is 0 or 1; preferably, each R 3 is the same or different, and each is independently selected from halogen, C 1-6 alkyl group, C 2-6 alkynyl group, C 1-6 haloal
  • the compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof wherein G 0 is O; G 1 is CR G1a H, and R G1a is C 1-6 alkyl ;T is a single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; p is 0; Selected from q1 is 2 or 3, R 3 is the same or different, and each is independently selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl and cyano; Selected from and for
  • the compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof wherein G 0 is O; G 1 is CR G1a H, and R G1a is C 1-6 alkyl ;T is a single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; for p is 0; Selected from and Selected from
  • the compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof wherein G 0 is O; G 1 is CR G1a H, R G1a is methyl; T is single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; for p is 0; Selected from and for
  • the compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof wherein G 0 is O; G 1 is CR G1a H, R G1a is methyl; T is single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; for p is 0; Selected from and Selected from
  • the compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof wherein G 0 is O; G 1 is CR G1a H, R G1a is methyl; T is single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; for p is 0; Selected from and for
  • the compound represented by general formula (IN) or a pharmaceutically acceptable salt thereof Among them, G 0 is O; G 1 is CR G1a H, R G1a is C 1-6 alkyl; T is a single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; for p is 0; Selected from and Selected from
  • the compound represented by the general formula (IN) or a pharmaceutically acceptable salt thereof wherein G 0 is O; G 1 is CR G1a H, R G1a is methyl; T is single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; for p is 0; Selected from and for
  • the compound represented by the general formula (IN) or a pharmaceutically acceptable salt thereof wherein G 0 is O; G 1 is CR G1a H, R G1a is methyl; T is single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; for p is 0; Selected from and Selected from
  • the compound represented by the general formula (IN) or a pharmaceutically acceptable salt thereof wherein G 0 is O; G 1 is CR G1a H, R G1a is methyl; T is single bond; Q is N; R 4a is halogen; G 2 is NH; L is O; for p is 0; Selected from and for
  • the compound represented by the general formula (II') or a pharmaceutically acceptable salt thereof wherein R G1a is a C 1-6 alkyl group; Selected from Q is N; ring A is phenyl or naphthyl; R 4a is halogen; G 2 is NH; L is O; p is 0; q is 2 or 3; and each R 3 is the same or different, and each is independently selected From halogen, C 1-6 alkyl and hydroxyl.
  • the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof wherein Selected from Q is N; ring A is phenyl or naphthyl; R 4a is halogen; G 2 is NH; L is O; p is 0; q is 2 or 3; and each R 3 is the same or different, and each is independently selected From halogen, C 1-6 alkyl and hydroxyl.
  • the compound represented by the general formula (III') or a pharmaceutically acceptable salt thereof wherein R G1a is methyl; Selected from Q is N; R 4a is halogen; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by the general formula (III'-1) or a pharmaceutically acceptable salt thereof wherein R G1a is methyl; Selected from Q is N; R 4a is halogen; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by the general formula (III'-1) or a pharmaceutically acceptable salt thereof wherein R G1a is methyl; for Q is N; R 4a is halogen; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, middle Selected from Q is N; R 4a is halogen; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by the general formula (IV') or a pharmaceutically acceptable salt thereof wherein R G1a is methyl; Selected from R 61 is a C 1-6 alkyl group, R 62 and R 63 are the same or different, and each is independently a hydrogen atom or a halogen, R 64 is a hydrogen atom or a C 1-6 alkyl group; Q is N; R 4a is a halogen ; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by the general formula (IV'-1) or a pharmaceutically acceptable salt thereof wherein R G1a is methyl; Selected from Q is N; R 4a is halogen; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by the general formula (IV'-1) or a pharmaceutically acceptable salt thereof wherein R G1a is methyl; Selected from Q is N; R 4a is halogen; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by the general formula (IV') or (V') or a pharmaceutically acceptable salt thereof wherein R G1a is methyl; Selected from R 61 is a C 1-6 alkyl group, R 62 and R 63 are the same or different, and each is independently a hydrogen atom or a halogen, R 64 is a hydrogen atom or a C 1-6 alkyl group; Q is N; R 4a is a halogen ; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by the general formula (IV'-1) or (V'-1) or a pharmaceutically acceptable salt thereof wherein R G1a is methyl; Selected from Q is N; R 4a is halogen; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • the compound represented by the general formula (IVV'), (VV') or a pharmaceutically acceptable salt thereof wherein R G1a is a hydrogen atom or a C 1-6 alkyl group; Selected from R 61 is a C 1-6 alkyl group, R 62 and R 63 are the same or different, and each is independently a hydrogen atom or a halogen, R 64 is a hydrogen atom or a C 1-6 alkyl group; Q is N; R 4a is a halogen ; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • R G1a is a hydrogen atom or a C 1-6 alkyl group
  • Selected from R 61 is a C 1-6 alkyl group
  • R 62 and R 63 are the same or different, and each is independently a hydrogen atom or a halogen
  • R 64 is a hydrogen atom or a C 1-6 alkyl group
  • the compound represented by the general formula (VV'), (VV'-1) or a pharmaceutically acceptable salt thereof wherein R G1a is a C 1-6 alkyl group; Selected from R 61 is a C 1-6 alkyl group, R 62 and R 63 are the same or different, and each is independently a hydrogen atom or a halogen, R 64 is a hydrogen atom or a C 1-6 alkyl group; Q is N; R 4a is a halogen ; G 2 is NH; L is O; p is 0; R 3a is halogen; and R 3b is C 1-6 alkyl.
  • R G1a is a C 1-6 alkyl group
  • Selected from R 61 is a C 1-6 alkyl group
  • R 62 and R 63 are the same or different, and each is independently a hydrogen atom or a halogen
  • R 64 is a hydrogen atom or a C 1-6 alkyl group
  • Q is N
  • R 4a is
  • Typical compounds of the present disclosure include, but are not limited to:
  • Another aspect of the present disclosure relates to compounds represented by general formula (INA) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • G 0 , G 1 , T, ring A, ring C, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , R x1 , p, q, t1 and r are as shown in the general formula ( IN).
  • Another aspect of the present disclosure relates to compounds represented by general formula (IN'A) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 0 , G 1 , T, ring A, ring C, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , R x1 , p, t1 and r are as shown in the general formula (IN' ) as defined in.
  • Another aspect of the present disclosure relates to compounds represented by general formula (IMA) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • G 0 , G 1 , T, ring A, ring B, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , p, q, t and r are as in the general formula (IM) defined.
  • Another aspect of the present disclosure relates to compounds represented by general formula (IM'A) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 0 , G 1 , T, ring A, ring B, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , p, t and r are as in the general formula (IM') definition.
  • Another aspect of the present disclosure relates to compounds represented by general formula (IA) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • G 0 , G 1 , T, ring A, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p, q and r are as defined in general formula (I).
  • Another aspect of the present disclosure relates to compounds represented by general formula (I'A) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 0 , G 1 , T, ring A, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and r are as defined in general formula (I').
  • Another aspect of the present disclosure relates to a compound represented by general formula (II'A) or a salt thereof,
  • R is an amino protecting group; preferably Boc;
  • Ring A, Q, L, R G1a , R 1 , R 3 , R 4a , R 6a , R 6b, R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and q are as shown in the general formula ( II') defined in.
  • Another aspect of the present disclosure relates to compounds represented by general formula (IIA) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • Ring A, Q, L, R 1 , R 3 , R 4a , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and q are as in the general formula (II) defined.
  • Another aspect of the present disclosure relates to a compound represented by general formula (III'A) or a salt thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Another aspect of the present disclosure relates to a compound represented by general formula (III'-1A) or a salt thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Another aspect of the present disclosure relates to a compound represented by general formula (IIIA) or a salt thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Another aspect of the present disclosure relates to compounds represented by general formula (IVV'A) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (IVV').
  • Another aspect of the present disclosure relates to compounds represented by general formula (IV'A) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in general formula (IV').
  • Another aspect of the present disclosure relates to compounds represented by general formula (IV'-1A) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (IV'-1).
  • VV'A general formula (VV'A) or salts thereof
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (VV').
  • Another aspect of the present disclosure relates to a compound represented by general formula (VV'-1A) or a salt thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (VV'-1).
  • Another aspect of the present disclosure relates to compounds represented by general formula (V'A) or salts thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (V').
  • Another aspect of the present disclosure relates to a compound represented by general formula (V'-1A) or a salt thereof,
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (V'-1).
  • Typical intermediate compounds of the present disclosure include, but are not limited to:
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IN) or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of the general formula (INA) or a salt thereof undergoes a deprotection reaction to obtain a compound of the general formula (IN) or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, during the deprotection Before, at the same time or after the protection reaction, the step of removing the protecting group on the R 3 group is also included;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, ring C, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , R x1 , p, q, t1 and r are as shown in the general formula ( IN).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IN') or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (IN'A) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (IN') or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, before, at the same time or after the deprotection reaction It also includes the step of removing the protecting group on the R 3 group;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, ring C, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , R x1 , p, t1 and r are as shown in the general formula (IN' ) as defined in.
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IM) or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (IMA) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (IM) or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, the deprotection reaction is Before, at the same time or after the protection reaction, the step of removing the protecting group on the R 3 group is also included;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, ring B, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , p, q, t and r are as in the general formula (IM) defined.
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IM') or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (IM'A) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (IM') or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, before, at the same time or after the deprotection reaction
  • the step also includes the step of removing the protecting group on the R 3 group;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, ring B, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , p, t and r are as in the general formula (IM') definition.
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (IA) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (I) or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, during the deprotection Before, at the same time or after the protection reaction, the step of removing the protecting group on the R 3 group is also included;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p, q and r are as defined in general formula (I).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (I') or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (I'A) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (I') or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, Before, at the same time or after the deprotection reaction, the step of removing the protecting group on the R 3 group is also included;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and r are as defined in general formula (I').
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (II') or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (II'A) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (II') or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, Before, at the same time or after the deprotection reaction, the step of removing the protecting group on the R 3 group is also included;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • Ring A, Q, L, R G1a , R 1 , R 3 , R 4a , R 6a , R 6b, R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and q are as shown in the general formula ( II') defined in.
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (IIA) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (II) or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, during the deprotection Before, at the same time or after the protection reaction, the step of removing the protecting group on the R 3 group is also included;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • Ring A, Q, L, R 1 , R 3 , R 4a , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and q are as in the general formula (II) defined.
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III') or a pharmaceutically acceptable salt thereof, the method comprising:
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III'-1) or a pharmaceutically acceptable salt thereof, the method comprising:
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof.
  • method which includes:
  • the compound of general formula (IIIA) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (III) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IVV') or a pharmaceutically acceptable salt thereof, the method comprising:
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (IVV').
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IV') or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (IV'A) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (IV') or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in general formula (IV').
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IV'-1) or a pharmaceutically acceptable salt thereof, the method comprising:
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (IV'-1).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (VV') or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (VV’A) or a salt thereof is subjected to a deprotection reaction to obtain a compound of general formula (VV’) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (VV').
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (VV'-1) or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (VV’-1A) or a salt thereof is subjected to a deprotection reaction to obtain a compound of general formula (VV’-1) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (VV'-1).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (V') or a pharmaceutically acceptable salt thereof, the method comprising:
  • the compound of general formula (V’A) or a salt thereof undergoes a deprotection reaction to obtain a compound of general formula (V’) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (V').
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (V'-1) or a pharmaceutically acceptable salt thereof, the method comprising:
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (V'-1).
  • Another aspect of the present disclosure relates to a pharmaceutical composition containing the general formulas (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), (III'), (III'-1), (III), (IV'), (IV'-1), (V'), (V'-1), ( IVV'), (VV'), (VV'-1) or a compound shown in Table A or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients .
  • the present disclosure further relates to general formulas (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), (III'), (III' -1), (III), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) or table Use of the compound shown in A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same in the preparation of a drug for inhibiting KRAS G12D.
  • the present disclosure further relates to general formulas (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), (III'), (III' -1), (III), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) or table Use of the compound shown in A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for the treatment and/or prevention of diseases or conditions mediated by KRAS G12D.
  • the present disclosure further relates to general formulas (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), (III'), (III' -1), (III), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) or table
  • the tumor is preferably selected from brain cancer, thyroid cancer, Head and neck cancer, nasopharyngeal cancer, throat cancer, oral cancer, salivary gland cancer, esophageal cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, pleural cancer, peritoneal cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, colorectal cancer, small intestine cancer, Gastrointestinal stromal tumor, urothelial cancer, urethra
  • the present disclosure further relates to a method of inhibiting KRAS G12D, comprising administering to a patient in need thereof a therapeutically effective amount of Formula (IN), (IN'), (IM), (IM'), (I), (I') , (II'), (II), (III'), (III'-1), (III), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) or the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same.
  • Formula (IN), (IN'), (IM), (IM'), (I), (I') , (II'), (II), (III'), (III'-1), (III), (IV'), (IV'-1), (V'), (V'), (VV'-1) or the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same.
  • the present disclosure further relates to a method of treating and/or preventing a disease or disorder mediated by KRAS G12D, comprising administering to a patient in need thereof a therapeutically effective amount of formula (IN), (IN'), (IM), (IM '), (I), (I'), (II'), (II), (III'), (III'-1), (III), (IV'), (IV'-1), ( V'), (V'-1), (IVV'), (VV'), (VV'-1) or the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same.
  • formula (IN), (IN'), (IM), (IM '), (I), (II'), (II), (III'), (III'-1), (III), (IV'), (IV'-1), ( V'), (V'-1), (IVV'), (VV'), (VV'-1) or the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same.
  • the present disclosure further relates to a method of treating and/or preventing tumors, comprising administering to a patient in need a therapeutically effective amount of general formula (IN), (IN'), (IM), (IM'), (I), ( I'), (II'), (II), (III'), (III'-1), (III), (IV'), (IV'-1), (V'), (V'- 1), (IVV'), (VV'), (VV'-1) or the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same;
  • the tumor is preferably selected from brain Cancer, thyroid cancer, head and neck cancer, nasopharyngeal cancer, throat cancer, oral cancer, salivary gland cancer, esophageal cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, pleural cancer, peritoneal cancer, pancreatic cancer, gallbladder cancer, cholangiocarcinoma, colorectal cancer Cancer, small bowel cancer, gastrointestinal stromal tumor,
  • the present disclosure further relates to a general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), (III'), ( III'-1), (III), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) Or the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same, which is used as a medicine.
  • the present disclosure further relates to a general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), (III'), ( III'-1), (III), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) Or the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same, which is used to inhibit KRAS G12D.
  • the present disclosure further relates to a general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), (III'), ( III'-1), (III), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) Or a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including it, which is used to treat and/or prevent diseases or conditions mediated by KRAS G12D.
  • the present disclosure further relates to a general formula (IN), (IN'), (IM), (IM'), (I), (I'), (II'), (II), (III'), ( III'-1), (III), (IV'), (IV'-1), (V'), (V'-1), (IVV'), (VV'), (VV'-1) Or the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition including the same, which is used to treat and/or prevent tumors; the tumor is preferably selected from brain cancer, thyroid cancer, head and neck cancer, nasal cancer, etc.
  • the diseases or conditions described in this disclosure are those that are treated and/or prevented by inhibiting KRAS G12D.
  • the disease or condition mediated by KRAS G12D of the present disclosure is a tumor; the tumor is preferably selected from the group consisting of brain cancer, thyroid cancer, head and neck cancer, nasopharyngeal cancer, throat cancer, oral cancer, salivary gland cancer, esophagus Cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, pleural cancer, peritoneal cancer, pancreatic cancer, gallbladder cancer, cholangiocarcinoma, colorectal cancer, small bowel cancer, gastrointestinal stromal tumor, urothelial cancer, urethra cancer, bladder cancer , anal cancer, joint cancer, breast cancer, vaginal cancer, ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, testicular cancer, prostate cancer, hemangioma, leukemia, lymphoma, myeloma, skin cancer, melanoma, Lipoma, bone cancer, soft tissue sarcoma, neurofibroma, gli
  • Colorectal cancer of the present disclosure is preferably colon cancer or rectal cancer.
  • the brain cancer described in the present disclosure is selected from glioblastoma multiforme or neuroblastoma;
  • the soft tissue cancer is selected from fibrosarcoma, gastrointestinal sarcoma, rhabdomyosarcoma, leiomyosarcoma, dedifferentiated liposarcoma, Pleomorphic liposarcoma, malignant fibrous histiocytoma, round cell sarcoma, and synovial sarcoma; lymphoma selected from Hodgkin's disease and non-Hodgkin's lymphoma (e.g., mantle cell lymphoma, diffuse large B-cell lymphoma , follicular center Lymphoma, marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma and peripheral T-cell lymphoma); liver cancer is preferably hepatocellular carcinoma; lung cancer (also known as bronchial lung cancer) is selected from non-small cell lung cancer (NSCLC
  • the active compounds may be prepared in a form suitable for administration by any appropriate route and the compositions of the present disclosure may be formulated by conventional means using one or more pharmaceutically acceptable carriers. Accordingly, the active compounds of the present disclosure may be formulated in various dosage forms for oral administration, injection (eg, intravenous, intramuscular or subcutaneous) administration, inhalation or insufflation administration. The compounds of the present disclosure may also be formulated in dosage forms such as tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injections, dispersible powders or granules, suppositories, lozenges, or syrups.
  • the active compounds of the present disclosure are preferably in unit dosage form, or in such form that a patient may self-administer a single dose.
  • the unit dosage form of a compound or composition of the present disclosure may be expressed as a tablet, capsule, cachet, bottled solution, powder, granule, lozenge, suppository, reconstituted powder or liquid preparation.
  • a suitable unit dose may be 0.1 to 1000 mg.
  • the pharmaceutical composition of the present disclosure may contain one or more auxiliary materials selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients wait.
  • auxiliary materials selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients wait.
  • the composition may contain from 0.1 to 99% by weight of active compound.
  • Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients suitable for the manufacture of tablets.
  • excipients may be inert excipients, granulating agents, disintegrating agents, binders and lubricants.
  • These tablets may be uncoated or may be coated by known techniques to mask the taste of the drug or to delay disintegration and absorption in the gastrointestinal tract, thereby providing sustained release over an extended period of time.
  • Oral formulations may also be presented in soft gelatin capsules in which the active ingredient is mixed with an inert solid diluent, or in which the active ingredient is mixed with a water-soluble carrier or oil vehicle.
  • Aqueous suspensions contain the active substances and excipients suitable for the preparation of aqueous suspensions for mixing. Such excipients are suspending, dispersing or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
  • Oil suspensions can be formulated by suspending the active ingredient in vegetable oil, or mineral oil. Oil suspensions may contain thickening agents. Sweetening and flavoring agents as described above may be added to provide a palatable preparation. These compositions can be preserved by adding antioxidants.
  • compositions of the present disclosure may also be in the form of oil-in-water emulsions.
  • the oil phase may be vegetable oil, or mineral oil or mixtures thereof.
  • Suitable emulsifiers may be naturally occurring phospholipids, and the emulsions may also contain sweeteners, flavoring agents, preservatives and antioxidants.
  • Such preparations may also contain demulcents, preservatives, coloring agents and antioxidants.
  • compositions of the present disclosure may be in the form of sterile injectable aqueous solutions.
  • Acceptable vehicles or solvents that may be used are water, Ringer's solution and isotonic sodium chloride solution.
  • Sterile injectable preparations may be sterile injectable oil-in-water microemulsions in which the active ingredient is dissolved in an oily phase.
  • injectable solutions or microemulsions may be injected into the patient's bloodstream by local mass injection.
  • solutions and microemulsions are preferably administered in a manner that maintains constant circulating concentrations of the compounds of the present disclosure.
  • continuous intravenous drug delivery devices can be used.
  • An example of such a device is the Deltec CADD-PLUS.TM.5400 intravenous pump.
  • compositions of the present disclosure may be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration.
  • the suspension may be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents such as those mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension prepared in a nontoxic parenterally acceptable diluent or solvent.
  • sterile fixed oil can be conveniently used as the solvent or suspending medium. For this purpose, any blend of fixed oils can be used.
  • fatty acids are also prepared as injectables.
  • the compounds of the present disclosure may be administered in the form of suppositories for rectal administration.
  • These pharmaceutical compositions may be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and will therefore dissolve in the rectum to release the drug.
  • compositions of the present disclosure may be administered by adding water to prepare water-suspended dispersible powders and granules.
  • These pharmaceutical compositions may be prepared by mixing the active ingredient with a dispersing or wetting agent, a suspending agent, or one or more preservatives.
  • the dosage of a drug depends on a variety of factors, including, but not limited to, the activity of the specific compound used, the severity of the disease, the patient's age, the patient's weight, the patient's health condition, patient's behavior, patient's diet, administration time, administration method, excretion rate, drug combination, etc.; in addition, the optimal treatment method such as mode of treatment, daily dosage of compound or pharmaceutically acceptable salt Types can be verified based on traditional treatment regimens.
  • alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably from 1 to 12 (e.g. 1, 2, 3, 4, 5, 6 , 7, 8, 9, 10, 11 and 12) alkyl groups of carbon atoms (i.e. C 1-12 alkyl), more preferably an alkyl group having 1 to 6 carbon atoms (i.e. C 1-6 alkyl ).
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -Methylhexyl, 3-methylhexyl, 4-methylhe
  • the alkyl group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment.
  • the substituent is preferably selected from the group consisting of D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, One or more of cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • alkenyl refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein the alkyl group is as defined above, preferably having 2 to 12 (for example, 2, 3, 4, 5, 6, 7, 8 , 9, 10, 11 and 12) carbon atoms (i.e., C 2-12 alkenyl), more preferably alkenyl having 2 to 6 carbon atoms (i.e., C 2-6 alkenyl).
  • Non-limiting examples include: vinyl, propenyl, isopropenyl, butenyl, and the like.
  • Alkenyl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl
  • substituents are preferably selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl
  • alkynyl refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, where alkyl is as defined above. Preferably there are 2 to 12 (eg 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms (i.e. C 2-12 alkynyl), more preferably 2 to 6 Alkynyl group of carbon atoms (i.e. C 2-6 alkynyl group).
  • Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
  • Alkynyl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl
  • substituents are preferably selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
  • the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 14 (e.g., 3, 4, 5, 6 , 7, 8, 9, 10, 11, 12, 13 and 14) carbon atoms (i.e. 3 to 14 membered cycloalkyl), preferably containing 3 to 8 (e.g. 3, 4, 5, 6, 7 and 8 ) carbon atoms (i.e., 3 to 8-membered cycloalkyl), more preferably 3 to 6 carbon atoms (i.e., 3 to 6-membered cycloalkyl).
  • Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene base, cyclooctyl, etc.; polycyclic cycloalkyl includes spirocycloalkyl, fused cycloalkyl and bridged cycloalkyl.
  • spirocycloalkyl refers to a 5- to 20-membered polycyclic group with one carbon atom (called a spiro atom) shared between the single rings, which may contain one or more double bonds. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan (for example, 7, 8, 9 or 10 yuan). According to the number of shared spiro atoms between the rings, spirocycloalkyl groups are divided into single spirocycloalkyl groups or polyspirocycloalkyl groups (such as double spirocycloalkyl groups), preferably single spirocycloalkyl groups and double spirocycloalkyl groups. base.
  • spirocycloalkyl groups include:
  • fused cycloalkyl refers to an all-carbon polycyclic group of 5 to 20 members in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, one or more of which may contain one or more rings. Multiple double bonds. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan (for example, 7, 8, 9 or 10 yuan).
  • bicyclic or polycyclic fused cycloalkyl groups such as tricyclic or tetracyclic
  • bicyclic or tricyclic more preferably 3-membered/4-membered, 3-membered/5-membered, 3-membered/ 6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/6 yuan, 5 yuan/7 yuan , 6 yuan/3 yuan, 6 yuan/4 yuan, 6 yuan/5 yuan, 6 yuan/5 yuan, 6 yuan/6 yuan, 6 yuan/7 yuan or 7 yuan/6 yuan bicyclo
  • bridged cycloalkyl refers to an all-carbon polycyclic group of 5 to 20 members, any two rings sharing two carbon atoms that are not directly connected, and may contain one or more double bonds. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan (for example, 7, 8, 9 or 10 yuan). According to the number of constituent rings, it can be divided into bicyclic or polycyclic (such as tricyclic, tetracyclic) bridged cycloalkyl groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
  • bridged cycloalkyl groups include:
  • the cycloalkyl ring includes a cycloalkyl group (including a monocyclic ring, a spiro ring, a condensed ring and a bridged ring) as described above fused to an aryl, heteroaryl or heterocycloalkyl ring, where it is connected to the parent structure Rings taken together are cycloalkyl, non-limiting examples include etc; preferred
  • Cycloalkyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from halogen, alkyl, alkoxy, haloalkyl, haloalkyl One or more of oxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • alkoxy refers to -O-(alkyl), where alkyl is as defined above.
  • alkoxy include: methoxy, ethoxy, propoxy and butoxy.
  • the alkoxy group may be optionally substituted or unsubstituted. When substituted, the substituent is preferably selected from D atom, halogen, alkoxy group, haloalkyl group, haloalkoxy group, cycloalkyloxy group, heterocyclyloxy group radical, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic substituent, which contains 3 to 20 (for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e. 3 to 20 membered heterocyclyl), one or more of which are heteroatoms selected from nitrogen, oxygen and sulfur, so
  • the sulfur mentioned above may optionally be oxosubstituted (i.e., to form a sulfoxide or sulfone), but does not include the -O-O-, -O-S- or -S-S- ring moiety, and the remaining ring atoms are carbon.
  • 3 to 14 ring atoms
  • 1 to 4 e.g., 1, 2,
  • Non-limiting examples of monocyclic heterocyclyl groups include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholine base, homopiperazine base, etc.
  • Polycyclic heterocyclyl groups include spiroheterocyclyl groups, fused heterocyclyl groups and bridged heterocyclyl groups.
  • spiroheterocyclyl refers to a polycyclic heterocyclic group with 5 to 20 members, sharing one atom (called a spiro atom) between the single rings, in which one or more ring atoms are heterocyclic groups selected from nitrogen, oxygen and sulfur.
  • Atoms, the sulfur may optionally be oxo-substituted (ie, form sulfoxide or sulfone), and the remaining ring atoms are carbon. It may contain one or more double bonds.
  • it is 6 to 14 members (such as 6, 7, 8, 9, 10, 11, 12, 13 and 14 members) (i.e.
  • spiroheterocyclyl 6 to 14 membered spiroheterocyclyl), more preferably 7 to 10 members (such as 7, 8, 9 or 10 members) (i.e. 7 to 10 membered spiroheterocyclyl).
  • spiroheterocyclyl is divided into single spiroheterocyclyl or polyspiroheterocyclyl (such as bispiroheterocyclyl), preferably single spiroheterocyclyl and double spiroheterocyclyl. base.
  • spiroheterocyclyl include:
  • fused heterocyclyl refers to a polycyclic heterocyclic group with 5 to 20 members, each ring in the system shares an adjacent pair of atoms with other rings in the system, and one or more rings may contain one or more Double bonds, in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur, the sulfur may be optionally oxo-substituted (ie, forming sulfoxide or sulfone), and the remaining ring atoms are carbon.
  • it is 6 to 14 yuan (for example, 6, 7, 8, 9, 10, 11, 12, 13 and 14-membered) (ie, 6 to 14-membered fused heterocyclyl), more preferably 7 to 10-membered (eg, 7, 8, 9 or 10-membered) (ie, 7 to 10-membered fused heterocyclyl).
  • bicyclic or polycyclic such as tricyclic, tetracyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 3-membered/4-membered, 3-membered/5-membered, 3-membered/ 6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/6 yuan, 5 yuan/7 yuan , 6-membered/3-membered, 6-membered/4-membered, 6-membered/5-membered, 6-membered/6-membered, 6-membered/7-membered, 7-membered/5-membered or 7-membered/6-membered bicyclic fused heterocyclic group.
  • bridged heterocyclyl refers to a polycyclic heterocyclic group of 5 to 20 members, any two rings sharing two atoms that are not directly connected, which may contain one or more double bonds, one or more of the ring atoms is a heteroatom selected from nitrogen, oxygen and sulfur, the sulfur may be optionally oxo-substituted (ie, forming a sulfoxide or sulfone), and the remaining ring atoms are carbon.
  • it is 6 to 14 yuan (such as 6, 7, 8, 9, 10, 11, 12, 13 and 14 yuan) (i.e.
  • yuan bridged heterocyclyl 6 to 14 yuan bridged heterocyclyl), more preferably 7 to 10 yuan (such as 7, 8, 9 or 10 members) (i.e. 7 to 10 membered bridged heterocyclyl).
  • it can be divided into bicyclic or polycyclic (eg tricyclic, tetracyclic) bridged heterocyclyl groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
  • bridged heterocyclyl groups include:
  • the heterocyclyl ring includes the heterocyclyl (including monocyclic, spiroheterocyclic, fused heterocyclic and bridged heterocyclic) as described above fused to an aryl, heteroaryl or cycloalkyl ring, wherein with the parent
  • the rings linked together by the structure are heterocyclyl groups, non-limiting examples of which include:
  • Heterocyclyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from halogen, alkyl, alkoxy, haloalkyl, haloalkyl Oxygen, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, One or more of aryl and heteroaryl.
  • aryl refers to a 6 to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic is a ring that shares adjacent pairs of carbon atoms) group having a conjugated ⁇ electron system, preferably 6 to 10 members , such as phenyl and naphthyl.
  • the aryl ring includes an aryl ring as described above fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include :
  • Aryl groups may be substituted or unsubstituted, and when substituted, they may be substituted at any available point of attachment, and the substituents are preferably selected from the group consisting of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy One or more of radical, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • heteroaryl refers to a heteroaromatic system containing from 1 to 4 (eg, 1, 2, 3, and 4) heteroatoms, and from 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen.
  • the heteroaryl group is preferably 5 to 10 yuan (for example, 5, 6, 7, 8, 9 or 10 yuan) (i.e., 5 to 10 yuan heteroaryl), and further preferably 8 to 10 yuan (for example, 8, 9 or 10 yuan) ), more preferably 5- or 6-membered (i.e.
  • heteroaryl such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridyl Azinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc.
  • the heteroaryl ring includes a heteroaryl group fused to an aryl, heterocyclyl or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples of which include :
  • Heteroaryl groups may be substituted or unsubstituted, and when substituted, they may be substituted at any available point of attachment, and the substituents are preferably selected from the group consisting of halogen, alkyl, alkoxy, haloalkyl, haloalkyl One or more of oxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • cycloalkyl, heterocyclyl, aryl and heteroaryl include residues derived by removing one hydrogen atom from the parent ring atom, or removing two hydrogens from the same ring atom or two different ring atoms of the parent
  • residues from which the atoms are derived are "bivalent cycloalkyl", "bivalent heterocyclyl", "arylene” and "heteroaryl”.
  • amino protecting group is used to protect the amino group with an easily removable group in order to keep the amino group unchanged when other parts of the molecule react.
  • Non-limiting examples include (trimethylsilyl)ethoxymethyl (SEM), tetrahydropyranyl, tert-butoxycarbonyl (Boc), acetyl, benzyl, allyl, p-toluenesulfonate Acyl (Ts) and p-methoxybenzyl, etc.
  • SEM trimethylsilyl)ethoxymethyl
  • Boc tetrahydropyranyl
  • Boc tert-butoxycarbonyl
  • acetyl benzyl
  • allyl allyl
  • These groups may be optionally substituted with 1 to 3 substituents selected from halogen, alkoxy and nitro; the amino protecting group
  • hydroxyl protecting group refers to hydroxyl derivatives commonly used to block or protect hydroxyl groups while reactions proceed on other functional groups of the compound.
  • the hydroxyl protecting group is: triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl (TBS), tert-butyldiphenylsilyl, methyl , tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), formyl, acetyl, benzoyl and p-nitrogen benzoyl group, etc.; the hydroxyl protecting group is preferably MOM.
  • alkynyl protecting group refers to an easily removable group introduced on an alkynyl group in order to keep the active hydrogen in acetylene or terminal alkynes unchanged when other parts of the molecule react.
  • Non-limiting examples include: trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBS), triisopropylsilyl (TIPS), tert-butyl Dimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-Tetrahydropyranyl (THP), formyl, acetyl, benzoyl, p-nitrobenzoyl, etc.; the alkynyl protecting group is preferably TIPS.
  • cycloalkyloxy refers to cycloalkyl-O-, where cycloalkyl is as defined above.
  • heterocyclyloxy refers to heterocyclyl-O-, wherein heterocyclyl is as defined above.
  • aryloxy refers to aryl-O-, where aryl is as defined above.
  • heteroaryloxy refers to heteroaryl-O-, where heteroaryl is as defined above.
  • alkylthio refers to alkyl-S-, where alkyl is as defined above.
  • haloalkyl refers to an alkyl group substituted with one or more halogens, where alkyl is as defined above.
  • haloalkoxy refers to an alkoxy group substituted with one or more halogens, where alkoxy is as defined above.
  • deuterated alkyl refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
  • hydroxyalkyl refers to an alkyl group substituted with one or more hydroxyl groups, where alkyl is as defined above.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • hydroxy refers to -OH.
  • mercapto refers to -SH.
  • amino refers to -NH2 .
  • cyano refers to -CN.
  • nitro refers to -NO2 .
  • carboxylate refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O- or (cycloalkyl)C(O )O-, where alkyl and cycloalkyl are as defined above.
  • Boc refers to tert-butoxycarbonyl.
  • TIPS refers to triisopropylsilyl.
  • TBS refers to tert-butyldimethylsilyl.
  • the compounds of the present disclosure may contain all manner of rotamers and conformationally restricted states thereof. Also included are atropisomers, the term "atropisomer” being one in which rotation about a single bond in the molecule is hindered or greatly slowed down (due to steric interactions with other parts of the molecule and at both ends of the single bond). The resulting conformational stereoisomers (results of asymmetry of the substituents) have interconversions that are slow enough to allow separation and isolation under predetermined conditions.
  • certain compounds of the present disclosure may be in the form of a mixture of atropisomers (e.g., an equal proportion mixture, a mixture enriched for one atropisomer, etc.) or as a purified form of one atropisomer. exist.
  • the compounds and intermediates of the present disclosure may also exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure.
  • tautomer or "tautomeric form” refers to structural isomers of different energies that can interconvert via a low energy barrier.
  • proton tautomers include tautomers via proton migration, such as keto-enol and imine-enamine, lactam-lactam isomerizations .
  • proton migration such as keto-enol and imine-enamine, lactam-lactam isomerizations .
  • keto-enol equilibrium is shown below:
  • stereoisomer refers to isomers that have the same structure but different arrangements of atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers Isomers, atropisomers, conformational isomers and their mixtures (such as racemates, diastereoisomer mixtures). Additional asymmetric atoms may be present for substituents in the compounds of the present disclosure.
  • An isomer of a certain compound of the present disclosure can be prepared through asymmetric synthesis or derivatization with chiral auxiliaries, or when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), Diastereomeric salts are formed with appropriate optically active acids or bases, and then the diastereoisomers are resolved by conventional methods known in the art to obtain pure isomers. Furthermore, the separation of enantiomers and diastereomers is usually accomplished by chromatography.
  • the bond Indicates that the configuration is not specified, i.e. if there are chiral isomers in the chemical structure, the bond can be or both Two configurations.
  • the compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof.
  • isotopic derivative refers to a compound in which at least one atom is replaced by an atom with the same atomic number but a different atomic mass.
  • isotopes that may be incorporated into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, iodine, and the like, such as 2 H (deuterium, D), respectively.
  • deuterated drugs Compared with non-deuterated drugs, deuterated drugs have the advantages of reducing side effects, increasing drug stability, enhancing efficacy, and extending the biological half-life of the drug. All variations in the isotopic composition of the compounds of the present disclosure, whether radioactive or not, are included within the scope of the present disclosure.
  • Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom, where the replacement of deuterium can be partial or complete.
  • the replacement of partial deuterium means that at least one hydrogen is replaced by at least one deuterium.
  • C 1-6 alkyl optionally substituted by halogen or cyano group means that halogen or cyano group may but does not have to be present. This description includes the case where the alkyl group is substituted by halogen or cyano group and the alkyl group is not substituted by halogen. and the case of cyano substitution.
  • Substituted means that one or more hydrogen atoms in the group, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms, are independently substituted by a corresponding number of substituents.
  • a person skilled in the art will be able to determine possible or impossible substitutions without undue effort (either experimentally or theoretically).
  • an amino or hydroxyl group with a free hydrogen may be unstable when combined with a carbon atom with an unsaturated (eg, olefinic) bond.
  • “Pharmaceutical composition” means a mixture containing one or more compounds described herein, or a pharmaceutically acceptable salt or prodrug thereof, and other chemical components, together with other ingredients such as pharmaceutically acceptable carriers and excipients .
  • the purpose of pharmaceutical compositions is to facilitate administration to living organisms and facilitate the absorption of active ingredients to exert biological activities. sex.
  • “Pharmaceutically acceptable salts” refer to salts of compounds of the present disclosure, which may be selected from inorganic salts or organic salts. This type of salt is safe and effective when used in mammals, and has due biological activity.
  • the salts can be prepared separately, during the final isolation and purification of the compound, or by reacting a suitable group with a suitable base or acid.
  • Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia.
  • Acids commonly used to form pharmaceutically acceptable salts include inorganic acids as well as organic acids.
  • therapeutically effective amount refers to an amount of the drug or agent sufficient to achieve, or at least partially achieve, the desired effect.
  • the determination of the therapeutically effective amount varies from person to person, depends on the age and general condition of the recipient, and also depends on the specific active substance.
  • the appropriate therapeutically effective amount in an individual case can be determined by those skilled in the art based on routine experiments.
  • pharmaceutically acceptable refers to compounds, materials, compositions and/or dosage forms which, within the scope of reasonable medical judgment, are suitable for contact with patient tissue without undue toxicity, irritation, allergic reaction or other problems or complications, has a reasonable benefit/risk ratio, and is effective for the intended use.
  • the present disclosure provides a method for preparing a compound represented by general formula (IN) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (INA) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (IN) or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, Before, at the same time or after the deprotection reaction, it also includes the step of removing the protecting group on the R 3 group under acidic or alkaline conditions;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, ring C, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , R x1 , p, q, t1 and r are as defined in general formula (IN).
  • the present disclosure provides a method for preparing a compound represented by general formula (IN') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IN'A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (IN') or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains protection group, the step of removing the protecting group on the R 3 group is also included before, at the same time or after the deprotection reaction;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, ring C, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , R x1 , p, t1 and r are as shown in the general formula (IN' ) as defined in.
  • the present disclosure provides a method for preparing a compound represented by general formula (IM) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IMA) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (IM) or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, Before, at the same time or after the deprotection reaction, it also includes the step of removing the protecting group on the R 3 group under acidic or alkaline conditions;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, ring B, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , p, q, t and r are as in the general formula (IM) defined.
  • the present disclosure provides a method for preparing a compound represented by general formula (IM') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IM'A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (IM') or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains protection group, before, simultaneously or after the deprotection reaction, it also includes the step of removing the protecting group on the R 3 group under acidic or alkaline conditions;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, ring B, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6 , p, t and r are as in the general formula (IM') definition.
  • the present disclosure provides a method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IA) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (I) or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, Before, at the same time or after the deprotection reaction, it also includes the step of removing the protecting group on the R 3 group under acidic or alkaline conditions;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p, q and r are as defined in general formula (I).
  • the present disclosure provides a method for preparing a compound represented by general formula (I') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (I'A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (I') or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains protection group, before, simultaneously or after the deprotection reaction, it also includes the step of removing the protecting group on the R 3 group under acidic or alkaline conditions;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • a 0, 1, 2, 3 or 4;
  • G 2 is NH
  • G 0 , G 1 , T, ring A, Q, L, R 1 , R 3 , R 4a , R 5a , R 5b , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and r are as defined in general formula (I').
  • the present disclosure provides a method for preparing a compound represented by general formula (II') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (II'A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (II') or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains protection group, before, simultaneously or after the deprotection reaction, it also includes the step of removing the protecting group on the R 3 group under acidic or alkaline conditions;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • Ring A, Q, L, R G1a , R 1 , R 3 , R 4a , R 6a , R 6b, R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and q are as shown in the general formula ( II') defined in.
  • the present disclosure provides a method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IIA) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (II) or a pharmaceutically acceptable salt thereof; optionally, when the R 3 group contains a protecting group, Before, at the same time or after the deprotection reaction, it also includes the step of removing the protecting group on the R 3 group under acidic or alkaline conditions;
  • R is an amino protecting group; preferably Boc;
  • G 2 is NH
  • Ring A, Q, L, R 1 , R 3 , R 4a , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , p and q are as in the general formula (II) defined.
  • the present disclosure provides a method for preparing a compound represented by general formula (III') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (III'A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (III') or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • the present disclosure provides a method for preparing a compound represented by general formula (III'-1) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (III'-1A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (III'-1) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • the present disclosure provides a method for preparing a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IIIA) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (III) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • the present disclosure provides a method for preparing a compound represented by general formula (IVV') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IVV'A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (IVV') or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (IVV').
  • the present disclosure provides a method for preparing a compound represented by general formula (IV') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IV'A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (IV') or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in general formula (IV').
  • the present disclosure provides a method for preparing a compound represented by general formula (IV'-1) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (IV'-1A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (IV'-1) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (IV'-1).
  • the present disclosure provides a method for preparing a compound represented by general formula (VV') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (VV’A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (VV’) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (VV').
  • the present disclosure provides a method for preparing a compound represented by general formula (VV'-1) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (VV’-1A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (VV’-1) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings C, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx1 , t1 and p are as defined in the general formula (VV'-1).
  • the present disclosure provides a method for preparing a compound represented by general formula (V') or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (V’A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (V’) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (V').
  • the present disclosure provides a method for preparing a compound represented by general formula (V'-1) or a pharmaceutically acceptable salt thereof, which method includes:
  • the compound of general formula (V’-1A) or a salt thereof undergoes a deprotection reaction under acidic conditions to obtain a compound of general formula (V’-1) or a pharmaceutically acceptable salt thereof;
  • R is an amino protecting group; preferably Boc;
  • R y is a hydroxyl protecting group; preferably MOM
  • G 2 is NH
  • Rings B, Q, L, RG1a , R1 , R3a , R3b , R4a , R6 , Rx , t and p are as defined in the general formula (V'-1).
  • the reagents that provide acidic conditions in the above synthesis scheme include organic acids and inorganic acids.
  • the organic acids include but are not limited to trifluoroacetic acid, formic acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, Me 3 SiCl and TMSOTf;
  • the inorganic acids include but are not limited to hydrogen chloride, dioxane hydrochloride solution, hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid; preferably dioxane hydrochloride solution.
  • the reagents that provide alkaline conditions in the above synthesis scheme include organic bases and inorganic bases.
  • the organic bases include but are not limited to triethylamine, N,N-diisopropylethylamine, n-butyllithium, diisopropylethylamine, Lithium propylamide, potassium acetate, sodium tert-butoxide, potassium tert-butoxide, tetrabutylammonium fluoride, tetrabutylammonium fluoride solution in tetrahydrofuran or 1,8-diazabicycloundecane-7- Alkene
  • the inorganic bases include but are not limited to sodium hydride, potassium phosphate, sodium carbonate, sodium acetate, potassium acetate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, cesium fluoride and potassium hydroxide.
  • the terminal alkyne can be protected by TIPS, and the reagent for removing TIPS is preferably a tetrabutylammonium fluoride solution in tetrahydrofuran or cesium fluoride.
  • the reaction of the above steps is preferably carried out in a solvent.
  • the solvents used include but are not limited to: pyridine, glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, Ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromo Ethane and its mixtures.
  • the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS). NMR shift( ⁇ ) Given in units of 10 -6 (ppm). NMR is measured using Bruker AVANCE-400 nuclear magnetic instrument or Bruker AVANCE NEO 500M.
  • the measurement solvents are deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), and deuterated methanol (CD 3 OD).
  • the internal standard is tetramethylsilane (TMS).
  • MS was measured using Agilent 1200/1290 DAD-6110/6120 Quadrupole MS liquid mass spectrometer (manufacturer: Agilent, MS model: 6110/6120 Quadrupole MS). waters ACQuity UPLC-QD/SQD (manufacturer: waters, MS model: waters ACQuity Qda Detector/waters SQ Detector) THERMO Ultimate 3000-Q Exactive (manufacturer: THERMO, MS model: THERMO Q Exactive).
  • HPLC High performance liquid chromatography
  • High-performance liquid phase preparation uses Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP and Gilson GX-281 preparative chromatographs.
  • Chiral preparation uses Shimadzu LC-20AP preparative chromatograph.
  • CombiFlash rapid preparation instrument uses Combiflash Rf200 (TELEDYNE ISCO).
  • Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates.
  • the specifications of silica gel plates used in thin layer chromatography (TLC) are 0.15mm ⁇ 0.2mm.
  • the specifications used for thin layer chromatography separation and purification products are 0.4mm. ⁇ 0.5mm.
  • Silica gel column chromatography generally uses Yantai Huanghai Silica Gel 200 ⁇ 300 mesh silica gel as the carrier.
  • the average kinase inhibition rate and IC 50 value were measured using NovoStar microplate reader (BMG Company, Germany).
  • the known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc), Darui Chemicals and other companies.
  • Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a volume of about 1L.
  • the hydrogen atmosphere refers to the reaction bottle connected to a hydrogen balloon with a volume of about 1L.
  • the pressurized hydrogenation reaction uses Parr 3916EKX hydrogenator and Clear Blue QL-500 hydrogen generator or HC2-SS hydrogenator.
  • the hydrogenation reaction is usually evacuated, filled with hydrogen, and repeated three times.
  • the microwave reaction uses CEM Discover-S 908860 microwave reactor.
  • the solution refers to an aqueous solution.
  • the reaction temperature is room temperature, which is 20°C to 30°C.
  • the reaction progress in the embodiment is monitored by thin layer chromatography (TLC).
  • TLC thin layer chromatography
  • the developing agent used in the reaction, the column chromatography eluent system and the thin layer chromatography developing agent system used to purify the compound include: A: Dichloromethane/methanol system, B: n-hexane/ethyl acetate, the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
  • the crude compound 1d (835 mg, 1.77 mmol) was dissolved in 7M ammonia-methanol solution (10 mL), and the reaction was stirred for 1 hour. The reaction solution was concentrated under reduced pressure. Methyl tert-butyl ether (10 mL) was added to the residue, and stirred for 0.5 hours. After filtering and drying the filter cake, the crude title compound 1e (400 mg, yield: 89.9%) was obtained. The product was directly used in the next reaction without purification.
  • Dissolve compound 1i (7.5g, 30.7mmol) in 150mL methanol, add 10% palladium carbon catalyst (wet) (1.5g), replace with hydrogen three times, heat to 50°C and stir for 24 hours, the reaction solution is cooled to room temperature, and passed Filter through diatomaceous earth, wash the filter cake with methanol, and concentrate the filtrate under reduced pressure to obtain the crude title compound 1j (5.6g). The product is directly used in the next reaction without purification.
  • the crude compound 1r (130 mg, 162.9 ⁇ mol) was dissolved in acetonitrile (3 mL), and morpholine (28.4 mg, 325.8 ⁇ mol), anhydrous potassium carbonate (67.6 mg, 488.8 ⁇ mol), and sodium iodide (24.4 mg, 162.9 ⁇ mol) were added. , heated to 80°C and stirred for 2 hours. The reaction solution was cooled to room temperature, diluted with water (20 mL), extracted with ethyl acetate (10 mL ⁇ 2), the organic phases were combined, and concentrated under reduced pressure to obtain the crude title compound 1s (128 mg). , the product was directly used in the next reaction without purification.
  • the crude compound 1s (128 mg, 162.2 ⁇ mol) was dissolved in ethyl acetate (3 mL), 2 mL of 4M dioxane hydrochloride solution was added under ice bath, and the temperature was maintained for 4 hours.
  • the reaction solution was concentrated under reduced pressure, and the residue was treated with high efficiency Liquid chromatography (Waters-2545, column: YMC Triart-Exrs C18, 30*150mm, 5 ⁇ m; mobile phase: aqueous phase (10mmol/L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 30%-45% , flow rate: 30 mL/min), the title compound 1 (35 mg, yield 33.4%) was purified.
  • the crude compound 1r (150 mg, 188 ⁇ mol) was dissolved in acetonitrile (3 mL), and (1R, 4R)-2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride (51 mg, 376.1 ⁇ mol, Shanghai Leyan), anhydrous potassium carbonate (100 mg, 723.5 ⁇ mol), and sodium iodide (28 mg, 187 ⁇ mol), heated to 80°C and stirred for 2 hours.
  • the reaction solution was cooled to room temperature, diluted with water (20 mL), and diluted with ethyl acetate. (10 mL ⁇ 2) extraction, combine the organic phases, and concentrate under reduced pressure to obtain the crude title compound 3a (150 mg).
  • the product was directly used in the next reaction without purification.
  • the crude compound 1r (100 mg, 125 ⁇ mol) was dissolved in acetonitrile (3 mL), and 4-oxa-7-azaspiro[2.5]octane hydrochloride (40 mg, 267 ⁇ mol, Shanghai Bide) and anhydrous potassium carbonate ( 70 mg, 506 ⁇ mol) and sodium iodide (20 mg, 133 ⁇ mol), heated to 80°C and stirred for 2 hours.
  • the reaction solution was cooled to room temperature, diluted with water (20 mL), extracted with ethyl acetate (10 mL ⁇ 2), and the organic phases were combined. , concentrated under reduced pressure to obtain the crude title compound 4a (102 mg).
  • the product was directly used in the next reaction without purification.
  • Example 6 The synthetic route in Example 6 was adopted, and the raw material compound 4-(difluoromethylylidene)piperidine hydrochloride in the fifth step was replaced with compound 7d to obtain the title compound 7 (3 mg, yield: 12%).
  • Example 6 The synthetic route in Example 6 was adopted, and the raw material 4-(difluoromethylylidene)piperidine hydrochloride in the fifth step was replaced with 1-(methylaminoylidene)-1 ⁇ 6 -thiomorpholine-1- Oxide (prepared using the method disclosed in Intermediate S on page 239 of the specification in the patent application "WO2022/23772,2022,A1") gave the title compound 9 (5 mg, yield: 6%).
  • Example 5 The synthetic route in Example 5 was adopted, and the raw material compound 5b in the fifth step was replaced with (2-(difluoromethylylidene)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (adopting the patent application "WO2022247757 "Prepared by the method disclosed in Example 11 on page 54 of the specification), the title compound 18 (50 mg, yield: 24.2%) (diastereoisomer mixture) was obtained.
  • Chiral HPLC analysis method of isomer mixture retention times are 10.274min and 14.616min respectively (chromatographic column: CHIRALPAK IG, 150*4.6mm, 5 ⁇ m; mobile phase A: 90% ethanol (containing 0.1% diethylamine) + 10 % Dichloromethane, mobile phase B: n-hexane, gradient ratio: A:B: 30:70, flow rate: 1.0mL/min).
  • Single configuration compound (shorter retention time): 10.274 min (10 mg, yield: 33%).
  • HPLC analysis retention time 1.45 minutes, purity: 90% (Column: ACQUITY C18, 1.7 ⁇ m, 2.1*50mm; mobile phase: water (10mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%).
  • HPLC analysis retention time 1.45 minutes, purity: 90% (Column: ACQUITY C18, 1.7 ⁇ m, 2.1*50mm; mobile phase: water (10mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

本公开涉及稠环类化合物、其制备方法及其在医药上的应用。具体而言，本公开涉及一种通式(IN)所示的稠环类化合物、其制备方法及含有该类化合物的药物组合物以及其作为治疗剂的用途，特别是其在制备用于抑制KRAS G12D的药物中的用途。其中通式(IN)中各基团如说明书中所定义。

Description

稠环类化合物、其制备方法及其在医药上的应用 技术领域
本公开属于医药领域，涉及一种稠环类化合物、其制备方法及其在医药上的应用。特别地，本公开涉及通式(IN)所示的稠环类化合物、其制备方法及含有该类化合物的药物组合物，以及其在制备用于抑制KRAS G12D的药物中的用途。
背景技术
RAS是在肿瘤中突变率最高的致癌基因之一，约30％的人类恶性肿瘤与RAS基因的突变有关。RAS家族包括KRAS、NRAS和HRAS，其中KRAS突变最为常见，约占85％。KRAS突变常见于实体瘤，在人类三大致命性癌症—肺癌(17％)、结直肠癌(33％)和胰腺癌(61％)中均存在高频突变。在KRAS的基因突变中，97％是第12号或者第13号氨基酸残基发生了突变，其中G12D是一个重要突变。对欧美人群的数据分析显示：在胰腺癌、结直肠癌及非小细胞肺癌中，G12D突变分别占病人的36％、12％和4％。
KRAS被激活以后，通过以RAF-MEK-ERK、PI3K-AKT-mTOR及TIAM1-RAc为代表的众多下游信号通路，调控细胞增殖、存活、迁移及代谢等多个方面的功能。KRAS基因突变后，蛋白持续处于活化状态，导致下游信号通路持续激活而促进肿瘤发生。
由于KRAS蛋白表面缺乏传统意义上的小分子结合位点，并与鸟苷酸有着超高亲和力而极难被抑制，长久以来被认为是不可成药的药物靶点。但基于KRAS异常激活在癌症进展中的重要性和普遍性，KRAS一直并仍然是药物开发非常关注的靶点。目前除了KRAS G12C抑制剂以外，仍缺乏对其他突变有效的KRAS抑制剂，使得大部分KRAS突变的病人依然无药可治。G12D，作为一个在多种肿瘤中广泛高表达的突变体，开发针对它的抑制剂有着重要的临床意义。
目前已公开的相关专利申请有WO2023030385A1、WO2023274383A1、WO2021041671A1、WO2020146613A1、WO2017172979A1、WO2020238791A1和WO2021000885A1等。
发明内容
本公开的目的在于提供一种通式(IN)所示的化合物或其可药用的盐：
其中：
环C为杂环基；
Rx1为氢原子或Rx；优选地，Rx1为Rx；
Rx选自＝N-O-R61、＝CR62R63和＝N-R64；
G0选自O、S、S(O)、S(O)2、CRG0aRG0b和NRG0c；
G1选自CRG1aRG1b、CRG1aRG1bCRG1cRG1d、C＝O和C(O)CRG1aRG1b；
G2为NRd；
T为化学键或选自CRaRb、NRT和O；
Q为N或CR2a；
环A为芳基或杂芳基；
L选自单键、O和NRe；
Ra、Rb、RG0a、RG0b、RG1a、RG1b、RG1c和RG1d相同或不同，且各自独立地选自氢原子、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基；或者，RG1a、RG1b与相连的碳原子一起形成环烷基；或者，RG1c、RG1d与相连的碳原子一起形成环烷基；
各个R1相同或不同，且各自独立地选自卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)u-NRfRg、羟基和羟烷基；
R2a和R4a相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)v-NRhRi、羟基、羟烷基和环烷基；
各个R3相同或不同，且各自独立地选自卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)w-NRjRk、-(CH2)w1-(O)x1-C(O)NRj1Rk1、-(CH2)w2-(O)x2-C(O)ORj2、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；
各个R6相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)y-NRmRn、-(CH2)y1-(O)z1-C(O)NRm1Rn1、-(CH2)y2-(O)z2-C(O)ORm2、＝N-O-R61、＝CR62R63、＝N-R64、硝基、羟基、羟烷基、氧代基、环烷基、杂环基、芳基和杂芳基；
R61、R62、R63和R64相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基和环烷基；
R5a和R5b相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氰基、羟基和羟烷基；或者
R5a、R5b与所连的碳原子一起形成环烷基或杂环基，所述的环烷基或杂环基各自独立地任选被选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、氨基、羟基和羟烷基中的一个或多个相同或不同的取代基取代；
RG0c、RT、Rd、Re、Rf、Rg、Rh、Ri、Rj、Rk、Rj1、Rk1、Rj2、Rm、Rn、Rm1、Rn1和Rm2相同或不同，且各自独立地选自氢原子、烷基、烯基、炔基、卤代烷基、羟烷基、环烷基、杂环基、芳基和杂芳基；
u、v、w、w1、w2、y、y1和y2相同或不同，且各自独立地选自0、1、2和3；
x1、x2、z1和z2相同或不同，且各自独立地选自0或1；
r为0、1、2或3；
p为0、1、2、3、4或5；
q为0、1、2、3、4或5；且
t1为0、1、2、3、4或5。
在本公开一些实施方案中，所述的通式(IN)所示的化合物或其可药用的盐，其为通式(IN’)所示的化合物或其可药用的盐：
其中
a为0、1、2、3或4；
G0、G1、G2、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、t1和r如通式(IN)中所定义。
本公开提供一种通式(IM)所示的化合物或其可药用的盐：
其中：
环B为杂环基；
G0选自O、S、S(O)、S(O)2、CRG0aRG0b和NRG0c；
G1选自CRG1aRG1b、CRG1aRG1bCRG1cRG1d、C＝O和C(O)CRG1aRG1b；
G2为NRd；
T为化学键或选自CRaRb、NRT和O；
Q为N或CR2a；
环A为芳基或杂芳基；
L选自单键、O和NRe；
Ra、Rb、RG0a、RG0b、RG1a、RG1b、RG1c和RG1d相同或不同，且各自独立地选自氢原子、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基；或者，RG1a、RG1b与相连的碳原子一起形成环烷基；或者，RG1c、RG1d与相连的碳原子一起形成环烷基；
各个R1相同或不同，且各自独立地选自卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)u-NRfRg、羟基和羟烷基；
R2a和R4a相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)v-NRhRi、羟基、羟烷基和环烷基；
各个R3相同或不同，且各自独立地选自卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)w-NRjRk、-(CH2)w1-(O)x1-C(O)NRj1Rk1、-(CH2)w2-(O)x2-C(O)ORj2、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；
各个R6相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)y-NRmRn、-(CH2)y1-(O)z1-C(O)NRm1Rn1、-(CH2)y2-(O)z2-C(O)ORm2、＝N-O-R61、＝CR62R63、＝N-R64、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；
R61、R62、R63和R64相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基和环烷基；
R5a和R5b相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氰基、羟基和羟烷基；或者
R5a、R5b与所连的碳原子一起形成环烷基或杂环基，所述的环烷基或杂环基各自独立地任选被选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、氨基、羟基和羟烷基中的一个或多个相同或不同的取代基取代；
RG0c、RT、Rd、Re、Rf、Rg、Rh、Ri、Rj、Rk、Rj1、Rk1、Rj2、Rm、Rn、Rm1、Rn1和Rm2相同或不同，且各自独立地选自氢原子、烷基、烯基、炔基、卤代烷基、羟烷基、环烷基、杂环基、芳基和杂芳基；
u、v、w、w1、w2、y、y1和y2相同或不同，且各自独立地选自0、1、2和 3；
x1、x2、z1和z2相同或不同，且各自独立地选自0或1；
r为0、1、2或3；
p为0、1、2、3、4或5；且
q为0、1、2、3、4或5；且
t为0、1、2、3、4或5。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)所示的化合物或其可药用的盐，其为通式(IM’)所示的化合物或其可药用的盐：
其中
a为0、1、2、3或4；
G0、G1、G2、T、环A、环B、Q、L、R1、R3、R4a、R5a、R5b、R6、p、t和r如通式(IM)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IM)所示的化合物或其可药用的盐，其为通式(I)所示的化合物或其可药用的盐：
其中：
G0选自O、S、S(O)、S(O)2、CRG0aRG0b和NRG0c；
G1选自CRG1aRG1b、CRG1aRG1bCRG1cRG1d、C＝O和C(O)CRG1aRG1b；
G2为NRd；
T为化学键或选自CRaRb、NRT和O；
Q为N或CR2a；
环A为芳基或杂芳基；
L选自单键、O和NRe；
Ra、Rb、RG0a、RG0b、RG1a、RG1b、RG1c和RG1d相同或不同，且各自独立地选自氢原子、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基；或者，RG1a、RG1b与相连的碳原子一起形成环烷基；或者，RG1c、RG1d与相连的碳原子一起形成环烷基；
各个R1相同或不同，且各自独立地选自卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)u-NRfRg、羟基和羟烷基；
R2a和R4a相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)v-NRhRi、羟基、羟烷基和环烷基；
各个R3相同或不同，且各自独立地选自卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)w-NRjRk、-(CH2)w1-(O)x1-C(O)NRj1Rk1、-(CH2)w2-(O)x2-C(O)ORj2、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；
R6a、R6b、R6c、R6d、R6e、R6f、R6g和R6h相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)y-NRmRn、-(CH2)y1-(O)z1-C(O)NRm1Rn1、-(CH2)y2-(O)z2-C(O)ORm2、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；或者
R6a和R6e与所连的碳原子、R6a和R6g与所连的碳原子、R6c和R6e与所连的碳原子或R6c和R6g与所连的碳原子一起形成桥，所述的桥具有1、2、3或4个CH2，其中任意一个CH2可任选被O、S、NH替代，所述的桥任选被选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、氨基、羟基和羟烷基中的一个或多个相同或不同的取代基取代；或者
R6a和R6b与所连的碳原子、R6c和R6d与所连的碳原子、R6e和R6f与所连的碳原子或R6g和R6h与所连的碳原子一起形成环烷基或杂环基，所述的环烷基或杂环基任选被选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、氨基、羟基和羟烷基中的一个或多个相同或不同的取代基取代；
R5a和R5b相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氰基、羟基和羟烷基；或者
R5a、R5b与所连的碳原子一起形成环烷基或杂环基，所述的环烷基或杂环基各自独立地任选被选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、氨基、羟基和羟烷基中的一个或多个相同或不同的取代基取代；
RG0c、RT、Rd、Re、Rf、Rg、Rh、Ri、Rj、Rk、Rj1、Rk1、Rj2、Rm、Rn、Rm1、Rn1和Rm2相同或不同，且各自独立地选自氢原子、烷基、烯基、炔基、卤代烷基、羟烷基、环烷基、杂环基、芳基和杂芳基；
u、v、w、w1、w2、y、y1和y2相同或不同，且各自独立地选自0、1、2和3；
x1、x2、z1和z2相同或不同，且各自独立地选自0或1；
r为0、1、2或3；
p为0、1、2、3、4或5；且
q为0、1、2、3、4或5。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)所示的化合物或其可药用的盐，其为通式(I’)所示的化合物或其可药用的盐：
其中
a为0、1、2、3或4；
G0、G1、G2、T、环A、Q、L、R1、R3、R4a、R5a、R5b、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和r如通式(I)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中选自 优选为 进一步优选为G0、G1、G2、R1和p如通式(I)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中G0选自O、CRG0aRG0b和NRG0c，RG0a和RG0b相同或不同，且各自独立地选自氢原子、卤素、C1-6烷基和C1-6卤代烷基，RG0c为氢原子或C1-6烷基；优选地，G0选自O、CH2和NH；进一步优选地，G0为O。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中G1为CRG1aRG1b、CRG1aRG1bCRG1cRG1d或C＝O， RG1a、RG1b、RG1c和RG1d相同或不同，且各自独立地选自氢原子、卤素、C1-6烷基和C1-6卤代烷基；优选地，G1为CH2或C＝O；进一步优选地，G1为CH2。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中G1为CRG1aH，RG1a如通式(IN)中所定义；优选地，G1为CRG1aH，RG1a选自氢原子、卤素、C1-6烷基和C1-6卤代烷基；进一步优选地，G1为CRG1aH，RG1a为氢原子或C1-6烷基；再优选地，G1为CRG1aH，RG1a为C1-6烷基；更优选地，G1为CRG1aH，RG1a为甲基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中-G0-G1-选自-O-CH2-、-NH-C(O)-、-NH-CH2-、-CH2-CH2-和-O-CH2-CH2-；优选为-O-CH2-或-NH-C(O)-；进一步优选为-O-CH2-；在一些实施方案中，-G0-G1-为-O-CH(CH3)-。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中T为化学键。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中R5a和R5b相同或不同，且各自独立地选自氢原子、卤素、C1-6烷基、C1-6卤代烷基、羟基和C1-6羟烷基，或者R5a、R5b与所连的碳原子一起形成3至8元环烷基；优选地，R5a和R5b为氢原子，或者R5a、R5b与所连的碳原子一起形成3至6元环烷基；更优选地，R5a和R5b为氢原子，或者R5a、R5b与所连的碳原子一起形成环丙基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中r为1或3。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)或(I’)所示的化合物或其可药用的盐，其中为-CH2-或优选为
在本公开一些实施方案中，所述的通式(IN)、(IM)、(I)所示的化合物或其可药用的盐，其为通式(II’)所示的化合物或其可药用的盐：
其中
环A、G2、Q、L、RG1a、R1、R3、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和q如通式(I)中所定义；优选地，RG1a为C1-6烷基。
在本公开一些实施方案中，所述的通式(IN)、(IM)、(I)或(II’)所示的化合物或其可药用的盐，其为通式(II)所示的化合物或其可药用的盐：
其中
环A、G2、Q、L、R1、R3、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和q如通式(I)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(IVV’)所示的化合物或其可药用的盐，其为通式(III’)所示的化合物或其可药用的盐：
其中
R3a和R3b相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、羟基、羟烷基、环烷基和杂环基；
G2、Q、L、RG1a、R1、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(I)中所定义；优选地，RG1a为C1-6烷基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(IVV’)所示的化合物或其可药用的盐，其为通式(III)所示的化合物或其可药用的盐：
其中
R3a和R3b相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、羟基、羟烷基、环烷基和杂环基；
G2、Q、L、R1、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(I)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IN’)所示的化合物或其可药用的盐，其为通式(IVV’)所示的化合物或其可药用的盐：
其中
R3a和R3b相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、羟基、羟烷基、环烷基和杂环基；
环C、G2、Q、L、RG1a、R1、R4a、R6、Rx1、t1和p如通式(IN)中所定义；优选地，RG1a为C1-6烷基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(IVV’)所示的化合物或其可药用的盐，其为通式(IV’)或(VV’)所示的化合物或其可药用的盐：
其中
Rx选自＝N-O-R61、＝CR62R63和＝N-R64；
R61、R62、R63和R64相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基和环烷基；
t为0、1、2、3或4；
R3a和R3b相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、羟基、羟烷基、环烷基和杂环基；
环B为杂环基；
Rx1、t1、环C、G2、Q、L、RG1a、R1、R4a、R6和p如通式(IN)中所定义；优选地，RG1a为C1-6烷基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(IVV’)所示的化合物或其可药用的盐，其为通式(IV’)所示的化合物或其可药用的盐：
其中
Rx选自＝N-O-R61、＝CR62R63和＝N-R64；
R61、R62、R63和R64相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基和环烷基；
t为0、1、2、3或4；
R3a和R3b相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、羟基、羟烷基、环烷基和杂环基；
环B、G2、Q、L、RG1a、R1、R4a、R6和p如通式(IM)中所定义；优选地，RG1a为C1-6烷基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)所示的化合物或其可药用的盐，其为通式(VV’)所示的化合物或其可药用的盐：
其中
R3a和R3b相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、羟基、羟烷基、环烷基和杂环基；
环C、G2、Q、L、RG1a、R1、R4a、R6、Rx1、t1和p如通式(IN)中所定义；优选地，RG1a为C1-6烷基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(VV’)所示的化合物或其可药用的盐，其为通式(V’)所示的化合物或其可药用的盐：
其中
Rx选自＝N-O-R61、＝CR62R63和＝N-R64；
R61、R62、R63和R64相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基和环烷基；
t为0、1、2、3或4；
R3a和R3b相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、羟基、羟烷基、环烷基和杂环基；
环B、G2、Q、L、RG1a、R1、R4a、R6和p如通式(IM)中所定义；优选地，RG1a为C1-6烷基。
在本公开一些实施方案中，所述的通式(II)或(III)所示的化合物或其可药用的盐，其中选自 优选为进一步优选为G2、R1和p如通式(I)中所定义。
在本公开一些实施方案中，所述的通式(II’)、(III’)、(IV’)、(V’)、(IVV’)、(VV’)所示的化合物或其可药用的盐，其中选自 优选选自更优选为本段中，RG1a选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基，G2、R1和p如通式(I)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(III’)、(IV’)、(IVV’)所示的化合物或其可药用的盐，其为通式(III’-1)所示的化合物或其可药用的盐：
其中：
RG1a选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基；优选地，RG1a为C1-6烷基；
G2、Q、L、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III’)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(IV’)、(IVV’)所示的化合物或其可药用的盐，其为通式(IV’-1)所示的化合物或其可药用的盐：
其中
RG1a选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基；优选地，RG1a为C1-6烷基；
环B、G2、Q、L、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(IV’)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(VV’)所示的化合物或其可药用的盐，其为通式(VV’-1)所示的化合物或其可药用的盐：
其中
RG1a选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基；优选地，RG1a为C1-6烷基；
环C、G2、Q、L、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(VV’)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(V’)、(VV’)所示的化合物或其可药用的盐，其为通式(V’-1)所示的化合物或其可药用的盐：
其中
RG1a选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基；优选地，RG1a为C1-6烷基；
G2、Q、L、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(V’)中所定义。
在本公开一些实施方案中，所述的通式(IM)、(IM’)、(IV’)、(IV’-1)、(V’)、(V’-1)所示的化合物或其可药用的盐，其中环B为3至8元杂环基；优选地，环B选自吗啉基、四氢吡咯基、哌啶基、 进一步优选地，环B选自哌啶基、四氢吡咯基、更优选地，环B选自哌啶基、四氢吡咯基、
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中环C为3至8元杂环基；优选地，环C选自氮杂环丁烷基、吗啉基、 四氢吡咯基、哌啶基、
在本公开一些实施方案中，所述的通式(IM)、(IM’)所示的化合物或其可药用的盐，其中选自 R61、R62、R63和R64如通式(IV’)中所定义；优选选自
在本公开一些实施方案中，所述的通式(IM)、(IM’)所示的化合物或其可药用的盐，其中选自 R61、R62、R63和R64如通式(IV’)中所定义；优选选自 更优选选自
在本公开一些实施方案中，所述的通式(IM)、(IM’)所示的化合物或其可药用的盐，其中选自 优选地，选自 更优选地，为
在本公开一些实施方案中，所述的通式(IM)、(IM’)所示的化合物或其可药用的盐，其中为R62和R63相同或不同，且各自独立地为氢原子或卤素；在一些实施方案中，为R62和R63均为卤素；在一些实施方案中，为R62为卤素，R63为氢原子。
在本公开一些实施方案中，所述的通式(IV’)、(IV’-1)、(V’)、(V’-1)所示的化合物或其可药用的盐，其中选自 R61、R62、R63和R64如通式(IV’)中所定义；优选选自 R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基；更优选选自
在本公开一些实施方案中，所述的通式(IV’)、(IV’-1)、(V’)、(V’-1)所示的化合物或其可药用的盐，其中选自 R61、R62、R63和R64如通式(IV’)中所定义；优选选自 R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基；更优选选自 进一步优选选自
在本公开一些实施方案中，所述的通式(IV’)、(IV’-1)、(V’)、(V’-1)所示的化合物或其可药用的盐，其中选自 优选选自 更优选地，为
在本公开一些实施方案中，所述的通式(IV’)、(IV’-1)、(V’)、(V’-1)所示的化合物或其可药用的盐，其中为R62和R63相同或不同，且各自独立地为氢原子或卤素；在一些实施方案中，为 R62和R63均为卤素；在一些实施方案中，为R62为卤素，R63为氢原子。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中选自 R61、R62、R63和R64如通式(IN)中所定义；优选选自 R61为C1-6烷基，R62和R63相同或不同，且各自 独立地为氢原子或卤素，R64为氢原子或C1-6烷基；进一步优选选自 更优选选自
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IVV’)所示的化合物或其可药用的盐，其中选自 R61、R62、R63和R64如通式(IN) 中所定义；优选选自 R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基；进一步优选选自 再优选选自 更优选选自 更优选地， 为
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IVV’)所示的化合物或其可药用的盐，其中为R62和R63相同或不同，且各自独立地为氢原子或卤素；在一些实施方案中，为R62和R63均为卤素；在一些实施方案中，为R62为卤素，R63为氢原子。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中为R62和R63如通式(IN)中所定义；优选为R62和R63相同或不同，且各自独立地为氢原子或卤素；更优选选自
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中t1为0或1；优选地，t1为0。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，各个R6相同或不同，且各自独立地选自＝N-O-R61、＝CR62R63、＝N-R64和氧代基，R61、R62、R63和R64如通式(IN)中所定义；优选地，各个R6相同或不同，且各自独立地选自＝N-O-R61、＝CR62R63、＝N-R64和氧代基，R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢 原子或C1-6烷基；更优选地，各个R6相同或不同，且各自独立地为＝CR62R63或氧代基，R62和R63相同或不同，且各自独立地为氢原子或卤素。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中R61为氢原子或C1-6烷基；优选地，R61为C1-6烷基；更优选地，R61为甲基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中R62和R63相同或不同，且各自独立地为氢原子或卤素；优选地，R62和R63相同或不同，且各自独立地为氢原子或F。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中R64为氢原子或C1-6烷基；优选地，R64为氢原子或甲基。
在本公开一些实施方案中，所述的通式(I)、(I’)、(II’)、(II)、(III’)、(III’-1)或(III)所示的化合物或其可药用的盐，其中选自 优选选自
在本公开一些实施方案中，所述的通式(I)、(I’)、(II’)、(II)、(III’)、(III’-1)或(III)所示的化合物或其可药用的盐，其中选自 优选选自 更优选为
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(III’)、(IV’)、(V’)、(IVV’)、(VV’)所示的化合物或其可药用的盐，其中RG1a 选自氢原子、卤素、C1-6烷基和C1-6卤代烷基；优选地，RG1a为氢原子或C1-6烷基；进一步优选地，RG1a为C1-6烷基；更优选地，RG1a为甲基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(III’)、(III’-1)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中RG1a选自卤素、C1-6烷基和C1-6卤代烷基；优选地，RG1a为C1-6烷基；更优选地，RG1a为甲基。
在本公开一些实施方案中，所述的通式(I)、(I’)、(II’)、(II)、(III’)、(III’-1)或(III)所示的化合物或其可药用的盐，其中R6c和R6g与所连的碳原子一起形成桥，所述的桥除桥头碳原子外还具有1、2、3或4个CH2；优选地，R6c和R6g与所连的碳原子一起形成桥，所述的桥除桥头碳原子外还具有1个CH2。
在本公开一些实施方案中，所述的通式(I)、(I’)、(II’)、(II)、(III’)、(III’-1)或(III)所示的化合物或其可药用的盐，其中R6a和R6b均为氢原子，或者R6a和R6b与所连的碳原子一起形成3至6元环烷基；优选地，R6a和R6b均为氢原子，或者R6a和R6b与所连的碳原子一起形成环丙基。
在本公开一些实施方案中，所述的通式(I)、(I’)、(II’)、(II)、(III’)、(III’-1)或(III)所示的化合物或其可药用的盐，其中R6c和R6d均为氢原子，或者R6c和R6d与所连的碳原子一起形成3至6元环烷基；优选地，R6c和R6d均为氢原子，或者R6c和R6d与所连的碳原子一起形成环丙基。
在本公开一些实施方案中，所述的通式(I)、(I’)、(II’)、(II)、(III’)、(III’-1)或(III)所示的化合物或其可药用的盐，其中R6e和R6f均为氢原子。
在本公开一些实施方案中，所述的通式(I)、(I’)、(II’)、(II)、(III’)、(III’-1)或(III)所示的化合物或其可药用的盐，其中R6g和R6h均为氢原子。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中Q为N或CH；优选为N。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中R2a选自氢原子、卤素、C1-6烷基和C1-6卤代烷基；优选地，R2a为氢原子或C1-6烷基；更优选地，R2a为氢原子。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)或(II)所示的化合物或其可药用的盐，其中环A为6至10元芳基或5至10元杂芳基；优选地，环A选自萘基、苯基、吡啶基、苯并噻吩基、苯并噻唑基和苯并吡唑基；再优选地，环A选自萘基、苯基和苯并噻吩基；进一步优选地，环A为苯基或萘基；更优选为萘基。
在本公开一些实施方案中，所述的通式(IN)、(IM)、(I)、(II’)、(II)所示的化合 物或其可药用的盐，其中选自 q1为0、1、2、3或4，R3如通式(IN)中所定义；优选地，选自 q1为2或3，R3相同或不同，且各自独立地选自卤素、C1-6烷基、C1-6卤代烷基和氰基；进一步优选地，选自 q1为2或3，R3相同或不同，且各自独立地选自卤素、C1-6烷基、C1-6卤代烷基和氰基；在一些实施方 案中，选自 在一些实施方案中，选自 在一些实施方案中，选自 在一些实施例方案中，选自 在一些实施方案中，选自
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、 (II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中R4a选自氢原子、卤素、C1-6烷基和C1-6卤代烷基；优选为氢原子或卤素；进一步优选为卤素；更优选为F。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中Rd为氢原子或C1-6烷基；优选地，Rd为氢原子。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中G2为NH。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中L选自CH2、NH和O；优选为O。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中Re为氢原子或C1-6烷基；优选地，Re为氢原子。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中各个R1相同或不同，且各自独立地选自卤素、C1-6烷基、C1-6卤代烷基、氰基、氨基、-(CH2)u-NRfRg、羟基和C1-6羟烷基，Rf和Rg相同或不同，且各自独立地为氢原子或C1-6烷基，u为0或1；优选地，各个R1相同或不同，且各自独立地选自卤素、C1-6烷基和C1-6卤代烷基。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中p为0或1，优选为0。
在本公开一些实施方案中，所述的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)或(II)所示的化合物或其可药用的盐，其中各个R3相同或不同，且各自独立地选自卤素、C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C1-6卤代烷基、C1-6卤代烷氧基、氰基、氨基、-(CH2)w-NRjRk、羟基和C1-6羟烷基，Rj和Rk相同或不同，且各自独立地为氢原子或C1-6烷基，w为0或1；优选地，各个R3相同或不同，且各自独立地选自卤素、C1-6烷基、C2-6炔基、C1-6卤代烷基、羟基、-O-C(O)NHC1-6烷基、氨基、氰基、C1-6羟烷基和3至8元环烷基；再优选地，R3相同或不同，且各自独立地选自卤素、C1-6烷基、C2-6炔基、C1-6卤代烷基、羟基、C1-6羟烷基和3至8元环烷基；进一步优选地，各个R3相同或不同，且各自独立地选自卤素、C1-6烷基、C2-6炔基、C1-6卤代烷基、羟基和环丙基；更进一步优选地，各个R3相同或 不同，且各自独立地选自卤素、C1-6烷基和羟基；最优选地，各个R3相同或不同，且各自独立地选自F、乙基和羟基；在一些实施方案中，各个R3相同或不同，且各自独立地选自卤素、C1-6烷基、C1-6卤代烷基、羟基、-O-C(O)NHC1-6烷基、氨基和氰基；在一些实施方案中，各个R3相同或不同，且各自独立地选自卤素、C1-6烷基、C1-6卤代烷基和氰基。
在本公开一些实施方案中，所述的通式(IN)、(IM)、(I)、(II’)或(II)所示的化合物或其可药用的盐，其中q为2、3或4，优选q为2或3，更优选为3。
在本公开一些实施方案中，所述的通式(IN)、(IM)、(I)、(II’)、(II)所示的化合物或其可药用的盐，其中q1为2或3，优选为2。
在本公开一些实施方案中，所述的通式(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中R3a选自氢原子、卤素、C1-6烷基、C2-6炔基、C1-6卤代烷基、C1-6羟烷基和3至8元环烷基；优选地，R3a选自氢原子、卤素和C1-6烷基；进一步优选地，R3a为卤素；更优选地，R3a为F。
在本公开一些实施方案中，所述的通式(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中R3b选自氢原子、卤素、C1-6烷基、C2-6炔基、C1-6卤代烷基、C1-6羟烷基和3至8元环烷基；优选地，R3b选自氢原子、卤素和C1-6烷基；进一步优选地，R3b为C1-6烷基；更优选地，R3b为乙基。
在本公开一些实施方案中，所述的通式(IM)所示的化合物或其可药用的盐，其中G0为O；G1为CRG1aH，RG1a为C1-6烷基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；p为0；选自 q1为2或3，R3相同或不同，且各自独立地选自卤素、C1-6烷基、C1-6卤代烷基和氰基；选自 且为
在本公开一些实施方案中，所述的通式(IM)所示的化合物或其可药用的盐，其中G0为O；G1为CRG1aH，RG1a为C1-6烷基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；为p为0；选自 且选自
在本公开一些实施方案中，所述的通式(IM)所示的化合物或其可药用的盐，其中G0为O；G1为CRG1aH，RG1a为甲基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；为p为0；选自 且为
在本公开一些实施方案中，所述的通式(IM)所示的化合物或其可药用的盐，其中G0为O；G1为CRG1aH，RG1a为甲基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；为p为0；选自 且选自
在本公开一些实施方案中，所述的通式(IM)所示的化合物或其可药用的盐，其中G0为O；G1为CRG1aH，RG1a为甲基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；为p为0；选自 且为
在本公开一些实施方案中，所述的通式(IN)所示的化合物或其可药用的盐，其 中G0为O；G1为CRG1aH，RG1a为C1-6烷基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；为p为0；选自 且选自
在本公开一些实施方案中，所述的通式(IN)所示的化合物或其可药用的盐，其中G0为O；G1为CRG1aH，RG1a为甲基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；为p为0；选自 且为
在本公开一些实施方案中，所述的通式(IN)所示的化合物或其可药用的盐，其中G0为O；G1为CRG1aH，RG1a为甲基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；为p为0；选自 且选自
在本公开一些实施方案中，所述的通式(IN)所示的化合物或其可药用的盐，其中G0为O；G1为CRG1aH，RG1a为甲基；T为单键；Q为N；R4a为卤素；G2为NH；L为O；为p为0；选自 且为
在本公开一些实施方案中，所述的通式(II’)所示的化合物或其可药用的盐，其中RG1a为C1-6烷基；选自Q为N；环A为苯基或萘基；R4a为卤素；G2为NH；L为O；p为0；q为2或3；且各个R3相同或不同，且各自独立地选自卤素、C1-6烷基和羟基。
在本公开一些实施方案中，所述的通式(II)所示的化合物或其可药用的盐，其中选自 Q为N；环A为苯基或萘基；R4a为卤素；G2为NH；L为O；p为0；q为2或3；且各个R3相同或不同，且各自独立地选自卤素、C1-6烷基和羟基。
在本公开一些实施方案中，所述的通式(III’)所示的化合物或其可药用的盐，其中RG1a为甲基；选自 Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(III’-1)所示的化合物或其可药用的盐，其中RG1a为甲基；选自 Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(III’-1)所示的化合物或其可药用的盐，其中RG1a为甲基；为Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(III)所示的化合物或其可药用的盐，其 中选自Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(IV’)所示的化合物或其可药用的盐，其中RG1a为甲基；选自 R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基；Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(IV’-1)所示的化合物或其可药用的盐，其中RG1a为甲基；选自 Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(IV’-1)所示的化合物或其可药用的盐，其中RG1a为甲基；选自 Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(IV’)或(V’)所示的化合物或其可药用的盐，其中RG1a为甲基；选自 R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基；Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(IV’-1)或(V’-1)所示的化合物或其可药用的盐，其中RG1a为甲基；选自 Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(IN)所示的化合物或其可药用的盐，其中Q为N；G0为O；G1为CRG1aH；RG1a为氢原子或C1-6烷基；G2为NH；T为化学键；R4a为卤素；L为O；环A为萘基；各个R3相同或不同，且各自独立地选自卤素、C1-6烷基和羟基；q为2或3；R5a和R5b为氢原子，或者R5a、R5b与所连的碳原子一起形成环丙基；r为1或3；环C为3至8元杂环基；R6为＝CR62R63或氧代基，Rx1选自＝N-O-R61、＝CR62R63和＝N-R64，R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基；t1为0或1；且p为0。
在本公开一些实施方案中，所述的通式(IVV’)、(VV’)所示的化合物或其可药用的盐，其中RG1a为氢原子或C1-6烷基；选自 R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基；Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
在本公开一些实施方案中，所述的通式(VV’)、(VV’-1)所示的化合物或其可药用的盐，其中RG1a为C1-6烷基；选自 R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基；Q为N；R4a为卤素；G2为NH；L为O；p为0；R3a为卤素；且R3b为C1-6烷基。
表A本公开的典型化合物包括但不限于：







































本公开的另一方面涉及通式(INA)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
G0、G1、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、q、t1和r如通式(IN)中所定义。
本公开的另一方面涉及通式(IN’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G0、G1、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、t1和r如通式(IN’)中所定义。
本公开的另一方面涉及通式(IMA)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
G0、G1、T、环A、环B、Q、L、R1、R3、R4a、R5a、R5b、R6、p、q、t和r如通式(IM)中所定义。
本公开的另一方面涉及通式(IM’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G0、G1、T、环A、环B、Q、L、R1、R3、R4a、R5a、R5b、R6、p、t和r如通式(IM’)中所定义。
本公开的另一方面涉及通式(IA)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
G0、G1、T、环A、Q、L、R1、R3、R4a、R5a、R5b、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p、q和r如通式(I)中所定义。
本公开的另一方面涉及通式(I’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G0、G1、T、环A、Q、L、R1、R3、R4a、R5a、R5b、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和r如通式(I’)中所定义。
本公开的另一方面涉及通式(II’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
环A、Q、L、RG1a、R1、R3、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和q如通式(II’)中所定义。
本公开的另一方面涉及通式(IIA)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
环A、Q、L、R1、R3、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和q如通式(II)中所定义。
本公开的另一方面涉及通式(III’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
Q、L、RG1a、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III’)中所定义。
本公开的另一方面涉及通式(III’-1A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
Q、L、RG1a、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III’-1)中所定义。
本公开的另一方面涉及通式(IIIA)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
Q、L、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III)中所定义。
本公开的另一方面涉及通式(IVV’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(IVV’)中所定义。
本公开的另一方面涉及通式(IV’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(IV’)中所定义。
本公开的另一方面涉及通式(IV’-1A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(IV’-1)中所定义。
本公开的另一方面涉及通式(VV’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(VV’)中所定义。
本公开的另一方面涉及通式(VV’-1A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(VV’-1)中所定义。
本公开的另一方面涉及通式(V’A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(V’)中所定义。
本公开的另一方面涉及通式(V’-1A)所示的化合物或其盐，
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(V’-1)中所定义。
在本公开一些实施方案中，所述的通式(IN)、(INA)、(IN’)、(IN’A)、(IVV’)、(IVV’A)、(VV’)、(VV’A)、(VV’-1)、(VV’-1A)所示的化合物或其可药用的盐，其中Rx1为Rx，Rx如通式(IN)中所定义；优选地，Rx1选自＝N-O-R61、＝CR62R63和＝N-R64，R61为C1-6烷基，R62和R63相同或不同，且各自独立地为氢原子或卤素，R64为氢原子或C1-6烷基。
表B本公开的典型中间体化合物包括但不限于：














本公开的另一方面涉及一种制备通式(IN)所示的化合物或其可药用的盐的方法，该方法包括：
通式(INA)的化合物或其盐经脱保护反应，得到通式(IN)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括脱去R3基团上的保护基的步骤；
其中，
R为氨基保护基；优选为Boc；
G2为NH；
G0、G1、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、q、t1和r如通式(IN)中所定义。
本公开的另一方面涉及一种制备通式(IN’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(IN’A)的化合物或其盐经脱保护反应，得到通式(IN’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后 还包括脱去R3基团上的保护基的步骤；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G2为NH；
G0、G1、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、t1和r如通式(IN’)中所定义。
本公开的另一方面涉及一种制备通式(IM)所示的化合物或其可药用的盐的方法，该方法包括：
通式(IMA)的化合物或其盐经脱保护反应，得到通式(IM)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括脱去R3基团上的保护基的步骤；
其中，
R为氨基保护基；优选为Boc；
G2为NH；
G0、G1、T、环A、环B、Q、L、R1、R3、R4a、R5a、R5b、R6、p、q、t和r如通式(IM)中所定义。
本公开的另一方面涉及一种制备通式(IM’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(IM’A)的化合物或其盐经脱保护反应，得到通式(IM’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之 后还包括脱去R3基团上的保护基的步骤；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G2为NH；
G0、G1、T、环A、环B、Q、L、R1、R3、R4a、R5a、R5b、R6、p、t和r如通式(IM’)中所定义。
本公开的另一方面涉及一种制备通式(I)所示的化合物或其可药用的盐的方法，该方法包括：
通式(IA)的化合物或其盐经脱保护反应，得到通式(I)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括脱去R3基团上的保护基的步骤；
其中，
R为氨基保护基；优选为Boc；
G2为NH；
G0、G1、T、环A、Q、L、R1、R3、R4a、R5a、R5b、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p、q和r如通式(I)中所定义。
本公开的另一方面涉及一种制备通式(I’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(I’A)的化合物或其盐经脱保护反应，得到通式(I’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括脱去R3基团上的保护基的步骤；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G2为NH；
G0、G1、T、环A、Q、L、R1、R3、R4a、R5a、R5b、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和r如通式(I’)中所定义。
本公开的另一方面涉及一种制备通式(II’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(II’A)的化合物或其盐经脱保护反应，得到通式(II’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括脱去R3基团上的保护基的步骤；
其中R为氨基保护基；优选为Boc；
G2为NH；
环A、Q、L、RG1a、R1、R3、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和q如通式(II’)中所定义。
本公开的另一方面涉及一种制备通式(II)所示的化合物或其可药用的盐的方法，该方法包括：
通式(IIA)的化合物或其盐经脱保护反应，得到通式(II)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括脱去R3基团上的保护基的步骤；
其中R为氨基保护基；优选为Boc；
G2为NH；
环A、Q、L、R1、R3、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和q如通式(II)中所定义。
本公开的另一方面涉及一种制备通式(III’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(III’A)的化合物或其盐经脱保护反应，得到通式(III’)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
Q、L、RG1a、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III’)中所定义。
本公开的另一方面涉及一种制备通式(III’-1)所示的化合物或其可药用的盐的方法，该方法包括：
通式(III’-1A)的化合物或其盐经脱保护反应，得到通式(III’-1)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
Q、L、RG1a、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III’-1)中所定义。
本公开的另一方面涉及一种制备通式(III)所示的化合物或其可药用的盐的方 法，该方法包括：
通式(IIIA)的化合物或其盐经脱保护反应，得到通式(III)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
Q、L、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III)中所定义。
本公开的另一方面涉及一种制备通式(IVV’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(IVV’A)的化合物或其盐经脱保护反应，得到通式(IVV’)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(IVV’)中所定义。
本公开的另一方面涉及一种制备通式(IV’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(IV’A)的化合物或其盐经脱保护反应，得到通式(IV’)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(IV’)中所定义。
本公开的另一方面涉及一种制备通式(IV’-1)所示的化合物或其可药用的盐的方法，该方法包括：
通式(IV’-1A)的化合物或其盐经脱保护反应，得到通式(IV’-1)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(IV’-1)中所定义。
本公开的另一方面涉及一种制备通式(VV’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(VV’A)的化合物或其盐经脱保护反应，得到通式(VV’)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(VV’)中所定义。
本公开的另一方面涉及一种制备通式(VV’-1)所示的化合物或其可药用的盐的方法，该方法包括：
通式(VV’-1A)的化合物或其盐经脱保护反应，得到通式(VV’-1)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(VV’-1)中所定义。
本公开的另一方面涉及一种制备通式(V’)所示的化合物或其可药用的盐的方法，该方法包括：
通式(V’A)的化合物或其盐经脱保护反应，得到通式(V’)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(V’)中所定义。
本公开的另一方面涉及一种制备通式(V’-1)所示的化合物或其可药用的盐的方法，该方法包括：
通式(V’-1A)的化合物或其盐经脱保护反应，得到通式(V’-1)的化合物或其可药用的盐；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(V’-1)中所定义。
本公开的另一方面涉及一种药物组合物，所述药物组合物含有本公开通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A中所示的化合物或其可药用的盐，以及一种或多种药学上可接受的载体、稀释剂或赋形剂。
本公开进一步涉及通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A中所示的化合物或其可药用的盐、或包括其的药物组合物在制备用于抑制KRAS G12D的药物中的用途。
本公开进一步涉及通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A中所示的化合物或其可药用的盐、或包括其的药物组合物在制备用于治疗和/或预防由KRAS G12D介导的疾病或病症的药物中的用途。
本公开进一步涉及通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A中所示的化合物或其可药用的盐、或包括其的药物组合物在制备用于治疗和/或预防肿瘤的药物中的用途；所述的肿瘤优选选自脑癌、甲状腺癌、头颈癌、鼻咽癌、咽喉癌、口腔癌、唾液腺癌、食道癌、胃癌、肺癌、肝癌、肾癌、胸膜癌、腹膜癌、胰腺癌、胆囊癌、胆管癌、结直肠癌、小肠癌、胃肠道间质瘤、尿路上皮癌、尿道癌、膀胱癌、肛门癌、关节癌、乳腺癌、阴道癌、卵巢癌、子宫内膜癌、宫颈癌、输卵管癌、睾丸癌、前列腺癌、血管瘤、白血病、淋巴瘤、骨髓瘤、皮肤癌、黑色素瘤、脂肪瘤、骨癌、软组织肉瘤、神经纤维瘤、神经胶质瘤、成神经细胞瘤和胶质母细胞瘤；进一步优选选自胰腺癌、结直肠癌和非小细胞肺癌。
本公开进一步涉及一种抑制KRAS G12D的方法，其包括给予所需患者治疗有效量的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A所示的化合物或其可药用的盐、或包括其的药物组合物。
本公开进一步涉及一种治疗和/或预防由KRAS G12D介导的疾病或病症的方法，其包括给予所需患者治疗有效量的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A所示的化合物或其可药用的盐、或包括其的药物组合物。
本公开进一步涉及一种治疗和/或预防肿瘤的方法，其包括给予所需患者治疗有效量的通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A所示的化合物或其可药用的盐、或包括其的药物组合物；所述的肿瘤优选选自脑癌、甲状腺癌、头颈癌、鼻咽癌、咽喉癌、口腔癌、唾液腺癌、食道癌、胃癌、肺癌、肝癌、肾癌、胸膜癌、腹膜癌、胰腺癌、胆囊癌、胆管癌、结直肠癌、小肠癌、胃肠道间质瘤、尿路上皮癌、尿道癌、膀胱癌、肛门癌、关节癌、乳腺癌、阴道癌、卵巢癌、子宫内膜癌、宫颈癌、输卵管癌、睾丸癌、前列腺癌、血管瘤、白血病、淋巴瘤、骨髓瘤、皮肤癌、黑色素瘤、脂肪瘤、骨癌、软组织肉瘤、神经纤维瘤、神经胶质瘤、成神经细胞瘤和胶质母细胞瘤；进一步优选选自胰腺癌、结直肠癌和非小 细胞肺癌。
本公开进一步涉及一种通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A所示的化合物或其可药用的盐、或包括其的药物组合物，其用作药物。
本公开进一步涉及一种通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A所示的化合物或其可药用的盐、或包括其的药物组合物，其用于抑制KRAS G12D。
本公开进一步涉及一种通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A所示的化合物或其可药用的盐、或包括其的药物组合物，其用于治疗和/或预防由KRAS G12D介导的疾病或病症。
本公开进一步涉及一种通式(IN)、(IN’)、(IM)、(IM’)、(I)、(I’)、(II’)、(II)、(III’)、(III’-1)、(III)、(IV’)、(IV’-1)、(V’)、(V’-1)、(IVV’)、(VV’)、(VV’-1)或表A所示的化合物或其可药用的盐、或包括其的药物组合物，其用于治疗和/或预防肿瘤；所述的肿瘤优选选自脑癌、甲状腺癌、头颈癌、鼻咽癌、咽喉癌、口腔癌、唾液腺癌、食道癌、胃癌、肺癌、肝癌、肾癌、胸膜癌、腹膜癌、胰腺癌、胆囊癌、胆管癌、结直肠癌、小肠癌、胃肠道间质瘤、尿路上皮癌、尿道癌、膀胱癌、肛门癌、关节癌、乳腺癌、阴道癌、卵巢癌、子宫内膜癌、宫颈癌、输卵管癌、睾丸癌、前列腺癌、血管瘤、白血病、淋巴瘤、骨髓瘤、皮肤癌、黑色素瘤、脂肪瘤、骨癌、软组织肉瘤、神经纤维瘤、神经胶质瘤、成神经细胞瘤和胶质母细胞瘤；进一步优选选自胰腺癌、结直肠癌和非小细胞肺癌。
本公开所述的疾病或病症是通过抑制KRAS G12D来治疗和/或预防的疾病或病症。
优选地，本公开所述的由KRAS G12D介导的疾病或病症为肿瘤；所述的肿瘤优选选自脑癌、甲状腺癌、头颈癌、鼻咽癌、咽喉癌、口腔癌、唾液腺癌、食道癌、胃癌、肺癌、肝癌、肾癌、胸膜癌、腹膜癌、胰腺癌、胆囊癌、胆管癌、结直肠癌、小肠癌、胃肠道间质瘤、尿路上皮癌、尿道癌、膀胱癌、肛门癌、关节癌、乳腺癌、阴道癌、卵巢癌、子宫内膜癌、宫颈癌、输卵管癌、睾丸癌、前列腺癌、血管瘤、白血病、淋巴瘤、骨髓瘤、皮肤癌、黑色素瘤、脂肪瘤、骨癌、软组织肉瘤、神经纤维瘤、神经胶质瘤、成神经细胞瘤和胶质母细胞瘤；进一步优选选自胰腺癌、结直肠癌和非小细胞肺癌。
本公开所述的结直肠癌优选为结肠癌或直肠癌。
优选地，本公开中所述的脑癌选自多形性成胶质细胞瘤或成神经细胞瘤；软组织癌选自纤维肉瘤、胃肠道肉瘤、横纹肌瘤、平滑肌肉瘤、去分化脂肉瘤、多形性脂肉瘤、恶性纤维组织细胞瘤、圆细胞肉瘤和滑膜肉瘤；淋巴瘤选自霍奇金氏疾病和非霍奇金淋巴瘤(例如套细胞淋巴瘤、弥漫性大B细胞淋巴瘤、滤泡中心 淋巴瘤、边缘区B细胞淋巴瘤、淋巴浆细胞淋巴瘤和外周T细胞淋巴瘤)；肝癌优选为肝细胞癌；肺癌(又称支气管肺癌)选自非小细胞肺癌(NSCLC)、小细胞肺癌(SCLC)和鳞状细胞癌；肾癌选自肾细胞癌、透明细胞和肾嗜酸细胞瘤；白血病选自慢性淋巴细胞性白血病(CLL)、慢性粒细胞性白血病、急性成淋巴细胞性白血病(ALL)、T-细胞急性成淋巴细胞性白血病(T-ALL)、慢性髓细胞性白血病(CML)和急性骨髓性白血病(AML)；皮肤癌选自恶性黑色素瘤、鳞状细胞癌、基底细胞癌和血管肉瘤；骨髓瘤优选为多发性骨髓瘤。
可将活性化合物制成适合于通过任何适当途径给药的形式，通过常规方法使用一种或多种药学上可接受的载体来配制本公开的组合物。因此，本公开的活性化合物可以配制成用于口服给药、注射(例如静脉内、肌肉内或皮下)给药，吸入或吹入给药的各种剂型。本公开的化合物也可以配制成例如片剂、硬或软胶囊、水性或油性混悬液、乳剂、注射液、可分散性粉末或颗粒、栓剂、锭剂或糖浆等剂型。
作为一般性指导，本公开的活性化合物优选是以单位剂量的方式，或者是以患者可以以单剂自我给药的方式。本公开化合物或组合物的单位剂量的表达方式可以是片剂、胶囊、扁囊剂、瓶装药水、药粉、颗粒剂、锭剂、栓剂、再生药粉或液体制剂。合适的单位剂量可以是0.1～1000mg。
本公开的药物组合物除活性化合物外，可含有一种或多种辅料，所述辅料选自以下成分：填充剂(稀释剂)、粘合剂、润湿剂、崩解剂或赋形剂等。根据给药方法的不同，组合物可含有0.1至99重量％的活性化合物。
片剂含有活性成分和用于混合的适宜制备片剂的无毒的可药用的赋形剂。这些赋形剂可以是惰性赋形剂、造粒剂、崩解剂、粘合剂和润滑剂。这些片剂可以不包衣或可通过掩盖药物的味道或在胃肠道中延迟崩解和吸收，因而在较长时间内提供缓释作用的已知技术将其包衣。
也可用其中活性成分与惰性固体稀释剂或其中活性成分与水溶性载体或油溶媒混合的软明胶胶囊提供口服制剂。
水混悬液含有活性物质和用于混合的适宜制备水悬浮液的赋形剂。此类赋形剂是悬浮剂、分散剂或湿润剂。水混悬液也可以含有一种或多种防腐剂、一种或多种着色剂、一种或多种矫味剂和一种或多种甜味剂。
油混悬液可通过使活性成分悬浮于植物油，或矿物油配制而成。油悬浮液可含有增稠剂。可加入上述的甜味剂和矫味剂，以提供可口的制剂。可通过加入抗氧化剂保存这些组合物。
本公开的药物组合物也可以是水包油乳剂的形式。油相可以是植物油，或矿物油或其混合物。适宜的乳化剂可以是天然产生的磷脂，乳剂也可以含有甜味剂、矫味剂、防腐剂和抗氧剂。此类制剂也可含有缓和剂、防腐剂、着色剂和抗氧剂。
本公开的药物组合物可以是无菌注射水溶液形式。可以使用的可接受的溶媒或溶剂有水、林格氏液和等渗氯化钠溶液。无菌注射制剂可以是其中活性成分溶于油相的无菌注射水包油微乳可通过局部大量注射，将注射液或微乳注入患者的血流中。或者，最好按可保持本公开化合物恒定循环浓度的方式给予溶液和微乳。为保持这种恒定浓度，可使用连续静脉内递药装置。这种装置的实例是Deltec CADD-PLUS.TM.5400型静脉注射泵。
本公开的药物组合物可以是用于肌内和皮下给药的无菌注射水或油混悬液的形式。可按已知技术，用上述那些适宜的分散剂或湿润剂和悬浮剂配制该混悬液。无菌注射制剂也可以是在肠胃外可接受的无毒稀释剂或溶剂中制备的无菌注射溶液或混悬液。此外，可方便地用无菌固定油作为溶剂或悬浮介质。为此目的，可使用任何调和固定油。此外，脂肪酸也可以制备注射剂。
可按用于直肠给药的栓剂形式给予本公开化合物。可通过将药物与在普通温度下为固体但在直肠中为液体，因而在直肠中会溶化而释放药物的适宜的无刺激性赋形剂混合来制备这些药物组合物。
可通过加入水来制备水混悬的可分散粉末和颗粒给予本公开化合物。可通过将活性成分与分散剂或湿润剂、悬浮剂或一种或多种防腐剂混合来制备这些药物组合物。
如本领域技术人员所熟知的，药物的给药剂量依赖于多种因素，包括但并非限定于以下因素：所用具体化合物的活性、疾病的严重性、患者的年龄、患者的体重、患者的健康状况、患者的行为、患者的饮食、给药时间、给药方式、排泄的速率、药物的组合等；另外，最佳的治疗方式如治疗的模式、化合物的日用量或可药用的盐的种类可以根据传统的治疗方案来验证。
术语说明
除非有相反陈述，在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选为具有1至12个(例如1、2、3、4、5、6、7、8、9、10、11和12个)碳原子的烷基(即C1-12烷基)，更优选为具有1至6个碳原子的烷基(即C1-6烷基)。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、 2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基，及其各种支链异构体等。烷基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点上被取代，取代基优选选自D原子、卤素、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。
术语“烯基”指分子中含有至少一个碳碳双键的烷基，其中烷基的定义如上所述，优选为具有2至12个(例如2、3、4、5、6、7、8、9、10、11和12个)碳原子(即C2-12烯基)，更优选具有2至6个碳原子的烯基(即C2-6烯基)。非限制性的实例包括：乙烯基、丙烯基、异丙烯基、丁烯基等。烯基可以是取代的或非取代的，当被取代时，取代基优选选自烷氧基、卤素、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。
术语“炔基”指分子中含有至少一个碳碳三键的烷基，其中烷基的定义如上所述。优选具有2至12个(例如2、3、4、5、6、7、8、9、10、11和12个)碳原子(即C2-12炔基)，更优选具有2至6个碳原子的炔基(即C2-6炔基)。非限制性的实例包括：乙炔基、丙炔基、丁炔基、戊炔基、己炔基等。炔基可以是取代的或非取代的，当被取代时，取代基优选选自烷氧基、卤素、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基，环烷基环包含3至20个碳原子，优选包含3至14个(例如3、4、5、6、7、8、9、10、11、12、13和14个)碳原子(即3至14元环烷基)，优选包含3至8个(例如3、4、5、6、7和8个)碳原子(即3至8元环烷基)，更优选包含3至6个碳原子(即3至6元环烷基)。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等；多环环烷基包括螺环烷基、稠环烷基和桥环烷基。
术语“螺环烷基”指5至20元，单环之间共用一个碳原子(称螺原子)的多环基团，其可以含有一个或多个双键。优选为6至14元，更优选为7至10元(例如7、8、9或10元)。根据环与环之间共用螺原子的数目将螺环烷基分为单螺环烷基或多螺环烷基(例如双螺环烷基)，优选为单螺环烷基和双螺环烷基。更优选为3元/4元、3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元/3元、5元/4元、5元/5元、5元/6元、5元/7元、6元/3元、6元/4元、6元/5元、6元/6元、6元/7元、7元/5元或7元/6元单螺环烷基。螺环烷基的非限制性实例包括：
术语“稠环烷基”指5至20元，系统中的每个环与体系中的其他环共享毗邻的一对碳原子的全碳多环基团，其中一个或多个环可以含有一个或多个双键。优选为6至14元，更优选为7至10元(例如7、8、9或10元)。根据组成环的数目可以分为双环或多环稠环烷基(例如三环、四环)，优选为双环或三环，更优选为3元/4元、3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元/3元、5元/4元、5元/5元、5元/6元、5元/7元、6元/3元、6元/4元、6元/5元、6元/6元、6元/7元、7元/5元或7元/6元双环烷基。稠环烷基的非限制性实例包括：
术语“桥环烷基”指5至20元，任意两个环共用两个不直接连接的碳原子的全碳多环基团，其可以含有一个或多个双键。优选为6至14元，更优选为7至10元(例如7、8、9或10元)。根据组成环的数目可以分为双环或多环(例如三环、四环)桥环烷基，优选为双环、三环或四环，更优选为双环或三环。桥环烷基的非限制性实例包括：
所述环烷基环包括如上所述的环烷基(包括单环、螺环、稠环和桥环)稠合于芳基、杂芳基或杂环烷基环上，其中与母体结构连接在一起的环为环烷基，非限制性实例包括等；优选
环烷基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点上被取代，所述取代基优选选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。
术语“烷氧基”指-O-(烷基)，其中烷基的定义如上所述。烷氧基的非限制性实例包括：甲氧基、乙氧基、丙氧基和丁氧基。烷氧基可以是任选取代的或非取代的，当被取代时，取代基优选选自D原子、卤素、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基。
术语“杂环基”指饱和或部分不饱和单环或多环环状取代基，其包含3至20个(例如3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)环原子(即3至20元杂环基)，其中一个或多个环原子为选自氮、氧和硫的杂原子，所述的硫可任选被氧代(即形成亚砜或砜)，但不包括-O-O-、-O-S-或-S-S-的环部分，其余环原子为碳。优选包含3至14个(例如3、4、5、6、7、8、9、10、11、12、13和14个)环原子(即3至14元杂环基)，其中1～4个(例如1、2、3和4个)是杂原子；更优选包含3至8个环原子(例如3、4、5、6、7和8个)(即3至8元杂环基)或6至14个环原子(例如6、7、8、9、10、11、12、13和14个)，其中1-3是杂原子(例如1、2和3个)；更优选包含3至8个环原子，其中1-3个(例如1、2和3个)是杂原子；最优选包含5或6个环原子(即5元或6元杂环基)，其中1-3个是杂原子。单环杂环基的非限制性实例包括吡咯烷基、四氢吡喃基、1,2,3,6-四氢吡啶基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基等。多环杂环基包括螺杂环基、稠杂环基和桥杂环基。
术语“螺杂环基”指5至20元，单环之间共用一个原子(称螺原子)的多环杂环基团，其中一个或多个环原子为选自氮、氧和硫的杂原子，所述的硫可任选被氧代(即形成亚砜或砜)，其余环原子为碳。其可以含有一个或多个双键。优选为6至14元(例如6、7、8、9、10、11、12、13和14元)(即6至14元螺杂环基)，更优选为7至10元(例如7、8、9或10元)(即7至10元螺杂环基)。根据环与环之间共用螺原子的数目将螺杂环基分为单螺杂环基或多螺杂环基(例如双螺杂环基)，优选为单螺杂环基和双螺杂环基。更优选为3元/4元、3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元/3元、5元/4元、5元/5元、5元/6元、5元/7元、6元/3元、6元/4元、6元/5元、6元/6元、6元/7元、7元/5元或7元/6元单螺杂环基。螺杂环基的非限制性实例包括：
术语“稠杂环基”指5至20元，系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环基团，一个或多个环可以含有一个或多个双键，其中一个或多个环原子为选自氮、氧和硫的杂原子，所述的硫可任选被氧代(即形成亚砜或砜)，其余环原子为碳。优选为6至14元(例如6、7、8、9、10、11、12、13 和14元)(即6至14元稠杂环基)，更优选为7至10元(例如7、8、9或10元)(即7至10元稠杂环基)。根据组成环的数目可以分为双环或多环(例如三环、四环)稠杂环基，优选为双环或三环，更优选为3元/4元、3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元/3元、5元/4元、5元/5元、5元/6元、5元/7元、6元/3元、6元/4元、6元/5元、6元/6元、6元/7元、7元/5元或7元/6元双环稠杂环基。稠杂环基的非限制性实例包括：
术语“桥杂环基”指5至20元，任意两个环共用两个不直接连接的原子的多环杂环基团，其可以含有一个或多个双键，其中一个或多个环原子为选自氮、氧和硫的杂原子，所述的硫可任选被氧代(即形成亚砜或砜)，其余环原子为碳。优选为6至14元(例如6、7、8、9、10、11、12、13和14元)(即6至14元桥杂环基)，更优选为7至10元(例如7、8、9或10元)(即7至10元桥杂环基)。根据组成环的数目可以分为双环或多环(例如三环、四环)桥杂环基，优选为双环、三环或四环，更优选为双环或三环。桥杂环基的非限制性实例包括：
所述杂环基环包括如上所述的杂环基(包括单环、螺杂环、稠杂环和桥杂环)稠合于芳基、杂芳基或环烷基环上，其中与母体结构连接在一起的环为杂环基，其非限制性实例包括：
等。
杂环基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点上被取代，所述取代基优选选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、 芳基和杂芳基中的一个或多个。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(稠合多环是共享毗邻碳原子对的环)基团，优选为6至10元，例如苯基和萘基。所述芳基环包括如上所述的芳基环稠合于杂芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为芳基环，其非限制性实例包括：
芳基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点上被取代，所述取代基优选选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。
术语“杂芳基”指包含1至4个(例如1、2、3和4个)杂原子、5至14个环原子的杂芳族体系，其中杂原子选自氧、硫和氮。杂芳基优选为5至10元(例如5、6、7、8、9或10元)(即5至10元杂芳基)，进一步优选为8至10元(例如8、9或10元)，更优选为5元或6元(即5元或6元杂芳基)，例如呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、哒嗪基、咪唑基、吡唑基、三唑基、四唑基等。所述杂芳基环包括如上述的杂芳基稠合于芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为杂芳基环，其非限制性实例包括：

杂芳基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点上被取代，所述取代基优选选自卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。
上述环烷基、杂环基、芳基和杂芳基包括从母体环原子上除去一个氢原子所衍生的残基，或从母体的相同环原子或两个不同的环原子上除去两个氢原子所衍生的残基即“二价环烷基”、“二价杂环基”、“亚芳基”和“亚杂芳基”。
术语“氨基保护基”是为了使分子其它部位进行反应时氨基保持不变，用易于脱去的基团对氨基进行保护。非限制性实施例包含(三甲基硅)乙氧基甲基(SEM)、四氢吡喃基、叔丁氧羰基(Boc)、乙酰基、苄基、烯丙基、对甲基苯磺酰基(Ts)和对甲氧苄基等。这些基团可任选地被选自卤素、烷氧基和硝基中的1-3个取代基所取代；氨基保护基优选为Boc。
术语“羟基保护基”是指通常用于阻断或保护羟基而反应在化合物的其它官能团上进行的羟基衍生物。作为示例，优选地，所述的羟基保护基例如：三乙基硅基、三异丙基硅基、叔丁基二甲基硅基(TBS)、叔丁基二苯基硅基、甲基、叔丁基、烯丙基、苄基、甲氧基甲基(MOM)、乙氧基乙基、2-四氢吡喃基(THP)、甲酰基、乙酰基、苯甲酰基和对硝基苯甲酰基等；羟基保护基优选为MOM。
术语“炔基保护基”是指为了使分子其它部位进行反应时乙炔或末端炔烃中的活泼氢保持不变，在炔基上引入的易于脱去的基团。非限制性的实例包括：三甲基硅基(TMS)、三乙基硅基(TES)、叔丁基二甲基硅基(TBS)、三异丙基硅基(TIPS)、叔丁基二甲基硅基(TBDMS)、叔丁基二苯基硅基(TBDPS)、甲基、叔丁基、烯丙基、苄基、甲氧基甲基(MOM)、乙氧基乙基、2-四氢吡喃基(THP)、甲酰基、乙酰基、苯甲酰基、对硝基苯甲酰基等；炔基保护基优选为TIPS。
术语“环烷基氧基”指环烷基-O-，其中环烷基如上所定义。
术语“杂环基氧基”指杂环基-O-，其中杂环基如上所定义。
术语“芳基氧基”指芳基-O-，其中芳基如上所定义。
术语“杂芳基氧基”指杂芳基-O-，其中杂芳基如上所定义。
术语“烷硫基”指烷基-S-，其中烷基如上所定义。
术语“卤代烷基”指烷基被一个或多个卤素取代，其中烷基如上所定义。
术语“卤代烷氧基”指烷氧基被一个或多个卤素取代，其中烷氧基如上所定义。
术语“氘代烷基”指烷基被一个或多个氘原子取代，其中烷基如上所定义。
术语“羟烷基”指烷基被一个或多个羟基取代，其中烷基如上所定义。
术语“卤素”指氟、氯、溴或碘。
术语“羟基”指-OH。
术语“巯基”指-SH。
术语“氨基”指-NH2。
术语“氰基”指-CN。
术语“硝基”指-NO2。
术语“氧代基”或“氧代”指“＝O”。
术语“羰基”指C＝O。
术语“羧基”指-C(O)OH。
术语“羧酸酯基”指-C(O)O(烷基)、-C(O)O(环烷基)、(烷基)C(O)O-或(环烷基)C(O)O-，其中烷基和环烷基如上所定义。
MOM指甲氧基甲基。
Boc指叔丁氧羰基。
TIPS指三异丙基硅基。
TBS指叔丁基二甲基硅基。
本公开的化合物可包含其所有方式的旋转异构体和构象上受限的状态。还包括阻转异构体，术语“阻转异构体”为由于围绕分子中单键的旋转受阻或大大减慢(这是由于与分子的其它部分的空间相互作用和在单键的两端处取代基是不对称的结果)而产生的构象立体异构体，其互变是足够慢的，以允许在预定条件下分开和分离。例如，某些本公开化合物可以以阻转异构体的混合物的形式(如等比例混合物、富集一种阻转异构体的混合物等)或经纯化的一种阻转异构体的形式存在。本公开的化合物和中间体还可以以不同的互变异构体形式存在，并且所有这样的形式包含于本公开的范围内。术语“互变异构体”或“互变异构体形式”是指可经由低能垒互变的不同能量的结构异构体。例如，质子互变异构体(也称为质子转移互变异构体)包括经由质子迁移的互变，如酮-烯醇及亚胺-烯胺、内酰胺-内酰亚胺异构化。酮-烯醇平衡实例是在如下所示：
所有的互变异构形式在本公开的范围内。化合物的命名不排除任何互变异构体。
本公开化合物可以存在特定的立体异构体形式。术语“立体异构体”是指结构相同但原子在空间中的排列不同的异构体。其包括顺式和反式(或Z和E)异构体、 (-)-和(+)-异构体、(R)-和(S)-对映异构体、非对映异构体、(D)-和(L)-异构体、互变异构体、阻转异构体、构象异构体及其混合物(如外消旋体、非对映异构体的混合物)。本公开化合物中的取代基可以存在另外的不对称原子。所有这些立体异构体以及它们的混合物，均包括在本公开的范围内。对于所有的碳-碳双键，即使仅命名了一个构型，Z型和E型均包括在内。可以通过手性合成、手性试剂或者其他常规技术制备光学活性的(-)-和(+)-异构体、(R)-和(S)-对映异构体以及(D)-和(L)-异构体。本公开某化合物的一种异构体，可以通过不对称合成或者具有手性助剂的衍生作用来制备，或者，当分子中含有碱性官能团(如氨基)或酸性官能团(如羧基)时，与适当的光学活性的酸或碱形成非对映异构体的盐，然后通过本领域所公知的常规方法进行非对映异构体拆分，得到纯的异构体。此外，对映异构体和非对映异构体的分离通常是通过色谱法完成。
本公开所述化合物的化学结构中，键表示未指定构型，即如果化学结构中存在手性异构体，键可以为或者同时包含两种构型。
本公开的化合物包括其化合物的所有合适的同位素衍生物。术语“同位素衍生物”是指至少一个原子被具有相同原子序数但原子质量不同的原子替代的化合物。可引入到本公开化合物中的同位素的实例包括氢、碳、氮、氧、磷、硫、氟、氯、溴和碘等的稳定和放射性的同位素，例如分别为2H(氘，D)、3H(氚，T)、11C、13C、14C、15N、17O、18O、32p、33p、33S、34S、35S、36S、18F、36Cl、82Br、123I、124I、125I、129I和131I等，优选氘。
相比于未氘代药物，氘代药物有降低毒副作用、增加药物稳定性、增强疗效、延长药物生物半衰期等优势。本公开的化合物的所有同位素组成的变换，无论放射性与否，都包括在本公开的范围之内。与碳原子连接的各个可用的氢原子可独立地被氘原子替换，其中氘的替换可以是部分或完全的，部分氘的替换是指至少一个氢被至少一个氘替换。
“任选地”或“任选”是指意味着随后所描述的事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生的场合。例如“任选的被卤素或者氰基取代的C1-6烷基”是指卤素或者氰基可以但不必须存在，该说明包括烷基被卤素或者氰基取代的情形和烷基不被卤素和氰基取代的情形。
“取代的”指基团中的一个或多个氢原子，优选为1～6个，更优选为1～3个氢原子彼此独立地被相应数目的取代基取代。本领域技术人员能够在不付出过多努力的情况下(通过实验或理论)确定可能或不可能的取代。例如，具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
“药物组合物”表示含有一种或多种本文所述化合物或其可药用的盐或前体药物与其他化学组分的混合物，以及其他组分例如药学上可接受的载体和赋形剂。药物组合物的目的是促进对生物体的给药，利于活性成分的吸收进而发挥生物活 性。
“可药用的盐”是指本公开化合物的盐，可选自无机盐或有机盐。这类盐用于哺乳动物体内时具有安全性和有效性，且具有应有的生物活性。可以在化合物的最终分离和纯化过程中，或通过使合适的基团与合适的碱或酸反应来单独制备盐。通常用于形成药学上可接受的盐的碱包括无机碱，例如氢氧化钠和氢氧化钾，以及有机碱，例如氨。通常用于形成药学上可接受的盐的酸包括无机酸以及有机酸。
针对药物或药理学活性剂而言，术语“治疗有效量”是指足以达到或至少部分达到预期效果的药物或药剂的用量。治疗有效量的确定因人而异，取决于受体的年龄和一般情况，也取决于具体的活性物质，个案中合适的治疗有效量可以由本领域技术人员根据常规试验确定。
本文所用的术语“药学上可接受的”是指这些化合物、材料、组合物和/或剂型，在合理的医学判断范围内，适用于与患者组织接触而没有过度毒性、刺激性、过敏反应或其他问题或并发症，具有合理的获益/风险比，并且对预期的用途是有效。
本文所使用的，单数形式的“一个”、“一种”和“该”包括复数引用，反之亦然，除非上下文另外明确指出。
当将术语“约”应用于如pH、浓度、温度等参数时，表明该参数可以变化±10％，并且有时更优选地在±5％之内。如本领域技术人员将理解的，当参数不是关键时，通常仅出于说明目的给出数字，而不是限制。
本公开化合物的合成方法
为了完成本公开的目的，本公开采用如下技术方案：
方案一-1
本公开提供通式(IN)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(INA)的化合物或其盐在酸性条件下经脱保护反应，得到通式(IN)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括在酸性或碱性条件下脱去R3基团上的保护基的步骤；
其中R为氨基保护基；优选为Boc；
G2为NH；
G0、G1、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、q、 t1和r如通式(IN)中所定义。
方案一-2
本公开提供通式(IN’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IN’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(IN’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括脱去R3基团上的保护基的步骤；
其中，
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G2为NH；
G0、G1、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、t1和r如通式(IN’)中所定义。
方案一-3
本公开提供通式(IM)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IMA)的化合物或其盐在酸性条件下经脱保护反应，得到通式(IM)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括在酸性或碱性条件下脱去R3基团上的保护基的步骤；
其中R为氨基保护基；优选为Boc；
G2为NH；
G0、G1、T、环A、环B、Q、L、R1、R3、R4a、R5a、R5b、R6、p、q、t和r如通式(IM)中所定义。
方案一-4
本公开提供通式(IM’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IM’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(IM’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括在酸性或碱性条件下脱去R3基团上的保护基的步骤；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G2为NH；
G0、G1、T、环A、环B、Q、L、R1、R3、R4a、R5a、R5b、R6、p、t和r如通式(IM’)中所定义。
方案二-1
本公开提供通式(I)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IA)的化合物或其盐在酸性条件下经脱保护反应，得到通式(I)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括在酸性或碱性条件下脱去R3基团上的保护基的步骤；
其中R为氨基保护基；优选为Boc；
G2为NH；
G0、G1、T、环A、Q、L、R1、R3、R4a、R5a、R5b、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p、q和r如通式(I)中所定义。
方案二-2
本公开提供通式(I’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(I’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(I’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括在酸性或碱性条件下脱去R3基团上的保护基的步骤；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
a为0、1、2、3或4；
G2为NH；
G0、G1、T、环A、Q、L、R1、R3、R4a、R5a、R5b、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和r如通式(I’)中所定义。
方案三-1
本公开提供通式(II’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(II’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(II’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括在酸性或碱性条件下脱去R3基团上的保护基的步骤；
其中R为氨基保护基；优选为Boc；
G2为NH；
环A、Q、L、RG1a、R1、R3、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和q如通式(II’)中所定义。
方案三-2
本公开提供通式(II)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IIA)的化合物或其盐在酸性条件下经脱保护反应，得到通式(II)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括在酸性或碱性条件下脱去R3基团上的保护基的步骤；
其中R为氨基保护基；优选为Boc；
G2为NH；
环A、Q、L、R1、R3、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h、p和q如通式(II)中所定义。
方案四-1
本公开提供通式(III’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(III’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(III’)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
Q、L、RG1a、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III’)中所定义。
方案四-2
本公开提供通式(III’-1)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(III’-1A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(III’-1)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
Q、L、RG1a、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III’-1)中所定义。
方案四-3
本公开提供通式(III)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IIIA)的化合物或其盐在酸性条件下经脱保护反应，得到通式(III)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
Q、L、R1、R3a、R3b、R4a、R6a、R6b、R6c、R6d、R6e、R6f、R6g、R6h和p如通式(III)中所定义。
方案五-1
本公开提供通式(IVV’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IVV’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(IVV’)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(IVV’)中所定义。
方案五-2
本公开提供通式(IV’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IV’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(IV’)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(IV’)中所定义。
方案五-3
本公开提供通式(IV’-1)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(IV’-1A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(IV’-1)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(IV’-1)中所定义。
方案六-1
本公开提供通式(VV’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(VV’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(VV’)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(VV’)中所定义。
方案六-2
本公开提供通式(VV’-1)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(VV’-1A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(VV’-1)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环C、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx1、t1和p如通式(VV’-1)中所定义。
方案六-3
本公开提供通式(V’)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(V’A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(V’)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(V’)中所定义。
方案六-4
本公开提供通式(V’-1)所示的化合物或其可药用的盐的制备方法，该方法包括：
通式(V’-1A)的化合物或其盐在酸性条件下经脱保护反应，得到通式(V’-1)的化合物或其可药用的盐；
其中
R为氨基保护基；优选为Boc；
Ry为羟基保护基；优选为MOM；
G2为NH；
环B、Q、L、RG1a、R1、R3a、R3b、R4a、R6、Rx、t和p如通式(V’-1)中所定义。
以上合成方案中提供酸性条件的试剂包括有机酸和无机酸，所述的有机酸包括但不限于三氟乙酸、甲酸、乙酸、甲磺酸、对甲苯磺酸、Me3SiCl和TMSOTf；所述的无机酸包括但不限于氯化氢、盐酸二氧六环溶液、盐酸、硫酸、硝酸和磷酸；优选为盐酸二氧六环溶液。
以上合成方案中提供碱性条件的试剂包括有机碱和无机碱类，所述的有机碱类包括但不限于三乙胺、N,N-二异丙基乙胺、正丁基锂、二异丙基氨基锂、醋酸钾、叔丁醇钠、叔丁醇钾、四丁基氟化铵、四丁基氟化铵的四氢呋喃溶液或1,8-二氮杂二环十一碳-7-烯，所述的无机碱类包括但不限于氢化钠、磷酸钾、碳酸钠、醋酸钠、醋酸钾、碳酸钾、碳酸铯、氢氧化钠、氢氧化锂、氟化铯和氢氧化钾。
以上合成方案中，当R3中含有末端炔基时，该末端炔可被TIPS保护，脱去TIPS的试剂优选为四丁基氟化铵的四氢呋喃溶液或氟化铯。
上述步骤的反应优选在溶剂中进行，所用的溶剂包括但不限于：吡啶、乙二醇二甲醚、醋酸、甲醇、乙醇、乙腈、正丁醇、甲苯、四氢呋喃、二氯甲烷、石油醚、乙酸乙酯、正己烷、二甲基亚砜、1,4-二氧六环、水、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、1,2-二溴乙烷及其混合物。
具体实施方式
以下结合实施例用于进一步描述本公开，但这些实施例并非限制着本公开的范围。
实施例
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移(δ) 以10-6(ppm)的单位给出。NMR的测定是用Bruker AVANCE-400核磁仪或Bruker AVANCE NEO 500M，测定溶剂为氘代二甲基亚砜(DMSO-d6)、氘代氯仿(CDCl3)、氘代甲醇(CD3OD)，内标为四甲基硅烷(TMS)。
MS的测定用Agilent 1200/1290 DAD-6110/6120 Quadrupole MS液质联用仪(生产商：Agilent，MS型号：6110/6120 Quadrupole MS)。waters ACQuity UPLC-QD/SQD(生产商：waters，MS型号：waters ACQuity Qda Detector/waters SQ Detector)THERMO Ultimate 3000-Q Exactive(生产商：THERMO，MS型号：THERMO Q Exactive)。
高效液相色谱法(HPLC)分析使用Agilent HPLC 1200DAD、Agilent HPLC 1200VWD和Waters HPLC e2695-2489高效液相色谱仪。
手性HPLC分析测定使用Agilent 1260DAD高效液相色谱仪。
高效液相制备使用Waters 2545-2767、Waters 2767-SQ Detecor2、Shimadzu LC-20AP和Gilson GX-281制备型色谱仪。
手性制备使用Shimadzu LC-20AP制备型色谱仪。
CombiFlash快速制备仪使用Combiflash Rf200(TELEDYNE ISCO)。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板，薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm～0.2mm，薄层层析分离纯化产品采用的规格是0.4mm～0.5mm。
硅胶柱色谱法一般使用烟台黄海硅胶200～300目硅胶为载体。
激酶平均抑制率及IC50值的测定用NovoStar酶标仪(德国BMG公司)。
本发明的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买自ABCR GmbH & Co.KG，Acros Organics，Aldrich Chemical Company，韶远化学科技(Accela ChemBio Inc)、达瑞化学品等公司。
实施例中无特殊说明，反应均能够在氩气氛或氮气氛下进行。
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气或氮气气球。
氢气氛是指反应瓶连接一个约1L容积的氢气气球。
加压氢化反应使用Parr 3916EKX型氢化仪和清蓝QL-500型氢气发生器或HC2-SS型氢化仪。
氢化反应通常抽真空，充入氢气，反复操作3次。
微波反应使用CEM Discover-S 908860型微波反应器。
实施例中无特殊说明，溶液是指水溶液。
实施例中无特殊说明，反应的温度为室温，为20℃～30℃。
实施例中的反应进程的监测采用薄层色谱法(TLC)，反应所使用的展开剂，纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂体系包括：A：二氯甲烷/甲醇体系，B：正己烷/乙酸乙酯，溶剂的体积比根据化合物的极性不同而进行调节，也可以加入少量的三乙胺和醋酸等碱性或酸性试剂进行调节。
实施例1
5-乙基-6-氟-4-((5aS,6S,9R)-1-氟-12-((1-(吗啉甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚1
第一步
4-((叔丁氧基羰基)氨基)-2,6-二氯-5-氟烟酸叔丁酯1b
将粗品2,6-二氯-3-氟吡啶-4-胺1a(1.8g，9.94mmol，采用专利申请“WO2016191524A1”中说明书第46页的Preparation 14(a)公开的方法制备而得)溶于四氢呋喃(50mL)，冰浴下加入2M的双三甲基硅基氨基钠四氢呋喃溶液(20mL)，搅拌反应0.5小时后，加入二碳酸二叔丁酯(6.5g，29.7mmol)，搅拌反应14小时，反应液中加入饱和氯化铵水溶液淬灭，乙酸乙酯萃取(50mL×3)，有机相合并，用无水硫酸钠干燥，过滤除去干燥剂后滤液减压浓缩，残余物以洗脱剂体系B纯化得到标题化合物1b(1g，产率：26.3％)。
MS m/z(ESI):381.1[M+1]。
第二步
4-氨基-2,6-二氯-5-氟烟酸叔丁酯1c
将化合物1b(1g，2.62mmol)溶于乙酸乙酯(8mL)中，加入4M的盐酸二氧六环溶液(3mL)，搅拌反应2小时，冰浴下用4M的氢氧化钠水溶液调节pH至中性，乙酸乙酯萃取(15mL×3)，合并有机相，无水硫酸钠干燥，过滤除去干燥剂后滤液减压浓缩，残余物以洗脱剂体系A纯化得到标题化合物1c(500mg，产率：67.8％)。
MS m/z(ESI):281.1[M+1]。
第三步
2,6-二氯-5-氟-4-(3-(2,2,2-三氯乙酰基)脲基)烟酸叔丁酯1d
将化合物1c(500mg，1.77mmol)溶于四氢呋喃(10mL)，加入三氯乙酰异氰酸酯(670mg，3.55mmol，上海瀚鸿)，搅拌反应30分钟，反应液减压浓缩即得到粗品标题化合物1d(835mg)，产品不经纯化直接用于下步反应。
MS m/z(ESI):467.9[M+1]。
第四步
5,7-二氯-8-氟-吡啶并[4,3-d]嘧啶-2,4-二酚1e
将粗品化合物1d(835mg，1.77mmol)溶于7M的氨甲醇溶液(10mL)，搅拌反应1小时，反应液减压浓缩，残余物中加入甲基叔丁基醚(10mL)，搅拌0.5小时后过滤，滤饼干燥后即得到粗品标题化合物1e(400mg，产率：89.9％)，产品不经纯化，直接用于下步反应。
MS m/z(ESI):249.9[M+1]。
第五步
2,4,5,7-四氯-8-氟-吡啶并[4,3-d]嘧啶1f
将粗品化合物1e(875mg，3.5mmol)溶于三氯氧磷(25mL)，加入N,N-二异丙基乙胺(2.3g，17.5mmol)，110℃搅拌反应1小时，反应液冷却至室温后减压浓缩即得粗品标题化合物1f(1.14g)，产物不经纯化直接用于下一步。
MS m/z(ESI):285.8[M+1]。
第六步
(R)-5-甲氧基-3,4-二氢-2H-吡咯-2-羧酸甲酯1h
将(R)-2-吡咯烷酮-5-甲酸甲酯1g(20g，139.7mmol，上海毕得)、硫酸二甲酯(22.1g，175.2mmol)混合，60℃反应22小时，反应液冷却至室温，冰浴下倒入三乙胺(20g)和水(100mL)的溶液中，用甲基叔丁基醚(60mL×6)萃取后，减压浓缩即得到粗品标题化合物1h(16.3g，产率：74.2％)，粗品不经纯化，直接用于下步反应。
MS m/z(ESI):158.1[M+1]。
第七步
(R)-5-(2-甲氧基-1-硝基-2-氧代乙亚基)吡咯烷-2-羧酸甲酯1i
将粗品化合物1h(16.3g，103.7mmol)、硝基乙酸甲酯(13.6g，114.2mmol，上海韶远)混合，加热至60℃搅拌反应24小时，反应液冷却至室温后，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物1i(8.37g，产率：33％)。
MS m/z(ESI):245.1[M+1]。
第八步
(1S,2S,5R)-4-氧代-3,8-二氮杂双环[3.2.1]辛烷-2-羧酸甲酯1j
将化合物1i(7.5g，30.7mmol)溶于150mL甲醇中，加入10％钯碳催化剂(湿)(1.5g)，氢气置换三次，加热至50℃搅拌反应24小时，反应液降至室温，通过硅藻土过滤，滤饼用甲醇洗涤，将滤液减压浓缩即得到粗品标题化合物1j(5.6g)，产物不经纯化直接用于下步反应。
MS m/z(ESI):185.2[M+1]。
第九步
8-(叔丁基)2-甲基(1S,2S,5R)-4-氧代-3,8-二氮杂双环[3.2.1]辛烷-2,8-二羧酸酯1k
将粗品化合物1j(5.65g，30.4mmol)溶于60mL二氯甲烷中，冰浴下加入三乙胺(6.2g，61.27mmol)、二碳酸二叔丁酯(6.6g，30.24mmol)，搅拌反应14小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物1k(3g，产率：34.7％)。
MS m/z(ESI):285.2[M+1]。
第十步
(1S,2S,5R)-2-(羟甲基)-3,8-二氮杂双环[3.2.1]辛烷-8-羧酸叔丁酯1l
将化合物1k(3g，10.55mmol)溶于30mL四氢呋喃中，冰浴下滴加32mL 1M的氢化铝锂四氢呋喃溶液，恢复室温搅拌反应4小时，冰浴下依次加入1.05mL水、1.05mL 15％氢氧化钠溶液和3.15mL水，恢复室温搅拌15分钟，加入无水硫酸镁(1g)，搅拌15分钟，过滤，滤液减压浓缩即得到粗品标题化合物1l(2.4g)，产物不经纯化直接用于下步反应。
MS m/z(ESI):243.2[M+1]。
第十一步
(1S,2S,5R)-2-(((叔丁基二甲基硅基)氧基)甲基)-3,8-二氮杂双环[3.2.1]辛烷-8-羧酸叔丁酯1m
将粗品化合物1l(2.4g，9.9mmol)溶于25mL二氯甲烷，加入叔丁基二甲基氯硅烷(4.48g，29.7mmol)、4-二甲氨基吡啶(122mg，990μmol)，滴加三乙胺(4g，39.5mmol)，搅拌反应16小时，反应液中加入20mL水，用二氯甲烷(20mL×2)萃取，合并有机相，用饱和氯化钠溶液洗涤后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物1m(1.95g，产率：55.2％)。
MS m/z(ESI):357.1[M+1]。
第十二步
(1S,2S,5R)-2-(((叔丁基二甲基硅基)氧基)甲基)-3-(2,5,7-三氯-8-氟吡啶并[4,3-d]嘧啶-4-基)-3,8-二氮杂双环[3.2.1]辛烷-8-羧酸叔丁酯1n
将化合物1f(50g，174mmol)、N,N-二异丙基乙胺(65g，503mmol)溶于75mL二氯甲烷中，-78℃滴加化合物1m(60g，168.3mmol)的二氯甲烷(250mL)溶液，自然恢复室温反应4小时，反应液减压浓缩，残余物以洗脱剂体系B纯化得到标题化合物1n(86g，产率：84％)。
MS m/z(ESI):606.2[M+1]。
第十三步
(1S,2S,5R)-2-(((叔丁基二甲基硅基)氧基)甲基)-3-(5,7-二氯-8-氟-2-((1-(羟甲基)环丙基)甲氧基)吡啶并[4,3-d]嘧啶-4-基)-3,8-二氮杂双环[3.2.1]辛烷-8-羧酸叔丁酯1o
将化合物1n(5g，8.23mmol)溶于1,4-二氧六环(80mL)，加入1,1-双(羟甲基)环丙烷(1.3g，12.7mmol，上海韶远)、碳酸铯(5.4g，16.6mmol)、分子筛(5g)，110℃搅拌反应14小时，反应液冷却至室温后过滤，减压浓缩即得粗品标题化合物1o(5.5g)，产物不经纯化直接用于下一步。
MS m/z(ESI):672.2[M+1]。
第十四步
(5aS,6S,9R)-2-氯-1-氟-12-((1-(羟甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯1p
将粗品化合物1o(5.5g，8.2mmol)溶于四氢呋喃(80mL)，加入四丁基氟化铵(5.57g，24.7mmol)、N,N-二异丙基乙胺(5.33g，41.2mmol)，搅拌1小时后加热至60℃搅拌反应2小时，反应液冷却至室温，加入水(80mL)稀释，用乙酸乙酯(50mL×2)萃取，合并有机相，减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物1p(3g，产率：69.7％)。
MS m/z(ESI):522.2[M+1]。
第十五步
(5aS,6S,9R)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-12-((1-(羟甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab] 并庚环-14-羧酸叔丁酯1q
将化合物1p(2g，3.83mmol)、2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷(2.1g，5.8mmol)、四(三苯基膦)钯(889mg，769μmol)、碳酸铯(3.8g，11.66mmol)溶于36mL 1,4-二氧六环和水(V:V＝10:1)的混合溶液中。氮气氛围下，100℃反应14小时，反应液减压浓缩后，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物1q(1g，产率：36.2％)。
MS m/z(ESI):720.2[M+1]。
第十六步
(5aS,6S,9R)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-12-((1-(((甲基磺酰基)氧基)甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯1r
将化合物1q(150mg，145.8μmol)、N,N-二异丙基乙胺(55.6mg，437.6μmol)溶于二氯甲烷(5mL)，冰浴下加入甲基磺酰氯(25mg，218.8μmol)，保持温度搅拌反应1小时，反应液中加入饱和氯化铵溶液淬灭，用二氯甲烷(5mL×2)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后滤液减压浓缩即得到粗品标题化合物1r(130mg)，产物不经纯化直接用于下步反应。
MS m/z(ESI):798.2[M+1]。
第十七步
(5aS,6S,9R)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-12-((1-(吗啉甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯1s
将粗品化合物1r(130mg，162.9μmol)溶于乙腈(3mL)，加入吗啡啉(28.4mg，325.8μmol)、无水碳酸钾(67.6mg，488.8μmol)、碘化钠(24.4mg，162.9μmol)，加热至80℃搅拌反应2小时，反应液冷却至室温，加入水(20mL)稀释，用乙酸乙酯(10mL×2)萃取，合并有机相，减压浓缩即得到粗品标题化合物1s(128mg)，产物不经纯化，直接用于下步反应。
MS m/z(ESI):789.2[M+1]。
第十八步
5-乙基-6-氟-4-((5aS,6S,9R)-1-氟-12-((1-(吗啉甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚1
将粗品化合物1s(128mg，162.2μmol)溶于乙酸乙酯(3mL)中，冰浴下加入2mL 4M的盐酸二氧六环溶液，保持温度反应4小时，反应液减压浓缩，残余物用高效液相色谱法(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)纯化得到标题化合物1(35mg，产率33.4％)。
MS m/z(ESI):645.2[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(t,1H),7.31-7.21(m,2H),7.06(d,1H),5.07(dd,2H),4.62(dd,1H),4.45(tt,3H),4.15(dd,1H),3.77(s,1H),3.66(d,4H),3.25(s,1H),2.57-2.43(m,6H),2.22(d,1H),1.90(dt,4H),0.93(t,2H),0.84(t,2H),0.73(s,2H),0.52(s,2H)。
实施例2
4-((5aS,6S,9R)-12-((1-(((1S,4S)-2-氧杂-5-氮杂双环[2.2.1]庚-5-基)甲基)环丙基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚2
第一步
(5aS,6S,9R)-12-(1-(((1S,4S)-2-氧杂-5-氮杂双环[2.2.1]庚-5-基)甲基)环丙基)甲氧基)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯2a
将粗品化合物1r(150mg，131.6μmol)溶于乙腈(3mL)，加入(1S,4S)-2-氧杂-5-氮杂双环[2.2.1]庚烷盐酸盐(35.7mg，263.2μmol，上海乐研)、无水碳酸钾(72.7mg，526.4μmol)、碘化钠(19.7mg，263.2μmol)，加热至80℃搅拌反应2小时，反应液冷却至室温，加入水(20mL)稀释，用乙酸乙酯(10mL×2)萃取，合并有机相，减压浓缩即得到粗品标题化合物2a(105mg)，产物不经纯化，直接用于下步反应。
MS m/z(ESI):801.2[M+1]。
第二步
4-((5aS,6S,9R)-12-((1-(((1S,4S)-2-氧杂-5-氮杂双环[2.2.1]庚-5-基)甲基)环丙基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚2
将粗品化合物2a(100mg，188μmol)溶于乙酸乙酯(3mL)中，冰浴下加入2mL4M的盐酸二氧六环溶液，保持温度反应4小时，反应液减压浓缩，残余物用高效液相色谱法(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min) 纯化得到标题化合物2(35mg，产率33.4％)。
MS m/z(ESI):657.2[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(s,1H),7.27(d,2H),7.06(d,1H),5.36(s,1H),5.06(dd,1H),4.61(s,1H),4.49(d,2H),4.40(s,1H),4.15(d,1H),3.99(s,1H),3.75(s,1H),3.65(s,1H),3.22(d,2H),2.98(s,1H),2.83(s,1H),2.66(d,2H),2.48(s,1H),2.22(s,1H),2.05(s,1H),1.89(d,4H),1.72(s,1H),1.62(s,1H),0.92(s,2H),0.84(d,1H),0.71(s,2H),0.57(d,2H)。
实施例3
4-((5aS,6S,9R)-12-((1-(((1R,4R)-2-氧杂-5-氮杂双环[2.2.1]庚-5-基)甲基)环丙基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚3
第一步
(5aS,6S,9R)-12-((1-(((1R,4R)-2-氧杂-5-氮杂双环[2.2.1]庚-5-基)甲基)环丙基)甲氧基)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯3a
将粗品化合物1r(150mg，188μmol)溶于乙腈(3mL)，加入(1R,4R)-2-氧杂-5-氮杂双环[2.2.1]庚烷盐酸盐(51mg，376.1μmol，上海乐研)、无水碳酸钾(100mg，723.5μmol)、碘化钠(28mg，187μmol)，加热至80℃搅拌反应2小时，反应液冷却至室温，加入水(20mL)稀释，用乙酸乙酯(10mL×2)萃取，合并有机相，减压浓缩即得到粗品标题化合物3a(150mg)，产物不经纯化，直接用于下步反应。
MS m/z(ESI):801.2[M+1]。
第二步
4-((5aS,6S,9R)-12-((1-(((1R,4R)-2-氧杂-5-氮杂双环[2.2.1]庚-5-基)甲基)环丙基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚3
将粗品化合物3a(100mg，124.8μmol)溶于乙酸乙酯(3mL)中，冰浴下加入2 mL 4M的盐酸二氧六环溶液，保持温度反应4小时，反应液减压浓缩，残余物用高效液相色谱法(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)纯化得到标题化合物3(10mg，产率：12.2％)。
MS m/z(ESI):657.2[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(d,1H),7.29(d,1H),7.28-7.23(m,1H),7.11(s,1H),5.12-5.00(m,2H),4.61(d,1H),4.47(dd,3H),4.15(d,1H),4.04(s,1H),3.73(d,2H),3.25(s,1H),3.02(d,1H),2.80(s,3H),2.58(d,1H),2.47(s,1H),2.25-2.17(m,1H),2.05(s,1H),2.00-1.71(m,6H),0.88(dq,3H),0.79-0.52(m,4H)。
实施例4
4-((5aS,6S,9R)-12-((1-((4-氧杂-7-氮杂螺[2.5]辛-7-基)甲基)环丙基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂[6,9]甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚4
第一步
(5aS,6S,9R)-12-((1-((4-氧杂-7-氮杂螺[2.5]辛-7-基)甲基)环丙基)甲氧基)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-[6,9]甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯4a
将粗品化合物1r(100mg，125μmol)溶于乙腈(3mL)，加入4-氧杂-7-氮杂螺[2.5]辛烷盐酸盐(40mg，267μmol，上海毕得)、无水碳酸钾(70mg，506μmol)、碘化钠(20mg，133μmol)，加热至80℃搅拌反应2小时，反应液冷却至室温，加入水(20mL)稀释，用乙酸乙酯(10mL×2)萃取，合并有机相，减压浓缩即得到粗品标题化合物4a(102mg)，产物不经纯化，直接用于下步反应。
MS m/z(ESI):815.2[M+1]。
第二步
4-((5aS,6S,9R)-12-((1-((4-氧杂-7-氮杂螺[2.5]辛-7-基)甲基)环丙基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂[6,9]甲桥萘并[1,8-ab]并庚环 -2-基)-5-乙基-6-氟萘-2-酚4
将粗品化合物4a(100mg，122μmol)溶于乙酸乙酯(3mL)中，冰浴下加入2mL4M的盐酸二氧六环溶液，保持温度反应4小时，反应液减压浓缩，残余物用高效液相色谱法(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)纯化得到标题化合物4(15mg，产率：18.2％)。
MS m/z(ESI):671.2[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(ddd,1H),7.31-7.22(m,2H),7.06(dd,1H),5.08(ddd,2H),4.68-4.56(m,2H),4.53-4.40(m,3H),4.16(dd,1H),3.82-3.72(m,3H),3.67(d,1H),3.27(d,1H),2.70-2.43(m,6H),2.29-2.19(m,1H),2.05(d,1H),2.01-1.79(m,4H),0.92(td,2H),0.84(t,1H),0.78-0.67(m,3H),0.56(d,3H)。
实施例5
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-5-甲基-12-((1-(吗啉甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚5
第一步
(1-(吗啉甲基)环丙基)甲醇5b
将1-氨基甲基环丙烷甲醇5a(1g，9.89mmol，上海韶远)、双(2-溴乙基)醚(2.3g，9.91mmol，上海毕得)溶于乙腈(60mL)，加入无水碳酸钠(3.1g，29.52mmol)，回流反应液14小时，反应液减压浓缩，残余物以洗脱剂体系A纯化得到标题化合物5b(1.3g，产率：76.7％)。
MS m/z(ESI):172.2[M+1]。
第二步
2,5,7-三氯-8-氟吡啶并[4,3-d]嘧啶-4-酚5c
将粗品化合物1e(2g，8mmol)溶于三氯氧磷(25mL)，加入N,N-二异丙基乙胺(5.16g，40mmol)，110℃搅拌反应14小时，反应液冷却至室温后减压浓缩，残余物溶于1,4-二氧六环，滴加20％碳酸钾溶液调节pH至2-3，搅拌2小时后过滤，滤饼用水洗涤，干燥后即得粗品标题化合物5c(1.5g)，产物不经纯化直接用于下一步。
MS m/z(ESI):267.8[M+1]。
第三步
(1S,2S,5R)-2-((S)-1-((2,7-二氯-8-氟-4-羟基吡啶并[4,3-d]嘧啶-5-基)氧基)乙基)-3,8-二氮杂双环[3.2.1]辛烷-8-羧酸叔丁酯5e
将(1S,2S,5R)-2-((S)-1-羟乙基)-3,8-二氮杂双环[3.2.1]辛烷-8-羧酸叔丁酯5d(370mg，1.44mmol，采用专利申请“WO2022173678A1”中说明书第164页的Intermediate 29公开的方法制备而得)溶于四氢呋喃(10mL)，冰浴下加入氢化钠(201mg，5.2mmol，60％purity)，反应30分钟后加入化合物5c(353mg，1.31mmol)，搅拌反应2小时，反应液中加入水淬灭后减压浓缩，即得粗品标题化合物5e(600mg)，产物不经纯化，直接用于下一步。
MS m/z(ESI):488.2[M+1]。
第四步
(5S,5aS,6S,9R)-2,12-二氯-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a，11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯5f
将化合物5e(78mg，159.7μmol)溶于二氯甲烷(2mL)，冰浴下加入N,N-二异丙基乙胺(61.9mg，478.9μmol)、三氯氧磷(122.4mg，798.2μmol)，搅拌反应2小时，反应液中加入饱和碳酸氢钠溶液淬灭，用二氯甲烷(10mL×2)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩即得粗品标题化合物5f(75mg)，产物不经纯化直接用于下步反应。
MS m/z(ESI):470.2[M+1]。
第五步
(5S,5aS,6S,9R)-2-氯-1-氟-5-甲基-12-((1-(吗啉甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯5g
将化合物5b(123.8mg，722.9μmol)，粗品化合物5f(170mg，361μmol)溶于二甲亚砜(4mL)，加入氟化钾(105mg，1.8mmol)，100℃反应14小时，反应液降至室温后加入水，用乙酸乙酯(30mL×2)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物5g(200mg，产率：91.4％)。
MS m/z(ESI):605.2[M+1]。
第六步
(5S,5aS,6S,9R)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-5-甲基-12-((1-(吗啉基甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁酯5h
将化合物5g(218mg，360μmol)、2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷(195mg，540μmol，采用专利申请“WO2021/041671”中说明书第104页的Intermediate 18公开的方法制备而得)溶于1.4-二氧六环(4mL)和水(0.5mL)，加入碳酸铯(352mg，1.08mmol)，四三苯基膦钯(83.26mg，72μmol)，氮气氛下，110℃反应14小时，反应液冷却至室温，减压浓缩，残余物用乙酸乙酯溶解，过滤，滤液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物5h(200mg，产率：69％)。
MS m/z(ESI):803.2[M+1]。
第七步
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-5-甲基-12-((1-(吗啉甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚5
将化合物5h(200mg，249μmol)溶于乙酸乙酯(5mL)，冰浴下加入4M氯化氢的1,4-二氧六环溶液(2mL)，保持温度反应0.5小时后，减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物5(90mg，产率：54.8％)。
MS m/z(ESI):659.2[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(dt,1H),7.29(t,1H),7.24(t,1H),7.05(dd,1H),5.40(ddd,1H),4.57(dt,1H),4.51-4.36(m,2H),4.11(t,1H),3.74(d,1H),3.70-3.60(m,5H),3.21(t,1H),2.60-2.39(m,7H),2.21(ddt,1H),2.10(dq,1H),1.94-1.75(m,3H),1.58(dd,3H),0.99(d,1H),0.81(t,2H),0.74(d,2H),0.59-0.48(m,2H)。
实施例6
4-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚6
第一步
(5S,5aS,6S,9R)-12-((1-(((叔丁基二甲基硅基)氧基)甲基)环丙基)甲氧基)-2-氯-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁基酯6b
将(1-(((叔丁基二甲基硅基)氧基)甲基)环丙基)甲醇6a(1.4g，6.4mmol)溶于四氢呋喃(15mL)，冰浴下加入2M双(三甲基硅基)氨基钠的四氢呋喃溶液，保持温度搅拌30分钟后，冰浴下加入粗品化合物5f(2.3g，4.9mmol)的四氢呋喃溶液(20mL)，保持温度搅拌反应1小时，反应液中加入饱和氯化铵溶液淬灭，用乙酸乙酯(30mL×2)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物6b(2g，产率：62.8％)。
MS m/z(ESI):650.2[M+1]。
第二步
(5S,5aS,6S,9R)-12-((1-(((叔丁基二甲基硅基)氧基)甲基)环丙基)甲氧基)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁酯6c
将化合物6b(2g，3.07mmol)、2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷(1.66g，4.6mmol)溶于1.4-二氧六环(40mL)和水(8mL)，加入碳酸铯(3g，9.2mmol)和四三苯基膦钯(710mg，615μmol)，氮气氛下，105℃反应14小时，反应液冷却至室温，减压浓缩，残余物用乙酸乙酯溶解，过滤，滤液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物6c(2.5g，产率：95.8％)。
MS m/z(ESI):848.2[M+1]。
第三步
(5S,5aS,6S,9R)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-12-((1-(羟甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁酯6d
将化合物6c(500mg，589.58μmol)溶于四氢呋喃(6mL)，加入四丁基氟化铵(160mg，710.5μmol)，搅拌反应1小时后反应液中加入乙酸乙酯(20mL)稀释，依次用水，饱和氯化钠溶液洗涤，有机相用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩即得粗品标题化合物6d(435mg)，产物不经纯化直接用于下步反应。
MS m/z(ESI):734.2[M+1]。
第四步
(5S,5aS,6S,9R)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-5-甲基-12-((1-((甲基磺酰基)氧基)甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁酯6e
将粗品化合物6d(435mg，592.8μmol)溶于二氯甲烷(10mL)，冰浴加入N,N-二异丙基乙胺(229mg，1.77mmol)、甲烷磺酰氯(95mg，829.3μmol)，保持温度搅拌反应30分钟，反应液中加入饱和氯化铵溶液淬灭，用二氯甲烷(10mL×2)萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后减压浓缩即得粗品标题化合物6e(480mg)，产物不经纯化直接用于下步反应。
MS m/z(ESI):812.2[M+1]。
第五步
(5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁基酯6f
将粗品化合物6e(235mg，289.4μmol)，4-(二氟甲亚基)哌啶盐酸盐(74mg，436.32μmol，采用文献“Bioorganic and Medicinal Chemistry,2004,vol.12,#7,p. 1713-1730”公开的方法制备而得)溶于乙腈(5mL)，加入无水碳酸钾(120mg，868.27μmol)和碘化钠(44mg，293.54μmol)，80℃搅拌反应1小时，反应液降至室温后过滤，滤液中加入水，用乙酸乙酯(10mL×2)萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后减压浓缩即得粗品标题化合物6f(245mg)，产物不经纯化直接用于下步反应
MS m/z(ESI):849.2[M+1]。
第六步
4-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚6
将粗品化合物6f(250mg，294.5μmol)溶于乙酸乙酯(5mL)，冰浴下加入4M氯化氢的1,4-二氧六环溶液(5mL)，保持温度反应0.5小时后，减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物6(140mg，产率：67.4％)。
MS m/z(ESI):705.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(dt,1H),7.32–7.22(m,2H),7.12-6.98(m,1H),5.40(ddt,1H),4.57(td,1H),4.53–4.36(m,2H),4.10(t,1H),3.72(d,1H),3.62(s,1H),3.20(t,1H),2.63–2.39(m,7H),2.29–2.01(m,6H),1.94–1.86(m,1H),1.81(dt,2H),1.58(dd,3H),0.89(dt,3H),0.75(d,2H),0.52(s,2H)。
实施例7
4-((5S,5aS,6S,9R)-12-((1-((3-(二氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚7
第一步 3-(二氟甲亚基)吡咯烷-1-甲酸叔丁酯7c
将叔丁醇钾(912mg，8.1mmol)溶于N,N-二甲基乙酰胺(3mL)，-40℃下加入1-叔丁氧基羰基-3-吡咯烷酮7a(1g，5.4mmol)和2-((二氟甲基)磺酰基)吡啶7b(872mg，4.5mmol，上海毕得)，保持温度反应15分钟，反应液中加入饱和氯化铵溶液淬灭，加入3N盐酸(10mL)，用乙酸乙酯(30mL×3)萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物7c(167mg，产率：16.8％)。
MS m/z(ESI):164[M-55]。
第二步
3-(二氟甲亚基)吡咯烷盐酸盐7d
将化合物7c(167mg，761.7μmol)溶于4M氯化氢的1，4-二氧六环溶液(2mL)，搅拌反应1小时，反应液减压浓缩得到粗品标题化合物7d(118mg)，产物不经纯化，直接用于下一步反应。
MS m/z(ESI):120.2[M+1]。
第三步
4-((5S,5aS,6S,9R)-12-((1-((3-(二氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚7
采用实施例6中的合成路线，将第五步原料化合物4-(二氟甲亚基)哌啶盐酸盐替换为化合物7d得到标题化合物7(3mg，产率：12％)。
MS m/z(ESI):691.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.68-7.63(m,1H),7.29-7.23(m,2H),7.12-7.01(m,1H),5.41-5.39(m,1H),4.59-4.42(m,3H),4.11-4.08(m,1H),3.70-3.61(m,3H),3.17-2.70(m,3H),2.70-2.44(m,7H),2.21-1.79(m,7H),1.59-1.57(m,3H),0.99-0.92(m,2H),0.75-0.73(m,2H)。
实施例8
1-((1-((((5S,5aS,6S,9R)-2-(8-乙基-7-氟-3-羟基萘-1-基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-12-基)氧基)甲基)环丙基)甲基)哌啶-4-酮O-甲基肟8
采用实施例6中的合成路线，将第五步原料4-(二氟甲亚基)哌啶盐酸盐替换 为哌啶-4-酮O-甲基肟(采用文献“Molecules,2016,vol.21,#12,art.no.1674”公开的方法制备而得)得到标题化合物8(5mg，产率：20％)。
MS m/z(ESI):700.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(dt,1H),7.32–7.21(m,2H),7.12-6.98(m,1H),5.42(ddd,1H),4.65–4.41(m,4H),4.12(t,1H),3.78(d,4H),3.66(s,1H),3.27–3.18(m,1H),2.68-2.67(m,2H),2.60-2.54(m,4H),2.52-2.44(m,2H),2.30(q,2H),2.24–2.17(m,1H),2.15–2.07(m,1H),1.91(d,1H),1.88–1.78(m,2H),1.59(dd,3H),0.99-0.95(m,3H),0.76(t,2H),0.54(s,2H)。
实施例9
4-((1-((((5S,5aS,6S,9R)-2-(8-乙基-7-氟-3-羟基萘-1-基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-12-基)氧基)甲基)环丙基)甲基)-1-(甲基氨亚基)-1λ6-硫代吗啉1-氧化物9
采用实施例6中的合成路线，将第五步原料4-(二氟甲亚基)哌啶盐酸盐替换为1-(甲基氨亚基)-1λ6-硫代吗啉-1-氧化物(采用专利申请“WO2022/23772,2022,A1”中说明书第239页的Intermediate S公开的方法制备而得)得到标题化合物9(5mg，产率：6％)。
MS m/z(ESI):720.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.68-7.64(m,1H),7.29-7.22(m,2H),7.13-7.01(m,1H),5.40-5.37(m,1H),4.61-4.39(m,3H),4.13-4.10(m,1H),3.77-3.66(m,2H),3.25-2.85(m,9H),2.82-2.46(m,6H),2.23-1.80(m,6H),1.58-1.57(m,3H),1.00-0.97(m,1H),0.83-0.77(m,3H),0.56-0.54(s,2H)。
实施例10
4-((1-((((5S,5aS,6S,9R)-2-(8-乙基-7-氟-3-羟基萘-1-基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-12-基)氧基)甲基)环丙基)甲基)-1-氨亚基-1λ6-硫代吗啉1-氧化物10
采用实施例6中的合成路线，将第五步原料4-(二氟甲亚基)哌啶盐酸盐替换为化合物1-氨亚基-1λ6-硫代吗啉-1-氧化物(采用文献“Tetrahedron,2014,vol.70,#37,p.6613-6622”公开的方法制备而得)得到标题化合物10(5mg，产率：6％)。
MS m/z(ESI):706.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.69-7.65(m,1H),7.30-7.22(m,2H),7.12-7.01(m,1H),5.44-5.42(m,1H),4.61-4.39(m,3H),4.14-4.12(m,1H),3.85-3.72(m,2H),3.27-2.90(m,9H),2.70-2.64(m,4H),2.25-1.74(m,7H),1.59-1.57(m,3H),1.00-0.97(m,1H),0.84-0.71(m,3H)。
实施例11
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-(((E)-3-(氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚11
第一步
(E)-3-(氟甲亚基)吡咯烷-1-甲酸叔丁酯11a-1
(Z)-3-(氟甲亚基)吡咯烷-1-甲酸叔丁酯11a-2
将2-((氟甲基)磺酰基)吡啶(4.7g，26.8mmol，上海韶远)溶于四氢呋喃(100mL)， -78℃下加入1M双(三甲基硅烷基)氨基钾的四氢呋喃溶液(33mL)，保持温度反应30分钟后加入1-叔丁氧基羰基-3-吡咯烷酮7a(5g，27mmol)，保持温度反应3小时后恢复室温反应1小时，反应液中加入饱和氯化铵溶液淬灭，加入3N盐酸(50mL)，搅拌1小时，用乙酸乙酯(50mL×3)萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物11a-1(800mg，产率：14.7％)和11a-2(800mg，产率：14.7％)。
MS m/z(ESI):146.2[M-55]。
11a-1:1H NMR(500MHz,CDCl3):δ6.70(s,0.5H),6.54(s,0.5H),3.93(s,2H),3.48(t,2H),2.66(t,2H),1.48(s,9H)。
11a-2:1H NMR(500MHz,CDCl3):δ6.61(s,0.5H),6.45(s,0.5H),4.07(s,2H),3.49(t,2H),2.49(t,2H),1.48(s,9H)。
第二步
(E)-3-(氟甲亚基)吡咯烷盐酸盐11b
将化合物11a-1(700mg，3.5mmol)溶于4M氯化氢的1，4-二氧六环溶液(10mL)，搅拌反应1小时，反应液减压浓缩得到粗品标题化合物11b(480mg)，产物不经纯化，直接用于下一步反应。
MS m/z(ESI):101.2[M+1]。
第三步
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-(((E)-3-(氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚11
采用实施例6中的合成路线，将第五步原料化合物4-(二氟甲亚基)哌啶盐酸盐替换为化合物11b得到标题化合物11(5mg，产率：12.1％)。
MS m/z(ESI):673.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(dt,1H),7.33–7.20(m,2H),7.11(d,1H),6.70(d,1H),5.40(ddd,1H),4.58(dd,1H),4.50–4.36(m,2H),4.10(t,1H),3.71(d,1H),3.62(s,1H),3.22–3.17(m,4H),2.75(s,2H),2.62–2.51(m,5H),2.25–2.06(m,2H),1.85–1.76(m,3H),1.58(dd,3H),1.31(s,2H),0.98(t,1H),0.81(t,2H),0.74-0.58(m,3H)。
实施例12
2-((1-((((5S,5aS,6S,9R)-2-(8-乙基-7-氟-3-羟基萘-1-基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-12-基)氧基)甲基)环丙基)甲基)六氢环戊并[c]吡咯-5(1H)-酮O-甲基肟12
MS m/z(ESI):726.3[M+1]。
实施例13
1-((1-((((5S,5aS,6S,9R)-2-(8-乙基-7-氟-3-羟基萘-1-基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-12-基)氧基)甲基)环丙基)甲基)氮杂环庚-4-酮O-甲基肟13(顺反异构体混合物)
采用实施例6中的合成路线，将第五步原料4-(二氟甲亚基)哌啶盐酸盐替换为氮杂环庚-4-酮O-甲基肟三氟醋酸盐(采用文献“RSC Advances,2017,vol.7,#3,p.1480-1483”公开的方法制备而得)得到标题化合物13。
MS m/z(ESI):714.3[M+1]。
实施例14
4-((5S,5aS,6S,9R)-12-(1-((5-(二氟甲亚基)六氢环戊烷并[c]吡咯-2(1H)基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚14
采用实施例7中的合成路线，将第一步原料化合物7a替换为N-叔丁氧基羰基-六氢-5-氧代环戊[c]并吡咯(上海毕得)得到标题化合物14(10mg，产率：39.9％)。
MS m/z(ESI):731.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.68-7.66(m,1H),7.29-7.26(m,2H),7.12-7.01(m,1H),5.41-5.39(m,1H),4.58-4.39(m,3H),4.11-4.10(m,1H),3.71-3.47(m,3H),3.19-3.18(m,3H),2.73-2.08(m,12H),1.82-1.79(m,3H),1.59-1.57(m,3H),0.99-0.92 (m,2H),0.72-0.54(m,5H)。
实施例15
4-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)氮杂环庚-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚15
采用实施例7中的合成路线，将第一步原料化合物7a替换为化合物4-氧代氮杂环庚烷-1-羧酸叔丁酯(上海毕得)得到标题化合物15(5mg，产率：19.3％)。
MS m/z(ESI):719.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.68-7.65(m,1H),7.29-7.24(m,1H),7.12-7.11(m,1H),6.98-6.95(m,1H),5.39-5.36(m,1H),4.59-4.57(m,1H),4.46-4.42(m,2H),4.14-4.10(m,1H),3.76-3.74(m,1H),3.68-3.63(m,1H),3.25-3.20(m,1H),2.98-2.81(m,6H),2.56-2.42(m,4H),2.33-2.30(m,2H),2.23-2.20(m,1H),2.18-2.06(m,2H),1.92-1.81(m,4H),1.62-1.59(m,3H),0.99-0.95(m,1H),0.93-0.91(m,1H),0.80-0.79(m,2H),0.62-0.60(m,2H)。
实施例16
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-(((Z)-2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚16(非对映异构体混合物)
实施例16-p1,16-p2
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-(((S,Z)-2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚16-p1
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-(((R,Z)-2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚16-p2
实施例17
4-((5S,5aS,6S,9R)-12-((2,6-二甲亚基四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚17
采用实施例5中的合成路线，将第五步原料化合物5b替换为(2,6-二甲亚基四氢-1H-吡咯嗪-7a(5H)-基)甲醇(采用专利申请“WO2022247757”中说明书第30页的实施例4公开的方法制备而得)，得到标题化合物17(20mg，产率：24.4％)。
MS m/z(ESI):653.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.72-7.56(m,1H),7.37-7.18(m,2H),7.12-6.91(m,1H),5.43-5.27(m,1H),5.11-4.95(m,2H),4.62-4.49(m,1H),4.44-4.21(m,2H),4.13-4.01(m,1H),3.85-3.54(m,4H),3.50-3.37(m,4H),3.23-3.08(m,2H),2.87-2.72(m,2H),2.70-2.39(m,3H),2.27-1.97(m,2H),1.97-1.66(m,3H),1.60-1.46(m,2H),1.02-0.90(m,1H),0.84-0.64(m,2H)。
实施例18
4-((5S,5aS,6S,9R)-12-((2-(二氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚18(非对映异构体混合物)
采用实施例5中的合成路线，将第五步原料化合物5b替换为(2-(二氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲醇(采用专利申请“WO2022247757”中说明书第54页的实施例11公开的方法制备而得)，得到标题化合物18(50mg，产率：24.2％)(非对映异构体混合物)。
MS m/z(ESI):677.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(dt,1H),7.32–7.21(m,2H),7.12-6.99(m,1H),5.39(ddd,1H),4.59(p,1H),4.37(dd,1H),4.29(d,1H),4.15–4.08(m,1H),3.81(dt,1H),3.71(d,1H),3.62(d,1H),3.48–3.40(m,1H),3.26–3.12(m,2H),2.88–2.77(m,1H),2.73(q,1H),2.64–2.45(m,2H),2.24–2.11(m,2H),2.04(dddd,2H),1.97–1.76(m,5H),1.58(dd,3H),0.99-0.79(m,3H)。
实施例18-p1,18-p2
4-((5S,5aS,6S,9R)-12-(((S)-2-(二氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚18-p1
4-((5S,5aS,6S,9R)-12-(((R)-2-(二氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚18-p1
异构体混合物18(30mg，44.3μmol)经手性柱拆分(Gilson 281，色谱柱：CHIRALPAK IG,20*250mm,5μm；流动相A：正己烷，流动相B：乙醇(0.5％NH3in MeOH)，梯度配比：A:B：75:25，流速：20mL/min)得到标题化合物10mg，10mg，产率：33％，33％。
异构体混合物手性HPLC分析方法：保留时间分别为10.274min、14.616min(色谱柱：CHIRALPAK IG，150*4.6mm，5μm；流动相A：90％乙醇(含0.1％二乙胺)+10％ 二氯甲烷，流动相B：正己烷，梯度配比：A:B：30:70，流速：1.0mL/min)。单一构型化合物(较短保留时间)：10.274min(10mg，产率：33％)。
MS m/z(ESI):677.3[M+1]。
HPLC分析：保留时间1.45分钟，纯度：90％(色谱柱:ACQUITYC18,1.7μm,2.1*50mm；流动相：水(10mM碳酸氢铵)，乙腈，梯度配比：乙腈10％-95％)。
1H NMR(500MHz,CD3OD):δ7.71–7.64(m,1H),7.33–7.22(m,2H),7.12-6.98(m,1H),5.54–5.47(m,1H),4.68(ddd,1H),4.56–4.49(m,1H),4.44(d,1H),4.24(t,1H),4.03(s,1H),3.93(s,1H),3.69(d,1H),3.36(s,2H),2.92(d,2H),2.67(d,1H),2.59–2.43(m,2H),2.32–1.87(m,9H),1.60(d,3H),0.89(dt,3H)。
单一构型化合物(较长保留时间)：14.616min(10mg，产率：33％)。
MS m/z(ESI):677.3[M+1]。
HPLC分析：保留时间1.45分钟，纯度：90％(色谱柱:ACQUITYC18,1.7μm,2.1*50mm；流动相：水(10mM碳酸氢铵)，乙腈，梯度配比：乙腈10％-95％)。
1H NMR(500MHz,CD3OD):δ7.68(dt,1H),7.33–7.22(m,2H),7.12-6.89(m,1H),5.53–5.46(m,1H),4.68(td,1H),4.54(d,1H),4.45(d,1H),4.24(t,1H),3.99(d,3H),3.70(d,1H),3.37(s,1H),3.01–2.88(m,2H),2.67(d,1H),2.52(ddt,2H),2.32–1.87(m,9H),1.61(dd,3H),0.89(dt,3H)。
实施例19
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-(((E)-2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚19(非对映异构体混合物)
实施例19-p1,19-p2
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-(((S,E)-2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚19-p1
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-(((R,E)-2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂 -6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚19-p2
实施例20
4-((5aS,6S,9R)-12-((2,6-二甲亚基四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚20
采用实施例1中的合成路线第一至第十五步和第十八步，将第十三步原料化合物1,1-双(羟甲基)环丙烷替换为2,6-二甲亚基四氢-1H-吡咯嗪-7a(5H)-基)甲醇得到标题化合物20(7mg，产率：8.5％)。
MS m/z(ESI):639.2[M+1]。
1H NMR(500MHz,CD3OD):δ7.69(ddd,1H),7.34–7.24(m,2H),7.08(dd,1H),5.11–5.02(m,4H),4.67–4.61(m,1H),4.51(ddd,1H),4.40-4.34(m,2H),4.17(dd,1H),3.82(d,2H),3.78–3.74(m,1H),3.70–3.66(m,1H),3.50–3.39(m,1H),3.32–3.19(m,3H),2.84(d,2H),2.63(d,2H),2.54–2.44(m,1H),2.29–2.20(m,1H),2.01–1.79(m,4H),0.90(dt,3H)。
实施例21
4-((5aS,6S,9R)-12-((2-(二氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6氟萘-2-酚21(非对映异构体混合物)
采用实施例1中的合成路线第一至第十五步和第十八步，将第十三步原料化合物1,1-双(羟甲基)环丙烷替换为(2-(二氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲醇(采用专利申请“WO2022247757”中说明书第54页的实施例11公开的方法制备而得)，得到标题化合物21(非对映异构体混合物)。
MS m/z(ESI):663.2[M+1]。
实施例21-p1,21-p2
4-((5aS,6S,9R)-12-(((S)-2-(二氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6氟萘-2-酚21-p1
4-((5aS,6S,9R)-12-(((R)-2-(二氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-1-氟-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6氟萘-2-酚21-p2
化合物21经手性柱拆分得到标题化合物。
MS m/z(ESI):663.2[M+1]。
实施例22
4-((5S,5aS,6S,9R)-12-((1-((3-(二氟甲亚基)氮杂环丁烷-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-乙基-6-氟萘-2-酚22
采用实施例7中的合成路线，将第一步原料化合物7a替换为化合物3-氧代氮杂环丁烷-1-羧酸叔丁酯(上海毕得)得到标题化合物22(5mg，产率：19.3％)。
MS m/z(ESI):677.2[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(dt,1H),7.33–7.21(m,2H),7.11(d,1H),5.40(ddd,1H),4.59(dd,1H),4.41–4.29(m,2H),4.11(t,1H),3.99–3.95(m,3H),3.73(d,1H),3.63(s,1H),3.31(t,1H),2.79–2.67(m,2H),2.52(dt,2H),2.15(d,2H), 1.97–1.78(m,3H),1.58(dd,3H),1.31(s,3H),0.98(t,1H),0.81(t,2H),0.72-0.59(m,3H)。
实施例23
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚23
第一步
4-(氟甲亚基)哌啶-1-甲酸叔丁酯23b
将2-((氟甲基)磺酰)吡啶(4.2g，23.97mmol)溶于四氢呋喃(50mL)，-78℃下加入1M双(三甲基硅烷基)氨基钾的四氢呋喃溶液(30mL)，保持温度反应30分钟后加入N-叔丁氧基羰基-4-哌啶酮23a(5g，25.09mmol，上海韶远)，保持温度反应3小时后恢复室温反应1小时，反应液中加入饱和氯化铵溶液淬灭，加入3N盐酸(100mL)，搅拌1小时后用乙酸乙酯(50mL×3)萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物23b(2g，产率：37％)。
第二步
4-(氟甲亚基)哌啶盐酸盐23c
将化合物23b(1g，4.64mmol)溶于4M氯化氢的1，4-二氧六环溶液(20mL)，搅拌反应1小时，反应液减压浓缩得到粗品标题化合物23c(700mg)，产物不经纯化，直接用于下一步反应。
MS m/z(ESI):116.1[M+1]。
第三步
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚23
采用实施例6中的合成路线，将第五步原料化合物4-(二氟甲亚基)哌啶盐酸盐替换为粗品化合物23c得到标题化合物23(15mg，产率：18.1％)。
MS m/z(ESI):687.2[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(dt,1H),7.32–7.21(m,2H),7.05(dd,1H),6.52(d,1H),5.45–5.38(m,1H),4.62–4.39(m,5H),4.11(t,2H),3.73(d,1H),3.63(s,1H),3.50–3.44(m,1H),3.28–3.17(m,3H),2.66–2.43(m,5H),2.35(s,2H),2.25–2.15(m,1H),2.10(s,2H),1.94–1.72(m,3H),1.58(dd,3H),0.98(t,1H),0.84–0.71(m,2H),0.54(s,1H)。
实施例24
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-萘-2-酚24(异构体混合物)
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-(((Z)-2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-萘-2-酚16(非对映异构体混合物)
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-(((E)-2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-萘-2-酚19(非对映异构体混合物)
采用实施例5中的合成路线，将第五步原料化合物5b替换为(2-(氟甲亚基)四氢-1H-吡咯嗪-7a(5H)-基)甲醇(采用专利申请“WO2022247757”中说明书第33页的实施例5公开的方法制备而得)，得到粗品标题化合物24(240mg)，用高效液相色谱法(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)纯化得到化合物16和19，(10mg，10mg，产率：15％，15％)。
非对映异构体混合物(较短保留时间)：(10mg，产率：15％)。
MS m/z(ESI):659.2[M+1]。
HPLC分析：保留时间1.40分钟，纯度：92％(色谱柱:ACQUITYC18,1.7μm,2.1*50mm；流动相：水(10mM碳酸氢铵)，乙腈，梯度配比：乙腈10％-95％)。
1H NMR(500MHz,CD3OD):δ7.65(dt,1H),7.30–7.18(m,2H),7.03(dd,1H), 6.73(d,1H),5.44–5.28(m,1H),4.57(t,1H),4.35(d,1H),4.28(dd,1H),4.09(t,1H),3.71(dd,2H),3.60(s,1H),3.40(d,1H),3.22–3.11(m,2H),2.85(d,1H),2.70(q,1H),2.62–2.41(m,2H),2.21–1.77(m,9H),1.56(dd,3H),0.85(dt,3H)。
非对映异构体混合物(较长保留时间)：(10mg，产率：15％)。
MS m/z(ESI):659.2[M+1]。
HPLC分析：保留时间1.41分钟，纯度：96％(色谱柱:ACQUITYC18,1.7μm,2.1*50mm；流动相：水(10mM碳酸氢铵)，乙腈，梯度配比：乙腈10％-95％)。
1H NMR(500MHz,CD3OD):δ7.66(dt,1H),7.31–7.20(m,2H),7.04(dd,1H),6.75(d,1H),5.43(d,1H),4.67–4.56(m,1H),4.55–4.39(m,2H),4.15(dd,2H),3.77(s,2H),3.45(s,1H),3.30–3.13(m,2H),3.04–2.80(m,2H),2.65–2.38(m,2H),2.32–1.81(m,9H),1.58(d,3H),0.96–0.74(m,3H)。
实施例25
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-(((Z)-3-(氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚25
采用实施例11中的合成路线，将第二步原料化合物11a-1替换为化合物11a-2得到标题化合物25(6mg，产率：14.5％)。
MS m/z(ESI):673.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.67(dt,1H),7.42–7.17(m,2H),7.05(dd,1H),6.56(dq,1H),5.40(ddd,1H),4.57(ddd,1H),4.48–4.32(m,2H),4.10(t,1H),3.86–3.60(m,2H),3.35(d,3H),3.29–3.07(m,1H),2.78–2.71(m,2H),2.70–2.45(m,4H),2.42(s,2H),2.26–2.05(m,2H),1.99–1.76(m,3H),1.58(dd,3H),0.98(t,1H),0.81(t,2H),0.74(d,2H),0.58(d,2H)。
实施例26
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-(((E)-3-(氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-胺26
MS m/z(ESI):672.3[M+1]。
实施例27
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-(((Z)-3-(氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-胺27
MS m/z(ESI):672.3[M+1]。
实施例28
(5S,5aS,6S,9R)-2-(8-乙基-7-氟萘-1-基)-1-氟-12-((1-(((Z)-3-(氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环28
采用实施例6中的合成路线，将第二步原料化合物2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷替换为2-(8-乙基-7-氟萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷(采用专利申请“WO2022232331”中说明书第93页的Intermediate L公开的方法制备而得)，第五步原料化合物4-(二氟甲亚基)哌啶盐酸盐替换为化合物11a-2得到标题化合物。
MS m/z(ESI):657.2[M+1]。
实施例29
(5S,5aS,6S,9R)-2-(8-乙基-7-氟萘-1-基)-1-氟-12-((1-(((E)-3-(氟甲亚基)吡咯烷-1-基) 甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环29
采用实施例6中的合成路线，将第二步原料化合物2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷替换为2-(8-乙基-7-氟萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷(采用专利申请“WO2022232331”中说明书第93页的Intermediate L公开的方法制备而得)，第五步原料化合物4-(二氟甲亚基)哌啶盐酸盐替换为化合物11a-1得到标题化合物。
MS m/z(ESI):657.2[M+1]。
实施例30
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-(((Z)-3-(氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-基甲基氨基甲酸酯30
MS m/z(ESI):730.2[M+1]。
实施例31
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-(((E)-3-(氟甲亚基)吡咯烷-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-基甲基氨基甲酸酯31
MS m/z(ESI):730.2[M+1]。
实施例32
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-胺32
MS m/z(ESI):686.2[M+1]。
实施例33
(5S,5aS,6S,9R)-2-(8-乙基-7-氟萘-1-基)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环33
采用实施例6中的合成路线，将第二步原料化合物2-(8-乙基-7-氟-3-(甲氧基甲氧基)萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷替换为2-(8-乙基-7-氟萘-1-基)-4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷(采用专利申请“WO2022232331”中说明书第93页的Intermediate L公开的方法制备而得)，第五步原料化合物4-(二氟甲亚基)哌啶盐酸盐替换为化合物23c得到标题化合物。
MS m/z(ESI):671.2[M+1]。
实施例34
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-基甲基氨基甲酸酯34
MS m/z(ESI):744.2[M+1]。
实施例35
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-((5-(氟甲亚基)六氢环戊并[c]吡咯-2(1H)-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚35
第一步
(3aR,6aS)-5-(氟甲亚基)六氢环戊并[c]吡咯-2(1H)-羧酸叔丁酯35b
将2-((氟甲基)磺酰)吡啶(1.8g，4.7mmol，上海韶远)溶于四氢呋喃(15mL)，-78℃下加入1M双(三甲基硅烷基)氨基钾的四氢呋喃溶液(5.4mL)，保持温度反应30分钟后加入顺式-5-氧代六氢环戊并[c]吡咯-2(1H)-羧酸叔丁酯35a(1g，4.4mmol，南京药石)的四氢呋喃溶液(3mL)，保持温度反应1小时后恢复室温反应16小时，反应液中加入饱和氯化铵溶液淬灭，用乙酸乙酯(20mL×3)萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物35b(760mg，产率：70.9％)。
第二步
(3aR,6aS)5-(氟甲亚基)八氢环戊并[c]吡咯盐酸盐35c
将化合物35b(760mg，3.1mmol)溶于乙腈(1.5mL)，加入4M氯化氢的1,4- 二氧六环溶液(6mL)，搅拌反应1小时，反应液减压浓缩得到粗品标题化合物35c(560mg)，产物不经纯化，直接用于下一步反应。
MS m/z(ESI):142.3[M+1]。
第三步
5-乙基-6-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-((5-(氟甲亚基)六氢环戊[c]吡咯-2(1H)-基)甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)萘-2-酚35
采用实施例6中的合成路线，将第五步原料化合物4-(二氟甲亚基)哌啶盐酸盐替换为化合物35c得到标题化合物35(5mg，产率：10.3％)。
MS m/z(ESI):713.3[M+1]。
1H NMR(500MHz,CD3OD):δ7.67-7.63(m,1H),7.28-7.21(m,2H),7.04(d,1H),6.50(d,1H),5.39-5.34(m,1H),4.58-4.53(m,1H),4.41(t,2H),4.08(t,1H),3.70(d,1H),3.60(s,1H),3.18(t,1H),2.98(s,2H),2.71-2.37(m,8H),2.29-2.16(m,3H),2.06-2.00(m,2H),1.91-1.76(m,3H),1.57(d,3H),0.96(t,1H),0.79(t,2H),0.72(s,2H),0.55(s,2H)。
实施例36
3-氯-5-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-4-(三氟甲基)苯胺36
第一步
(5S,5aS,6S,9R)-2-氯-1-氟-12-((1-(羟甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-4-羧酸叔丁酯36a
将化合物6b(100mg，153.8μmol)溶于四氢呋喃(4mL)，加入1M四丁基氟化铵的四氢呋喃溶液(187μL)，搅拌反应2小时，反应液中加入饱和氯化铵水溶液淬灭，乙酸乙酯萃取(15mL×3)，合并有机相，依次用水，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后滤液减压浓缩，即得到粗品标题化合物36a(82mg)，产品不经纯化直接用于下步反应。
MS m/z(ESI):536.2[M+1]。
第二步
(5S,5aS,6S,9R)-2-氯-1-氟-5-甲基-12-((1-((甲基磺酰基)氧基)甲基)环丙基)甲氧基)-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14羧酸叔丁酯36b
将粗品化合物36a(83mg，154.9μmol)、N,N-二异丙基乙胺(60mg，464.2μmol)溶于二氯甲烷(3mL)中，冰浴下加入甲烷磺酰氯(25mg，218.2μmol)，自然恢复室温反应30分钟，反应液中加入饱和氯化铵水溶液淬灭，乙酸乙酯萃取(10mL×3)，有机相合并，依次用水、饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后滤液减压浓缩，即得到粗品标题化合物36b(95mg)，产品不经纯化直接用于下步反应。
MS m/z(ESI):614.2[M+1]。
第三步
(5S,5aS,6S,9R)-2-氯-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁酯36c
将粗品化合物36b(95mg，154.7μmol)、化合物23c(35.5mg，234.5μmol溶于乙腈(4mL)，加入无水碳酸钾(64mg，463μmol)和碘化钠(70mg，467μmol)，80℃搅拌反应2小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物36c(80mg，产率：81.6％)。
MS m/z(ESI):633.2[M+1]。
第四步
(5S,5aS,6S,9R)-2-(5-氨基-3-氯-2-(三氟甲基)苯基)-1-氟-12-((1-(4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯36e
将化合物36c(20mg，31.6μmol)、3-氯-5-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊-2-基)-4-(三氟甲基)苯胺36d(15mg，46.6μmol，采用专利申请“WO2022148422”中说明书第257页的Example 80公开的方法制备而得)、四(三苯基膦)钯(7mg,6.1μmol)、碳酸铯(31mg，95.1μmol)混于1,4-二氧六环(1mL)和水(0.2mL)，氮气氛下，100℃反应1小时，反应液降至室温后加入乙酸乙酯稀释，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩即得粗品标题化合物36e(20mg)，产物不经纯化 直接用于下步反应。
MS m/z(ESI):792.2[M+1]。
第五步
3-氯-5-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-4-(三氟甲基)苯胺36
将粗品化合物36e(15mg，18.9μmol)溶于二氯甲烷(1mL)，冰浴下加入4M盐酸的1,4-二氧六环溶液(0.5mL)，保持温度反应0.5小时后，减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物36(4mg，产率：30.5％)。
MS m/z(ESI):690.3[M-1]。
1H NMR(500MHz,CD3OD):δ6.90(s,1H),6.58(d,1H),6.42(s,1H),5.37(dd,1H),4.58–4.39(m,3H),4.07(t,1H),3.70(d,1H),3.60(d,1H),3.20–3.14(m,1H),2.61–2.42(m,6H),2.33(s,2H),2.08(s,3H),1.92–1.74(m,3H),1.58(d,3H),0.74(s,2H),0.52(s,2H)。
实施例37
2-氨基-7-氟-4-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)苯并[b]噻吩-3-甲腈37
采用实施例36中的合成路线，将第四步原料化合物36d替换为化合物(3-氰基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊-2-基)-7-氟苯并[b]噻吩-2-基)氨基甲酸叔丁酯(采用专利申请“WO2021118877”中说明书第50页的preparation 15公开的方法制备而得)，得到标题化合物37(4mg，产率：34.4％)。
MS m/z(ESI):687.3[M-1]。
1H NMR(500MHz,CD3OD):δ7.39(dd,1H),7.04(t,1H),6.51(d,1H),5.41(dd,1H),4.53–4.46(m,2H),4.40(d,1H),4.10(d,1H),3.70(d,1H),3.60(d,1H),3.19(s,1H),2.62–2.31(m,8H),2.09(d,3H),1.92–1.75(m,3H),1.61(d,3H),0.75(s,2H),0.52(s,2H)。
实施例38
2-氟-3-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-甲基-4-(三氟甲基)苯胺38
第一步
(5S,5aS,6S,9R)-2-(3-(双(4-甲氧基苄基)氨基)-2-氟-5-甲基苯基)-12-((1-(((叔丁基二甲基硅基)氧基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯38b
将化合物6b(200mg，307.6μmol)、2-氟-N,N-双(4-甲氧基苄基)-5-甲基-3-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊-2-基)苯胺38a(200mg，407μmol，采用专利申请“WO2020035031”中说明书第308页的Example 27a and 27b公开的方法制备而得)、四(三苯基膦)钯(55mg，47.6μmol)、碳酸铯(300mg，920.7μmol)混于1,4-二氧六环(5mL)和水(1mL)，氮气氛下，100℃反应1小时，反应液降至室温后加入乙酸乙酯稀释，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩即得粗品标题化合物38b(280mg)，产物不经纯化直接用于下步反应。
MS m/z(ESI):979.2[M+1]。
第二步
(5S,5aS,6S,9R)-2-(3-(双(4-甲氧基苄基)氨基)-2-氟-6-碘-5-甲基苯基)-12-((1-(((叔丁基二甲基硅基)氧基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁基酯38c
将粗品化合物38b(280mg，285.91μmol)溶于N,N-二甲基甲酰胺(DMF)(4mL)，依次加入乙酸银(120mg，718.9μmol)、碘(145mg，571.3μmol)，15℃反应 1小时，反应液中加入水稀释，用乙酸乙酯(20mL×2)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物38c(180mg，产率：57％)。
MS m/z(ESI):1105.2[M+1]。
第三步
(5S,5aS,6S,9R)-2-(3-(双(4-甲氧基苄基)氨基)-2-氟-5-甲基-6-(三氟甲基)苯基)-12-((1-(((叔丁基二甲基硅基)氧基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯38d
将化合物38c(150mg，135.7μmol)溶于N,N-二甲基甲酰胺(DMF)(1mL)，依次加入碘化亚铜(125mg，656.3μmol)、氟磺酰基二氟乙酸甲酯(260mg，1.4mmol，上海毕得)，100℃反应1小时，反应液中加入水稀释，用乙酸乙酯(20mL×2)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物38d(80mg，产率：57.6％)。
MS m/z(ESI):1047.2[M+1]。
第四步
(5S,5aS,6S,9R)-2-(3-(双(4-甲氧基苄基)氨基)-2-氟-5-甲基-6-(三氟甲基)苯基)-1-氟-12-(1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯38e
采用实施例36中的合成路线第一至三步，将第一步原料化合物6b替换为化合物38d得到粗品标题化合物38e(40mg)。
MS m/z(ESI):1030.2[M+1]。
第五步
2-氟-3-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-5-甲基-4-(三氟甲基)苯胺38
将粗品化合物38e(40mg，38.8μmol)溶于三氟醋酸(1mL)，冰浴下加入三氟甲磺酸(0.1mL)，搅拌反应1小时后，反应液减压浓缩，用少量碳酸氢钠饱和溶液调节pH至7左右，减压浓缩，残余物用甲醇溶解后过滤，滤液减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物38(10mg，产率：37.3％)。
MS m/z(ESI):690.2[M+1]。
1H NMR(500MHz,CD3OD):δ6.87(d,1H),6.51(d,1H),5.41–5.34(m,1H),4.61–4.39(m,3H),4.08(t,1H),3.70(d,1H),3.60(s,1H),3.47(q,1H),3.18(d,1H), 2.61–2.29(m,7H),2.21(t,1H),2.07(s,2H),1.83(dd,3H),1.59(dd,3H),1.36(s,3H)，0.74(s,2H),0.52(s,2H)。
实施例39
3-氯-5-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-4-(三氟甲基)苯胺39
第一步
(5S,5aS,6S,9R)-2-氯-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁酯39a
将粗品化合物36c(50mg，81.4μmol)，4-(二氟甲亚基)哌啶盐酸盐(54.2mg，319μmol)溶于乙腈(5mL)，加入无水碳酸钾(56.3mg，407μmol)和碘化钠(36.6mg，244μmol)，80℃搅拌反应2小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物39a(50mg，产率：94.3％)。
MS m/z(ESI):651.2[M+1]。
第二步
(5S,5aS,6S,9R)-2-(5-氨基-3-氯-2-(三氟甲基)苯基)-12-((1-(4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯39b
将化合物39a(50mg，76.8μmol)、化合物36d(37mg，115μmol)，四(三苯基 膦)钯(17.7mg,15.3μmol)，碳酸铯(75mg，230μmol)混于1,4-二氧六环(3mL)和水(0.5mL)，氮气置换，100℃反应16小时，反应液降至室温后加入乙酸乙酯稀释，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩即得粗品标题化合物39b(60mg)，产物不经纯化直接用于下步反应。
MS m/z(ESI):810.2[M+1]。
第三步
3-氯-5-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-4-(三氟甲基)苯胺39
将粗品化合物39b(50mg，61.7μmol)溶于二氯甲烷(3mL)，冰浴下加入4M氯化氢的1,4-二氧六环溶液(1mL)，自然恢复室温反应1小时后，减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物39(4mg，产率：9％)。
MS m/z(ESI):710.2[M+1]
1H NMR(500MHz,CD3OD):δ6.90(d,1H),6.56(s,1H),6.42(s,1H),5.38(d,1H),4.44(s,3H),4.10(s,2H),3.71(d,2H),3.20(d,1H),2.63(s,5H),2.26–2.05(m,3H),1.82(s,2H),1.59(d,2H),1.31(s,3H),0.77(s,2H),0.56(s,2H)。
实施例40
3-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-2-氟-5-甲基-4-(三氟甲基)苯胺40
第一步
(5S,5aS,6S,9R)-2-(3-(双(4-甲氧基苄基)氨基)-2-氟-5-甲基-6-(三氟甲基)苯基)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环 -14-羧酸叔丁基酯40a
采用实施例6中的合成路线第三至五步，将第三步原料化合物6c替换为化合物38d得到粗品标题化合物40a(31mg)。
MS m/z(ESI):1048.2[M+1]。
第二步
3-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-2-氟-5-甲基-4-(三氟甲基)苯胺40
将粗品化合物40a(31mg，19.7μmol)溶于三氟醋酸(1mL)，冰浴下加入三氟甲磺酸(0.1mL)，搅拌反应1小时后，反应液减压浓缩，用少量碳酸氢钠饱和溶液调节pH至7左右，减压浓缩，残余物用甲醇溶解后过滤，滤液减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物40(5mg，产率：24.6％)。
MS m/z(ESI):708.2[M+1]。
1H NMR(500MHz,CD3OD):δ6.87(d,1H),5.38–5.36(m,1H),4.61–4.39(m,3H),4.08(t,1H),3.70(d,1H),3.60(s,1H),3.47(q,1H),3.18(d,1H),2.61–2.29(m,7H),2.21(t,1H),2.07(s,2H),1.83(dd,3H),1.59(dd,3H),1.35(s,3H)，0.74(s,2H),0.52(s,2H)。
实施例41
2-氨基-4-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-7-氟苯并[b]噻吩-3-甲腈41

第一步
(5S,5aS,6S,9R)-2-氯-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁酯41a
将粗品化合物36b(30mg，48.8μmol)、4-(二氟甲亚基)哌啶盐酸盐(12.4mg，73.2μmol)溶于乙腈(4mL)，加入无水碳酸钾(20.2mg，146.5μmol)和碘化钠(22mg，146.5μmol)，80℃搅拌反应1小时，反应液降至室温后过滤，滤液加水稀释，乙酸乙酯萃取(5mL×3)，有机相合并，依次用水、饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂后滤液减压浓缩，即得到粗品标题化合物41a(31mg)，产品不经纯化直接用于下步反应。
MS m/z(ESI):651.2[M+1]。
第二步
(5S,5aS,6S,9R)-2-(2-((叔丁氧基羰基)氨基)-3-氰基-7-氟苯并[b]噻吩-4-基)-12-(1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-甲酸叔丁酯41b
将粗品化合物41a(31mg，47.6μmol)、(3-氰基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊-2-基)-7-氟苯并[b]噻吩-2-基)氨基甲酸叔丁酯(26.9mg，66.6μmol)、四(三苯基膦)钯(11mg，9.5μmol)、碳酸铯(46.5mg，142.8μmol)混于N,N-二甲基甲酰胺(1mL)，氮气氛下，100℃反应3小时，反应液降至室温后过滤，滤液减压浓缩即得粗品标题化合物41b(43mg)，产物不经纯化直接用于下步反应。
MS m/z(ESI)：907.2[M+1]。
第三步
2-氨基-4-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-7-氟苯并[b]噻吩-3-甲腈41
将粗品化合物41b(40mg，44.1μmol)溶于二氯甲烷(0.5mL)，加入三氟醋酸(0.5 mL)，搅拌反应1小时后，减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物41(2mg，产率：6.4％)。MS m/z(ESI):707.2[M+1]。1H NMR(500MHz,CD3OD):δ7.39(dd,1H),7.04(t,1H),5.41(dd,1H),4.91(s,3H),4.54(d,1H),4.48(d,1H),4.39(d,1H),4.10(d,1H),3.71(d,1H),3.61(s,1H),3.19(d,1H),2.70–2.41(m,5H),2.22(s,3H),2.10(q,2H),2.01–1.83(m,2H),1.79(d,2H),1.61(d,3H),0.75(s,2H),0.52(s,2H)。
实施例42
4-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-6-甲基-5-(三氟甲基)吡啶-2-胺42
第一步
(5S,5aS,6S,9R)-2-(6-(双(4-甲氧基苄基)氨基)-2-甲基-3-(三氟甲基)吡啶-4-基)-1-氟-12-(1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-4-羧酸叔丁基酯42b
将化合物36c(100mg，157.9μmol)、N,N-双(4-甲氧基苄基)-6-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊-2-基)-5-(三氟甲基)吡啶-2-胺42a(111.4mg，205.3μmol，采用专利申请“WO2022042630”中说明书第244页的Example 60公开的方法制备而得)、四(三苯基膦)钯(36.5mg，31.6μmol)、碳酸铯(128.7mg，394.8μ mol)混于1,4-二氧六环(2mL)和水(0.4mL)，氮气氛下，100℃反应16小时，反应液降至室温后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物42b(160mg，产率：99.9％)。
MS m/z(ESI)：1014.1[M+1]。
第二步
4-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-6-甲基-5-(三氟甲基)吡啶-2-胺42
将化合物42b(15mg，157.9μmol)溶于三氟醋酸(2mL)，100℃反应5小时，减压浓缩，残余物溶于二氯甲烷，用饱和碳酸氢钠溶液洗涤，分离有机相，减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物42(30mg，产率：28.2％)。
MS m/z(ESI):673.2[M+1]。
1H NMR(500MHz,CD3OD):δ6.49(d,1H),5.35(d,1H),4.51(d,1H),4.41(q,2H),4.06(d,1H),3.69(d,1H),3.59(s,1H),3.15(d,1H),2.57–2.42(m,8H),2.31(s,2H),2.19(d,1H),2.06(s,3H),1.77(d,2H),1.67–1.51(m,4H),0.89(d,1H),0.72(s,2H),0.50(s,2H)。
实施例43
2-氟-5-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-3-甲基-4-(三氟甲基)苯胺43

第一步
6-溴-3-氟-2-甲基-4-硝基苯胺43b
将3-氟-2-甲基-4-硝基苯胺43a(2.2g，12.9mmol，采用专利申请“US7626018”中说明书第10页的EXAMPLE 7公开的方法制备而得)溶于乙腈(80mL)中，加入N-溴代丁二酰亚胺(2.7g，15.5mmol)，80℃搅拌反应6小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物43b(2.9g，产率：90％)。MS m/z(ESI):247.0[M-1]。
第二步
1-溴-4-氟-2-碘-3-甲基-5-硝基苯43c
0℃下，将浓盐酸(10mL)加入化合物43b(1.5g，6.0mmol)中，保持温度搅拌10分钟后，加入2M亚硝酸钠水溶液(9mL)，0℃下搅拌反应1小时后加入2M碘化钾水溶液(12mL)，保持温度搅拌10分钟后加热至80℃反应1小时，反应液冷却至室温后加入饱和硫代硫酸钠淬灭，用乙酸乙酯(20mL×3)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，即得粗品标题化合物43c(2.1g)，产物不经纯化直接用于下步反应。
第三步
5-溴-2-氟-4-碘-3-甲基苯胺43d
将化合物43c(2.1g，5.83mmol)混于乙醇(20mL)和水(40mL)中，加入铁粉(1.3g，23.3mmol)和氯化铵(6g，35mmol)，90℃搅拌反应3小时，反应液降至室温后过滤，滤液用二氯己烷(50mL×2)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物43d(1.5g，产率：77.9％)。
MS m/z(ESI):327.9[M-1]。
第四步
(5-溴-2-氟-4-碘-3-甲基苯基)氨基甲酸叔丁酯43e
将化合物43d(0.8g，2.42mmol)溶于1,4-二氧六环(5mL)中，加入二碳酸二叔丁酯(BOC酸酐)(3.7g，16.9mmol)，100℃搅拌反应48小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物43e(1g，产率：95.9％)。MS m/z(ESI):427.9[M-1]。
第五步
(5-溴-2-氟-3-甲基-4-(三氟甲基)苯基)氨基甲酸叔丁酯43f
将化合物43e(1.2g，2.79mmol)，碘化亚铜(1.32g，6.97mmol)，六甲基磷酰三胺(1.5g，8.37mmol，上海韶远)，氟磺酰基二氟乙酸甲酯(1.6g，8.37mmol，上海韶远)溶于N,N-二甲基甲酰胺(DMF)(10mL)，氮气置换，90℃搅拌反应2小时，反应液降至室温后过滤，滤液加入乙酸乙酯稀释，水洗，分离有机相，减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物43f(500mg，产率：48.1％)。
MS m/z(ESI):370.0[M-1]。
第六步
(5-氨基-4-氟-3-甲基-2-(三氟甲基)苯基)硼酸43g
将化合物43f(391mg，1.05mmol)、联硼酸频那醇酯(400.2mg，1.57mmol)、1,1'-二(二苯膦基)二茂铁二氯化钯(76.9mg，105.1μmol)、乙酸钾(309.3mg，3.15mmol)混于二甲亚砜(5mL)，置换氮气三次，加热100℃反应16小时，反应液降至室温后过滤，滤液加入水稀释，用乙酸乙酯(10mL×2)萃取，合并有机相，用无水硫酸钠干燥，过滤除去干燥剂后减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系B纯化得到标题化合物43g(100mg，产率：40.1％)。
MS m/z(ESI):237.9[M+1]。
第七步
(5S,5aS,6S,9R)-2-(5-氨基-4-氟-3-甲基-2-(三氟甲基)苯基)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-14-羧酸叔丁酯43h
将化合物36c(70mg，110.5μmol)、化合物43g(26.2mg，110.5μmol)，四(三苯基膦)钯(25.5mg，25.2μmol)，碳酸铯(108mg，331.6μmol)混于1,4-二氧六环(1mL)和水(0.2mL)，氮气置换，100℃反应16小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物43h(40mg，产率：45.8％)。MS m/z(ESI):790.2[M+1]。
第八步
2-氟-5-((5S,5aS,6S,9R)-1-氟-12-((1-((4-(氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并 [1,8-ab]并庚环-2-基)-3-甲基-4-(三氟甲基)苯胺43
将化合物43h(97.7mg，123.7μmol)溶于二氯甲烷(1mL)，加入三氟乙酸(1mL)，搅拌反应2小时后减压浓缩，残余物用高效液相制备色谱法纯化(Waters-2545，色谱柱：YMC Triart-Exrs C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)得到标题化合物43(5mg，产率：5.8％)。
MS m/z(ESI):690.2[M+1]。
1H NMR(500MHz,CD3OD):δ6.87(d,1H),6.52(d,1H),5.38(d,1H),4.57(d,2H),4.53–4.31(m,2H),4.09(d,1H),3.71(s,1H),3.61(s,1H),3.47(s,1H),3.17(d,2H),2.55(s,5H),2.36(t,4H),2.10(s,3H),1.90–1.76(m,3H),1.60(d,3H),1.33(d,2H),0.75(d,2H),0.53(d,2H).
实施例44
5-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-2-氟-3-甲基-4-(三氟甲基)苯胺44
采用实施例43中的合成路线，将第七步原料化合物36c替换为化合物41a得到标题化合物44(3mg，产率：3.4％)。
MS m/z(ESI):708.2[M+1]。
1H NMR(500MHz,CD3OD):δ6.87(d,1H),5.38(d,1H),4.73–4.52(m,2H),4.49–4.35(m,2H),4.08(d,1H),3.71(s,1H),3.61(s,1H),3.17(d,2H),2.75–2.42(m,5H),2.36(s,3H),2.21(s,3H),2.08(s,1H),1.79(d,4H),1.60(d,3H),1.33(d,2H),0.74(d,2H),0.52(d,2H).
实施例45
4-((5S,5aS,6S,9R)-12-((1-((4-(二氟甲亚基)哌啶-1-基)甲基)环丙基)甲氧基)-1-氟-5-甲基-5a,6,7,8,9,10-六氢-5H-4-氧杂-3,10a,11,13,14-五氮杂-6,9-甲桥萘并[1,8-ab]并庚环-2-基)-6-甲基-5-(三氟甲基)吡啶-2-胺45
采用实施例42中的合成路线，将第一步原料化合物36c替换为化合物41a得到标题化合物45(20mg，产率：25％)。
MS m/z(ESI):691.2[M+1]。
1H NMR(500MHz,CD3OD):δ6.36(s,1H),5.37(dd,1H),4.60(s,1H),4.53(dt,1H),4.43(s,2H),4.08(d,1H),3.71(d,1H),3.65–3.58(m,1H),3.18(d,1H),2.55(d,7H),2.20(d,4H),2.07(d,2H),1.95–1.74(m,3H),1.59(d,3H),0.74(s,2H),0.53(s,2H)。
生物学评价
测试例1：AGS细胞ERK磷酸化抑制实验生物学评价(HTRF法)
一、测试目的
本实验通过检测化合物对细胞ERK磷酸化抑制作用，根据IC50大小评价本公开化合物对KRAS靶点的抑制作用。
二、实验方法
AGS细胞用含有10％胎牛血清的RPMI1640(Hyclone，SH30809.01)完全培养基进行培养。实验第一天，使用完全培养基将AGS细胞以40000个/孔的密度种于96孔板，每孔190μL细胞悬液，放置37℃，5％CO2细胞培养箱培养过夜。
第二天，每孔加入10μL用完全培养基配制的梯度稀释的待测化合物，化合物的终浓度是从10μM开始进行5倍梯度稀释的9个浓度点，设置含有0.5％DMSO的空白对照，孔板放置37℃，5％CO2的细胞培养箱孵育1个小时。孵育完成后，取出96孔细胞培养板，吸掉培养基，每孔加入200μL PBS(上海源培生物科技股份有限公司，B320)洗一遍。吸掉PBS，每孔加入50μL含封闭液(blocking reagent)(Cisbio，64KB1AAC)的裂解缓冲液(lysis buffer)(Cisbio，64KL1FDF)，孔板放置振荡器上室温震荡裂解40分钟。裂解后用移液器吹打混匀，每孔各转移16μL裂解液分别至两块HTRF 96孔检测板(Cisbio，66PL96100)中，之后两块板每孔分别加入4μL预混的磷酸化ERK1/2抗体溶液(Cisbio，64AERPEG)或4μL预混的总ERK1/2抗体溶液(Cisbio，64NRKPEG)。微孔板用封板膜密封，在微孔板离心机中离心1分钟，室温避光孵育过夜。
第三天，使用多功能微孔板酶标仪(PerkinElmer，EnVision)读取337nm波长激发，665nm和620nm波长发射的荧光值。
三、数据分析
分别计算化合物各浓度磷酸化ERK1/2和总ERK1/2的665nm和620nm荧光信号比值，用Graphpad Prism软件根据化合物浓度和总ERK1/2比值校正后的磷酸化ERK1/2比值计算化合物抑制活性的IC50值，结果参见下表1。
表1 AGS细胞ERK磷酸化抑制活性数据
结论：本公开化合物对AGS细胞ERK磷酸化具有较好的抑制作用。
测试例2：GP2d、AGS细胞3D增殖抑制实验生物学评价
一、测试目的
通过测试本公开化合物对GP2d、AGS细胞的3D增殖抑制作用，评价本公开化合物对KRAS靶点的抑制作用。
二、实验方法
GP2d细胞用完全培养基即含有10％胎牛血清(Corning，35-076-CV)的DMEM/高糖培养基(Hyclone，SH30243.01)进行培养。实验第一天，使用完全培养基将GP2d细胞以1000个细胞/孔的密度种于96孔低吸附板(Corning，CLS7007-24EA)，每孔90μL细胞悬液，2000转室温离心5分钟后放置37℃，5％CO2细胞培养箱培养过夜。
AGS细胞用完全培养基即含有10％胎牛血清(Corning，35-076-CV)的RPMI1640培养基(Hyclone，SH30809.01)进行培养。实验第一天，使用完全培养基将AGS细胞以1000个细胞/孔的密度种于96孔低吸附板(Corning，CLS7007-24EA)，每孔90μL细胞悬液，2000转室温离心5分钟后放置37℃，5％CO2细胞培养箱培养过夜。
第二天，每孔加入10μL用完全培养基配制的梯度稀释的待测化合物，GP2d细胞的化合物终浓度是从1μM开始进行5倍梯度稀释的9个浓度点，AGS细胞的化合物终浓度是从10μM开始进行5倍梯度稀释的9个浓度点，都设置含有0.5％DMSO的空白对照。孔板放置37℃，5％CO2的细胞培养箱培养5天。第七天，取出96孔细胞培养板，每孔加入50μL3D Cell Viability Assay试剂(Promega，G9682)，室温避光震荡25分钟后，吹吸混匀并每孔取出100μL转移至白色不透底的96孔板(PerkinElmer，6005290)中，使用多功能微孔板酶标仪(PerkinElmer，EnVision2105)读取发光信号值。
三、数据分析
用Graphpad Prism软件计算化合物抑制活性的IC50值，结果参见下表2。
表2 AGS、GP2d细胞3D增殖抑制活性数据
结论：本公开化合物对AGS、GP2d细胞3D增殖具有较好的抑制作用。
测试例3：AsPC-1细胞3D增殖抑制实验生物学评价
实验第一天，将生长良好、达70％-80％汇合度的AsPC-1细胞消化后，用含有10％FBS的RPMI 1640(Hyclone，SH30809.01)培养基重悬，并调整细胞密度至所需。在U形低吸附96孔板中(Corning，CLS7007-24EA)每孔加入90μL细胞悬液，细胞密度为1500个/孔。将细胞板在2500转离心5分钟后，置于37℃，5％CO2培养箱中培养过夜。第二天，将溶于DMSO的20mM受试化合物用DMSO稀释至首浓度2mM，然后再以5倍梯度稀释，共9个浓度点，对照孔为DMSO。然后用培养基将梯度稀释的化合物进一步稀释20倍。在细胞板每孔加入10μL培养基稀释后的受试化合物，化合物终浓度为首浓度10μM，5倍梯度稀释的9个浓度点。设置含有0.5％DMSO的细胞孔为溶媒对照孔，仅有培养基和0.5％DMSO的孔为空白对照孔。化合物各浓度和对照孔均设置复孔，每孔DMSO终浓度为0.5％。将细胞板在2500转离心3分钟后，置于37℃，5％CO2培养箱中培养5天。第七天取出96孔细胞培养板，每孔加入50μL发光细胞活性检测试剂3D Cell Viability Assay(Promega，G9683)，于室温避光震荡25分钟，用移液器上下吹吸混匀后每孔转移100μL至白色不透底OptiPlateTM-96孔板(PerkinElmer，6005290)，使用多功能微孔板酶标仪(PerkinElmer，EnVision2105)读取发光信 号值。
使用以下公式计算抑制率：抑制率＝(发光值溶媒对照孔-发光值受试化合物)/(发光值溶 媒对照孔-发光值空白对照孔)×100％。用GraphPad Prism软件根据化合物各浓度与相应的抑制率绘出曲线，并计算化合物的IC50值。
表3、AsPC-1细胞3D增殖抑制活性数据
结论：本公开化合物对AsPC-1细胞3D增殖具有较好的抑制作用。
测试例4、药代动力学评价
1、摘要
以balb/c裸鼠为受试动物，应用LC/MS/MS法测定了balb/c裸鼠灌胃(i.g.)给予实施例化合物后不同时刻血浆中的药物浓度。研究本公开化合物在balb/c裸鼠体内的药代动力学行为，评价其药动学特征。
2、试验方案
2.1、试验药品
化合物37和39。
2.2、试验动物
balb/c裸鼠18只，雌性，平均分成2组，由维通利华实验动物技术有限公司提供，生产许可证SCXK(浙)2019-0001。
2.3、药物配制
分别称取一定量的受试化合物，加5％DMF+45％PG+50％(10％HS15-pH7.4buffer)+400mpk SNAC，配制成4mg/mL无色澄明溶液。
2.4、给药
给药剂量为40.0mg/kg，给药体积为10mL/kg。
3、操作
于给药前及给药后0.25、0.5、1.0、2.0、4.0、6.0、8.0、11.0、24.0小时，由眼眶采血0.1mL，置EDTA-K2抗凝试管中，10000rpm离心1分钟(4℃)，1小时内分离血浆，-20℃保存待测。采血至离心过程在冰浴条件下操作。
测定不同浓度的药物给药后，balb/c裸鼠血浆中的待测化合物含量：取给药后各时刻的balb/c裸鼠血浆样品25μL，200μL含内标(化合物37：内标为维拉帕米100ng/mL；化合物39：内标为双氯芬酸100ng/mL)的乙腈，涡旋混合5分钟，并在3700rpm下离心20分钟，将上清液与水混合(1:1)。取上清液0.5-2μL进行LC/MS/MS分析。
4、药代动力学参数结果
表4、本公开化合物在balb/c裸鼠体内的药代动力学参数
结论：本公开化合物在balb/c裸鼠体内具有较好的药代动力学优势。

Claims (21)

  1. 一种通式(IN)所示的化合物或其可药用的盐：
    其中：
    环C为杂环基；
    Rx1为氢原子或Rx；
    Rx选自＝N-O-R61、＝CR62R63和＝N-R64；
    G0选自O、S、S(O)、S(O)2、CRG0aRG0b和NRG0c；
    G1选自CRG1aRG1b、CRG1aRG1bCRG1cRG1d、C＝O和C(O)CRG1aRG1b；
    G2为NRd；
    T为化学键或选自CRaRb、NRT和O；
    Q为N或CR2a；
    环A为芳基或杂芳基；
    L选自单键、O和NRe；
    Ra、Rb、RG0a、RG0b、RG1a、RG1b、RG1c和RG1d相同或不同，且各自独立地选自氢原子、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基和杂环基；或者，RG1a、RG1b与相连的碳原子一起形成环烷基；或者，RG1c、RG1d与相连的碳原子一起形成环烷基；
    各个R1相同或不同，且各自独立地选自卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)u-NRfRg、羟基和羟烷基；
    R2a和R4a相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)v-NRhRi、羟基、羟烷基和环烷基；
    各个R3相同或不同，且各自独立地选自卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)w-NRjRk、-(CH2)w1-(O)x1-C(O)NRj1Rk1、-(CH2)w2-(O)x2-C(O)ORj2、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；
    各个R6相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)y-NRmRn、-(CH2)y1-(O)z1-C(O)NRm1Rn1、-(CH2)y2-(O)z2-C(O)ORm2、＝N-O-R61、＝CR62R63、＝N-R64、 硝基、羟基、羟烷基、氧代基、环烷基、杂环基、芳基和杂芳基；
    R61、R62、R63和R64相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基和环烷基；
    R5a和R5b相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氰基、羟基和羟烷基；或者
    R5a、R5b与所连的碳原子一起形成环烷基或杂环基，所述的环烷基或杂环基各自独立地任选被选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、氨基、羟基和羟烷基中的一个或多个相同或不同的取代基取代；
    RG0c、RT、Rd、Re、Rf、Rg、Rh、Ri、Rj、Rk、Rj1、Rk1、Rj2、Rm、Rn、Rm1、Rn1和Rm2相同或不同，且各自独立地选自氢原子、烷基、烯基、炔基、卤代烷基、羟烷基、环烷基、杂环基、芳基和杂芳基；
    u、v、w、w1、w2、y、y1和y2相同或不同，且各自独立地选自0、1、2和3；
    x1、x2、z1和z2相同或不同，且各自独立地选自0或1；
    r为0、1、2或3；
    p为0、1、2、3、4或5；
    q为0、1、2、3、4或5；且
    t1为0、1、2、3、4或5。
  2. 根据权利要求1所述的化合物或其可药用的盐，其中G1为CRG1aH，RG1a如权利要求1中所定义；优选地，G1为CRG1aH，RG1a为甲基。
  3. 根据权利要求1或2所述的化合物或其可药用的盐，其中G0为O。
  4. 根据权利要求1至3中任一项所述的化合物或其可药用的盐，其中选自 R61、R62、R63和R64如权利要求1中所定义。
  5. 根据权利要求1至3中任一项所述的化合物或其可药用的盐，其为通式(II’)所示的化合物或其可药用的盐：
    其中，
    R6a、R6b、R6c、R6d、R6e、R6f、R6g和R6h相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、-(CH2)y-NRmRn、-(CH2)y1-(O)z1-C(O)NRm1Rn1、-(CH2)y2-(O)z2-C(O)ORm2、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；或者
    R6a和R6e与所连的碳原子、R6a和R6g与所连的碳原子、R6c和R6e与所连的碳原子或R6c和R6g与所连的碳原子一起形成桥，所述的桥具有1、2、3或4个CH2，其中任意一个CH2可任选被O、S、NH替代，所述的桥任选被选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、氨基、羟基和羟烷基中的一个或多个相同或不同的取代基取代；或者
    R6a和R6b与所连的碳原子、R6c和R6d与所连的碳原子、R6e和R6f与所连的碳原子或R6g和R6h与所连的碳原子一起形成环烷基或杂环基，所述的环烷基或杂环基任选被选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、氨基、羟基和羟烷基中的一个或多个相同或不同的取代基取代；
    环A、G2、Q、L、RG1a、R1、R3、R4a、Rm、Rn、Rm1、Rn1、Rm2、y、y1、y2、z1、z2、p和q如权利要求1中所定义；优选地，RG1a为C1-6烷基。
  6. 根据权利要求1至5中任一项所述的化合物或其可药用的盐，其中Q为N。
  7. 根据权利要求1至3中任一项所述的化合物或其可药用的盐，其为通式(IV’)或(VV’)所示的化合物或其可药用的盐：
    其中，
    Rx选自＝N-O-R61、＝CR62R63和＝N-R64；
    R61、R62、R63和R64相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基和环烷基；
    t为0、1、2、3或4；
    R3a和R3b相同或不同，且各自独立地选自氢原子、卤素、烷基、烯基、炔基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、羟基、羟烷基、环烷基和杂环基；
    环B为杂环基；
    Rx1、t1、环C、G2、Q、L、RG1a、R1、R4a、R6和p如权利要求1中所定义；优选地，RG1a为C1-6烷基。
  8. 根据权利要求1至6中任一项所述的化合物或其可药用的盐，其中环A选自萘基、苯基、吡啶基、苯并噻吩基、苯并噻唑基和苯并吡唑基。
  9. 根据权利要求1至8中任一项所述的化合物或其可药用的盐，其中R4a为氢原子或卤素。
  10. 根据权利要求1至9中任一项所述的化合物或其可药用的盐，其中G2为NH。
  11. 根据权利要求1至10中任一项所述的化合物或其可药用的盐，其中L为O。
  12. 根据权利要求1至11中任一项所述的化合物或其可药用的盐，其中p为0。
  13. 根据权利要求1至6、8至12中任一项所述的化合物或其可药用的盐，其中各个R3相同或不同，且各自独立地选自卤素、C1-6烷基、C2-6炔基、C1-6卤代烷基、羟基、-O-C(O)NHC1-6烷基、氨基、氰基、C1-6羟烷基和3至8元环烷基；优选地，R3相同或不同，且各自独立地选自卤素、C1-6烷基、C1-6卤代烷基、羟基、 -O-C(O)NHC1-6烷基、氨基和氰基。
  14. 根据权利要求1至13中任一项所述的化合物或其可药用的盐，其为如下化合物：






  15. 一种通式(IN’A)所示的化合物或其盐：
    其中，
    R为氨基保护基；优选为Boc；
    Ry为羟基保护基；优选为MOM；
    a为0、1、2、3或4；
    G0、G1、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、t1和r如权利要求1中所定义。
  16. 化合物或其盐，其为如下化合物：





  17. 一种制备通式(IN’)所示的化合物或其可药用的盐的方法，该方法包括：
    通式(IN’A)的化合物或其盐经脱保护反应，得到通式(IN’)的化合物或其可药用的盐；任选地，当R3基团上含有保护基时，在所述脱保护反应之前、同时或之后还包括脱去R3基团上的保护基的步骤；
    其中，
    R为氨基保护基；优选为Boc；
    Ry为羟基保护基；优选为MOM；
    a为0、1、2、3或4；
    G2为NH；
    G0、G1、T、环A、环C、Q、L、R1、R3、R4a、R5a、R5b、R6、Rx1、p、t1和r如权利要求1中所定义。
  18. 一种药物组合物，所述药物组合物含有根据权利要求1至14中任一项所述的化合物或其可药用的盐，以及一种或多种药学上可接受的载体、稀释剂或赋形剂。
  19. 根据权利要求1至14中任一项所述的化合物或其可药用的盐或根据权利要求18所述的药物组合物在制备用于抑制KRAS G12D的药物中的用途。
  20. 根据权利要求1至14中任一项所述的化合物或其可药用的盐或根据权利要求18所述的药物组合物在制备用于治疗和/或预防由KRAS G12D介导的疾病或病症的药物中的用途。
  21. 根据权利要求1至14中任一项所述的化合物或其可药用的盐或根据权利要求18所述的药物组合物在制备用于治疗和/或预防肿瘤的药物中的用途；所述的肿瘤优选选自脑癌、甲状腺癌、头颈癌、鼻咽癌、咽喉癌、口腔癌、唾液腺癌、食道癌、胃癌、肺癌、肝癌、肾癌、胰腺癌、胆囊癌、胆管癌、结直肠癌、小肠癌、胃肠道间质瘤、尿路上皮癌、尿道癌、膀胱癌、乳腺癌、阴道癌、卵巢癌、子宫内膜癌、宫颈癌、输卵管癌、睾丸癌、前列腺癌、血管瘤、白血病、淋巴瘤、骨髓瘤、皮肤癌、脂肪瘤、骨癌、软组织肉瘤、神经纤维瘤、神经胶质瘤、成神经细胞瘤和胶质母细胞瘤；更优选选自胰腺癌、结直肠癌和非小细胞肺癌。
PCT/CN2023/109598 2022-07-27 2023-07-27 稠环类化合物、其制备方法及其在医药上的应用 Ceased WO2024022444A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202380046968.5A CN119365465A (zh) 2022-07-27 2023-07-27 稠环类化合物、其制备方法及其在医药上的应用
KR1020257005109A KR20250042155A (ko) 2022-07-27 2023-07-27 축합 고리계 화합물, 이의 제조 방법 및 이의 의학적 응용
JP2025502591A JP2025524846A (ja) 2022-07-27 2023-07-27 縮合環系化合物、その調製方法及びその医薬的使用
CA3261072A CA3261072A1 (en) 2022-07-27 2023-07-27 Fused cyclic compound, its preparation process and its medicinal application
EP23845651.1A EP4563580A4 (en) 2022-07-27 2023-07-27 Fused cyclic compound, its preparation process and its medicinal application
MX2025001020A MX2025001020A (es) 2022-07-27 2025-01-24 Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
CN202210891331 2022-07-27
CN202210891331.3 2022-07-27
CN202211467809.6 2022-11-22
CN202211467809 2022-11-22
CN202211724856 2022-12-27
CN202211724856.4 2022-12-27
CN202211724115 2022-12-30
CN202211724115.6 2022-12-30
CN202310120312.5 2023-02-15
CN202310120312 2023-02-15
CN202310234194.0 2023-03-10
CN202310234194 2023-03-10
CN202310676437.6 2023-06-08
CN202310676437 2023-06-08

Publications (1)

Publication Number Publication Date
WO2024022444A1 true WO2024022444A1 (zh) 2024-02-01

Family

ID=89705453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/109598 Ceased WO2024022444A1 (zh) 2022-07-27 2023-07-27 稠环类化合物、其制备方法及其在医药上的应用

Country Status (8)

Country Link
EP (1) EP4563580A4 (zh)
JP (1) JP2025524846A (zh)
KR (1) KR20250042155A (zh)
CN (1) CN119365465A (zh)
CA (1) CA3261072A1 (zh)
MX (1) MX2025001020A (zh)
TW (1) TW202409051A (zh)
WO (1) WO2024022444A1 (zh)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024125642A1 (zh) * 2022-12-15 2024-06-20 上海翰森生物医药科技有限公司 含嘧啶多元并环类衍生物抑制剂、其制备方法和应用
US12059425B2 (en) 2022-08-05 2024-08-13 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024208305A1 (zh) * 2023-04-07 2024-10-10 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025016432A1 (zh) * 2023-07-18 2025-01-23 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
CN119490512A (zh) * 2024-01-26 2025-02-21 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
WO2025045141A1 (en) * 2023-08-31 2025-03-06 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
CN119661556A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119684316A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
US12338256B2 (en) 2022-05-19 2025-06-24 Genentech, Inc. Aza-tetracyclic oxazepine compounds and uses thereof
WO2025108443A3 (en) * 2023-11-23 2025-07-10 Beigene Switzerland Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025153038A1 (en) * 2024-01-17 2025-07-24 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
WO2025157246A1 (zh) * 2024-01-24 2025-07-31 上海翰森生物医药科技有限公司 嘧啶多环类衍生物抑制剂、其制备方法和应用
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
WO2025157260A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物的可药用盐及其晶型
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
EP4397664A4 (en) * 2021-08-31 2025-09-03 Genfleet Therapeutics Shanghai Inc CYCLIC COMPOUND FUSED TO A PYRIMIDINE, PROCESS FOR ITS PREPARATION AND ITS USE
US12448400B2 (en) 2023-09-08 2025-10-21 Gilead Sciences, Inc. KRAS G12D modulating compounds
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025256655A1 (zh) * 2024-06-14 2025-12-18 上海翰森生物医药科技有限公司 一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026073024A1 (en) * 2024-09-30 2026-04-02 Gilead Sciences, Inc. Kras g12d inhibitors for the treatment of cancer
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7626018B2 (en) 2004-09-10 2009-12-01 bioMérieux Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity
WO2016191524A1 (en) 2015-05-28 2016-12-01 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2020035031A1 (en) 2018-08-16 2020-02-20 Genentech, Inc. Fused ring compounds
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2020238791A1 (zh) 2019-05-24 2020-12-03 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2021000885A1 (zh) 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021118877A1 (en) 2019-12-11 2021-06-17 Eli Lilly And Company Kras g12c inhibitors
WO2022023772A1 (en) 2020-07-31 2022-02-03 AdoRx Therapeutics Limited Antagonist compounds
WO2022042630A1 (en) 2020-08-26 2022-03-03 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
WO2022148422A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022173678A1 (en) 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
WO2022188729A1 (en) * 2021-03-07 2022-09-15 Jacobio Pharmaceuticals Co., Ltd. Fused ring derivatives useful as kras g12d inhibitors
WO2022194245A1 (zh) * 2021-03-17 2022-09-22 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022232331A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
WO2022247757A1 (zh) 2021-05-26 2022-12-01 南京明德新药研发有限公司 氟取代的嘧啶并吡啶类化合物及其应用
WO2022268051A1 (zh) * 2021-06-21 2022-12-29 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2023274383A1 (zh) 2021-07-02 2023-01-05 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
WO2023001123A1 (zh) * 2021-07-19 2023-01-26 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
WO2023025116A1 (zh) * 2021-08-25 2023-03-02 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2023030385A1 (zh) 2021-08-31 2023-03-09 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205719A1 (en) * 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202400170A (zh) * 2022-05-19 2024-01-01 美商建南德克公司 氮雜－四環氧氮呯化合物及其用途

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7626018B2 (en) 2004-09-10 2009-12-01 bioMérieux Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity
WO2016191524A1 (en) 2015-05-28 2016-12-01 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2020035031A1 (en) 2018-08-16 2020-02-20 Genentech, Inc. Fused ring compounds
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2020238791A1 (zh) 2019-05-24 2020-12-03 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2021000885A1 (zh) 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN114615981A (zh) * 2019-08-29 2022-06-10 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021118877A1 (en) 2019-12-11 2021-06-17 Eli Lilly And Company Kras g12c inhibitors
WO2022023772A1 (en) 2020-07-31 2022-02-03 AdoRx Therapeutics Limited Antagonist compounds
WO2022042630A1 (en) 2020-08-26 2022-03-03 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
WO2022148422A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022173678A1 (en) 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
WO2022188729A1 (en) * 2021-03-07 2022-09-15 Jacobio Pharmaceuticals Co., Ltd. Fused ring derivatives useful as kras g12d inhibitors
WO2022194245A1 (zh) * 2021-03-17 2022-09-22 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022232331A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
WO2022247757A1 (zh) 2021-05-26 2022-12-01 南京明德新药研发有限公司 氟取代的嘧啶并吡啶类化合物及其应用
WO2022268051A1 (zh) * 2021-06-21 2022-12-29 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2023274383A1 (zh) 2021-07-02 2023-01-05 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
WO2023001123A1 (zh) * 2021-07-19 2023-01-26 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
WO2023025116A1 (zh) * 2021-08-25 2023-03-02 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2023030385A1 (zh) 2021-08-31 2023-03-09 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 12, no. 7, 2004, pages 1713 - 1730
KARGBO ROBERT B.: "Targeting KRAS G12D Mutations: Discovery of Small Molecule Inhibitors for the Potential Treatment of Intractable Cancers", ACS MEDICINAL CHEMISTRY LETTERS, AMERICAN CHEMICAL SOCIETY, US, vol. 14, no. 8, 10 August 2023 (2023-08-10), US , pages 1041 - 1042, XP093133604, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.3c00277 *
MOLECULES, vol. 21, no. 12, 2016, pages 1674
RSC ADVANCES, vol. 7, no. 3, 2017, pages 1480 - 1483
See also references of EP4563580A4
TETRAHEDRON, vol. 70, no. 37, 2014, pages 6613 - 6622

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4397664A4 (en) * 2021-08-31 2025-09-03 Genfleet Therapeutics Shanghai Inc CYCLIC COMPOUND FUSED TO A PYRIMIDINE, PROCESS FOR ITS PREPARATION AND ITS USE
US12338256B2 (en) 2022-05-19 2025-06-24 Genentech, Inc. Aza-tetracyclic oxazepine compounds and uses thereof
US12059425B2 (en) 2022-08-05 2024-08-13 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024125642A1 (zh) * 2022-12-15 2024-06-20 上海翰森生物医药科技有限公司 含嘧啶多元并环类衍生物抑制剂、其制备方法和应用
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024208305A1 (zh) * 2023-04-07 2024-10-10 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025016432A1 (zh) * 2023-07-18 2025-01-23 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025045141A1 (en) * 2023-08-31 2025-03-06 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
US12448400B2 (en) 2023-09-08 2025-10-21 Gilead Sciences, Inc. KRAS G12D modulating compounds
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025108443A3 (en) * 2023-11-23 2025-07-10 Beigene Switzerland Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025153038A1 (en) * 2024-01-17 2025-07-24 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
WO2025157246A1 (zh) * 2024-01-24 2025-07-31 上海翰森生物医药科技有限公司 嘧啶多环类衍生物抑制剂、其制备方法和应用
CN119613432A (zh) * 2024-01-26 2025-03-14 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119684315A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
CN119684316A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
CN119661555A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
WO2025157260A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物的可药用盐及其晶型
CN119661556A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119490512A (zh) * 2024-01-26 2025-02-21 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661556B (zh) * 2024-01-26 2025-12-09 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025256655A1 (zh) * 2024-06-14 2025-12-18 上海翰森生物医药科技有限公司 一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026073024A1 (en) * 2024-09-30 2026-04-02 Gilead Sciences, Inc. Kras g12d inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
CN119365465A (zh) 2025-01-24
EP4563580A4 (en) 2025-10-29
TW202409051A (zh) 2024-03-01
JP2025524846A (ja) 2025-08-01
KR20250042155A (ko) 2025-03-26
MX2025001020A (es) 2025-03-07
EP4563580A1 (en) 2025-06-04
CA3261072A1 (en) 2025-04-07

Similar Documents

Publication Publication Date Title
WO2024022444A1 (zh) 稠环类化合物、其制备方法及其在医药上的应用
WO2022268051A1 (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
TW202337890A (zh) 橋環類化合物、其製備方法及其在醫藥上的應用
CN115368383A (zh) 稠合含氮杂环类化合物、其制备方法及其在医药上的应用
TW202325298A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
CN117486901A (zh) 稠合哌啶类化合物、其制备方法及其在医药上的应用
CN116199703A (zh) 稠合四环杂环化合物、其制备方法及其在医药上的应用
WO2025092798A1 (zh) 稠合杂芳基类化合物、其制备方法及其在医药上的应用
TW202322819A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
CN115385937A (zh) 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
CN115385938A (zh) 苯并嘧啶类化合物、其制备方法及其在医药上的应用
WO2024208305A1 (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
TW202313630A (zh) 含氮雜環類化合物、其製備方法及其在醫藥上的應用
WO2021249475A1 (zh) 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
JP2023509155A (ja) ビフェニル系誘導体阻害剤、その調製方法及び使用
CN120230123A (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN120365289A (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN115403595A (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN115594695A (zh) 大环类化合物、其制备方法及其在医药上的应用
JP2022527744A (ja) チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用
WO2024046420A1 (zh) 稠合二环类化合物、其制备方法及其在医药上的应用
WO2024094171A1 (zh) 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用
WO2024041643A1 (zh) 稠合三环类化合物、其制备方法及其在医药上的应用
TW202246260A (zh) 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23845651

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 202380046968.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2025502591

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/001020

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 202380046968.5

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025000355

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20257005109

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025104286

Country of ref document: RU

Ref document number: 2023845651

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: MX/A/2025/001020

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2023845651

Country of ref document: EP

Effective date: 20250227

WWP Wipo information: published in national office

Ref document number: 1020257005109

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2023845651

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112025000355

Country of ref document: BR

Free format text: 1) APRESENTE NOVO RELATORIO DESCRITIVO ADAPTADO AO ART. 26 INCISO I DA PORTARIA/INPI NO 14/2024, UMA VEZ QUE O CONTEUDO ENVIADO NA PETICAO NO 870250001742 DE 09/01/2025 ENCONTRA-SE FORA DA NORMA EM RELACAO AO TITULO, CONTENDO TEXTO DIFERENTE DO TITULO INCIANDO A PAGINA. 2) APRESENTE NOVAS FOLHAS DO RELATORIO DESCRITIVO ADAPTADAS AO ART. 20 DA PORTARIA/INPI NO 14/2024, UMA VEZ QUE O CONTEUDO ENVIADO NA PETICAO NO 870250001742 DE 09/01/2025 ENCONTRA-SE FORA DA NORMA, ESTANDO A NUMERACAO DAS TABELAS INCORRETAS MISTURANDO LETRAS E NUMEROS NA IDENTIFICACAO DAS MESMAS. A NUMERACAO DEVE SER SEQUENCIAL, DO MESMO TIPO, PARA TODAS AS TABELAS APRESENTADAS. 3) APRESENTE NOVO RESUMO ADAPTADO AO ART. 40 I

WWP Wipo information: published in national office

Ref document number: 2025104286

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112025000355

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250109